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ABSTRACT 
Malaysia is labelled as an aging nation because of its rapidly expanding older 
population. Falls are the commonest cause of accidents, injuries, disability and death 
among the geriatric population. While older people are the highest users of medications; 
polypharmacy and “fall risk increasing drugs”(FRID) are widely related to falls. The 
falls prevention guidelines recommend medication reviews and FRID withdrawal 
among older fallers. We aimed to evaluate the association between medications and 
falls among older Malaysian urban community dwellers.This study was performed and 
analysed in 2sections; case control comparisons and prospective intervention study. The 
fallers were recruited as the participants aged ≥65years with ≥2falls or 1 injurious fall in 
the previous year who visited the primary care clinics, geriatric medicine clinics and the 
emergency department of a hospital. The non-fallers were the volunteers aged≥65 years 
with no falls over the past year. Case-control-comparisons were performed between 
fallers and non-fallers to assess the association between falls and FRID, possible 
mechanisms and mediators of FRID and the appropriateness of prescription drugs using 
STOPP2 criteria. A prospective study was performed to assess the feasibility and 
effectiveness of medication review as an intervention for fall prevention.We found that 
use of multiple FRID was associated with falls rather than polypharmacy or single 
FRID. Contrary to the previous preconceptions that antihypertensives are associated 
with falls through the mechanism of orthostatic hypotension; we found that 
antihypertensives were not associated with orthostatic hypotension or falls. Rather 
fallers had significantly lower standing systolic blood pressure obtained 2-3 minutes 
after standing. We observed that anticholinergic burden of drugs is associated with falls 
due to reduced physical performance exhibited by the deterioration in timed up and go 
and functional reach scores. We found that prescribing of potentially inappropriate 
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drugs to older adults was significantly associated with falls; while polypharmacy, 
orthostatic hypotension and poorer timed-up-and-go scores were associated with 
potentially inappropriate prescriptions. In prospective study, out of 205 fallers with 
FRID, 98(47.8%) were randomized to intervention, and 107(52.2%) to conventional 
care, the medications were changed in 19(9.3%) participants of the intervention group. 
There was no significant difference in falls outcomes among the fallers with FRID 
regardless of whether they received medication review. While our study is the first 
assessment of the role of medications in falls in Malaysia, it uniquely found that the 
presence of multiple FRID, anticholinergic burden even with the lowest score and 
potentially inappropriate prescriptions instead of single FRID or polypharmacy are 
associated with falls.  Furthermore, instead of antihypertensives or orthostatic 
hypotension, a lower standing systolic blood pressure is associated with falls. The 
positive association between anticholinergic score and falls is mediated by gait and 
balance impairment. An attempt to reduce FRID burden via medication review remains 
unsuccessful as it is not feasible to withdraw FRID without affecting patient’s disease 
management. While future research is needed to consolidate our findings, our 
prospective study may serve as a pilot of a larger randomized controlled study 
evaluating the usefulness and longer term effects of medication reviews in addressing 
falls. 
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ABSTRAK 
Penduduk yang lebih tua di Malaysia dijangka meningkat 210 % antara 1990-2020 . 
Falls adalah punca yang paling biasa kemalangan, kecederaan, hilang upaya dan 
kematian di kalangan penduduk yang berkembang pesat yang lebih tua. Polypharmacy 
dan penggunaan ubat-ubatan yang dikenali sebagai " risiko jatuh dadah semakin 
meningkat " ( Frid ) secara meluas yang berkaitan dengan jatuh ; jatuh garis panduan 
pencegahan mengesyorkan ulasan ubat -hati di kalangan fallers berisiko tinggi. Kami 
bertujuan untuk menilai hubungan antara ubat-ubatan dan jatuh di kalangan masyarakat 
bandar Malaysia kediaman orang dewasa yang lebih tua.Kita diambil fallers berisiko 
tinggi sebagai peserta berumur ≥65years dengan ≥2falls atau 1 kejatuhan mendatangkan 
bencana pada tahun sebelumnya yang melawat klinik penjagaan utama , klinik 
perubatan geriatrik dan jabatan kecemasan hospital. Bukan fallers adalah sukarelawan 
aged≥65 tahun yang tidak mempunyai sejarah jatuh sepanjang tahun lalu . Perbandingan 
kes-kawalan telah dijalankan antara fallers dan bukan fallers untuk menilai persatuan 
antara jatuh dan Frid , mekanisme yang mungkin jatuh Frid berkaitan dan kesesuaian 
ubat-ubatan preskripsi menggunakan kriteria STOPP2 . Kajian rintis campur tangan 
bakal ulasan ubat juga telah dijalankan untuk menilai sama ada ia boleh dilaksanakan 
dan berkesan untuk melaksanakan jatuh tradisional disyorkan ulasan ubat pencegahan. 
Kami mendapati bahawa penggunaan pelbagai Frid dengan luka kira ≥2FRID dikaitkan 
dengan jatuh bukannya polypharmacy atau penggunaan tunggal Frid. Lebih-lebih lagi, 
bertentangan dengan prasangka sebelum ini bahawa antihypertensives dikaitkan dengan 
jatuh melalui mekanisme yang dianggap mendorong atau semakin teruk hypotension 
orthostatic kami mendapati bahawa antihipertensi tidak dikaitkan dengan hypotension 
orthostatic atau jatuh. Sebaliknya fallers mempunyai jauh lebih rendah tekanan darah 
sistolik berdiri diperolehi 2-3 minit selepas memegang postur yang tegak tetapi 
hypotension orthostatic tidak berkaitan dengan jatuh berulang atau memudaratkan. 
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Kami juga mendapati bahawa beban kognitif antikolinergik dadah dikaitkan dengan 
jatuh disebabkan oleh prestasi fizikal dikurangkan dipamerkan oleh kemerosotan dalam 
masa yang ditetapkan dan pergi dan berfungsi skor jangkauan. Kami diperiksa yang 
menetapkan berpotensi tidak sesuai oleh pakar-pakar perubatan telah ketara yang 
berkaitan dengan jatuh; manakala polypharmacy, hypotension orthostatic dan miskin 
ditetapkan masa-up-dan-pergi skor dikaitkan dengan preskripsi yang berpotensi tidak 
sesuai. Dalam bakal kajian, daripada 205 fallers dengan Frid, 98 (47.8%) secara 
rambang untuk campur tangan, dan 107 (52.2%) kepada penjagaan biasa, ubat-ubatan 
telah berubah di 19 (9.3%) daripada kumpulan campur tangan. Tidak ada perbezaan 
yang signifikan dalam hasil jatuh di fallers dengan Frid tanpa mengira sama ada mereka 
menerima kajian ubat. Walaupun kajian kami adalah penilaian yang komprehensif 
pertama peranan ubat-ubatan dalam jatuh di Malaysia, ia unik mendapati bahawa 
≥2FRID bukannya Frid tunggal dikaitkan dengan terjatuh. Tambahan pula, bukan 
antihipertensi atau hypotension orthostatic, kedudukan tekanan darah sistolik yang lebih 
rendah dikaitkan dengan peningkatan risiko berulang atau jatuh memudaratkan. 
Terdapat juga persatuan yang positif antara skor antikolinergik dengan jatuh yang 
diselesaikan oleh gaya berjalan dan kemerosotan nilai-kira. Manakala penggunaan Frid 
tidak dapat dielakkan untuk pengurusan penyakit berkesan, penggunaan STOPP2 
mungkin membuktikan berguna semasa pencegahan jatuh ulasan ubat. Kajian rintis 
bakal kami boleh berkhidmat sebagai asas rawak yang lebih besar dikawal, mungkin 
kajian pelbagai pusat menilai kegunaan dan jangka panjang kesan ulasan ubat dalam 
menangani jatuh dalam suasana budaya kita. 
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CHAPTER 1: INTRODUCTION 
 
With the increase in life expectancy, older people are making up a large and 
rapidly growing percentage of the world population. According to United Nations, the 
population of adults aged 60 years and older is expected to increase from 507.95 million 
(11.6% of the population) in 2015 to 1,293.7 million (24.6% of the total population) by 
2050 (UnitedNations, 2015). The majority of older people live in middle to low income 
countries (Ebrahim, 2002). The population of Malaysia is also expanding rapidly and is 
expected to increase by 80% between 1990 to 2020,  however the aged population is 
expected to exponentially increase by 210% during this time span (Mafauzy, 2000). 
Among the total Malaysian population of approximately 26 million, 6.5% of people are 
of age above 65 years, with a projected population growth of 2% annually, this 
percentage of older population is expected to reach 9.5%. In the year 2035, the country 
is expected to have a population of about 46 million, of which 6.9 million (15%) will be 
above 65 years (Azhar et al., 2013). Due to this ticking of demographic time bomb and 
its associated chaos, the issues associated with population aging need to be dealt 
urgently and efficiently.  
The physical and social changes associated with the aging are pooled with the 
debilitating effects of multiple pathologies. The physiological process of aging is related 
to a marked decline in health, including for example reduced muscle and bone strength, 
gait and balance problems, visual deficits, multiple comorbidities, multiple medication 
usage and frailty, all of which increase the risk for falling and falls associated 
complications. Therefore, as the number of older adults increases, so does the incidence 
of falls and falls related injuries with one in every third adult experiencing a fall per 
annum (Azhar et al., 2013). Falls are the most common cause of accidents among the 
older population leading to both fatal and nonfatal injuries often ending up in prolonged 
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hospitalizations or early institutionalizations (CDC, 2013). Aside from physical effects, 
the psychological fear of falling results in the restriction of physical and social activity 
with subsequent physical deconditioning, depression, poor quality of life and increased 
frailty. Falling, therefore, is a major health challenge among countries with rapidly 
growing older populations. 
Due to an increased number of comorbidities, the use of medications also 
increases with increasing age. More than one-half of all prescription medications are 
dispensed to individuals older than 60 years (Tangiisuran et al., 2014). Therefore, this 
segment of the population accounts for about 25% of the total drug expenditures, this 
figure is predicted to reach 40% by 2030 (Williams et al., 1992). Although medication 
has helped to cure and control disease, it has also led to serious iatrogenic illnesses and 
adverse drug events. Almost 41% of patients admitted to the hospital are 65 years or 
older and are involved in 41% of the adverse drug reaction reports, 60% of these are 
related to medication-related falls (de Jong et al., 2013). In spite of all this evidence, 
older people with falls are exposed to polypharmacy and the studies on medication 
withdrawal among fallers are scarce, the handful of studies performed either yielded 
negative results or have low clinical implications (Costello et al., 2008). Only the 
studies on psychotropic medication withdrawal yielded positive results but suggested 
that it is difficult to achieve permanent drug withdrawal (Campbell et al., 1999). 
Therefore, the problems of multiple comorbidities, multiple medication usage 
and falls are closely linked among older individuals. While falls have serious 
consequences and should be prevented at all cost if possible, medications are also 
necessary for the secondary prevention of non-communicable diseases which become 
more prevalent in older age and can lead to disability and death if left untreated. Hence, 
every medication cannot be “avoided” or “omitted/ deprescribed” merely for the 
purpose of falls prevention.  While the studies on the association of medication 
 3 
 
associated falls, their mechanisms or medication review interventions among older 
individuals are scarcely done in middle to low income countries, none of the study has 
been conducted in Malaysia. This critical issue of medication involvement with falls 
needs to be thoroughly explored to provide a significant evidence for benefit versus risk 
ratio for the consumption of drugs against falls among the older adults in this region.  
This thesis is presented in article style as due to the nature of the study, the 
analysis were conducted from different aspects at different phases of recruitment 
culminating in different sample sizes. Chapter 2 will first of all comprise the literature 
review, much of the contents of literature review were published as two clinical reviews 
in Postgraduate Medicine (ISI listed Q2) (A. Zia et al., 2015a, 2015b). The chapter 3 
presents the overall methodology of the study; the specific details of methods are 
mentioned in the relevant chapters. Chapter 4 addresses the association between FRID, 
polypharmacy and falls; the results of this chapter were published as an article in 
Geriatrics and Gerontology International (ISI listed Q3) (Anam Zia et al., 2016). 
Chapter 5 illustrates the complex association between antihypertensives, postural blood 
pressure changes and falls, the article is published in European Journal of Clinical 
Investigations (ISI listed Q1) (Anam Zia et al., 2015). Chapter 6 addresses the 
mediators behind the positive association between anticholinergic burden and falls, the 
results are published in Maturitas (ISI listed Q2) (A. Zia et al., 2016).  Chapter 7 
explains the association of PIP with falls among community dwelling older adults, the 
article is submitted to Age and Aging. Chapter 8 is the longitudinal assessment of the 
medication review intervention on the risk of falls while chapter 9 concludes the finding 
of this whole study.  
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1.1. Research question, Hypothesis and Objectives 
1.1.1. Research questions 
The related research questions for this study were: What is the role of FRID count in the 
association between polypharmacy and falls? (i) Are antihypertensives associated with 
falls through the mechanism of postural drop in blood pressure? (ii) What are the 
possible mediators of anticholinergic burden associated falls? (iii) Is PIP associated 
with falls and what are the factors associated with PIP? (iv) Can medication review 
actually be feasible and effective in reducing falls among high risk older fallers? 
1.1.2. Hypothesis 
Hypothesis 1: There is a positive association between polypharmacy, FRID count and 
falls among the community-dwelling older adults.  
Hypothesis 2: There is a positive association between antihypertensives, postural blood 
pressure drop and falls.  
Hypothesis 3: Functional performance is the mediator of anticholinergic burden 
associated falls.  
Hypothesis 4: Potentially inappropriate prescriptions are significantly associated with 
falls.  
Hypothesis 5: The intervention of medication review is feasible and beneficial to reduce 
falls among high risk older fallers. 
1.1.3 Objectives of the study 
1.1.3.1. General Objective 
To evaluate the relationship between medications and falls among urban community-
dwelling older adults in a middle-income developing country. 
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1.1.3.2. Specific Objective 
I. To assess the association between polypharmacy, FRID count and falls among 
the community-dwelling older adults in a case control manner.  
II. To evaluate the relationship between antihypertensives, postural blood pressure 
drop and falls in case control fashion. 
III. To determine the association of anticholinergic burden and its mediators with 
the risk of falls in a case control analysis. 
IV. To determine the association between potentially inappropriate prescribing and 
falls in case control comparisons. 
V. To determine the effect of medication review as an intervention on falls 
reduction in a prospective manner. 
1.2. Definition of terms 
1.2.1. Falls  
“An unexpected event in which the person comes to rest on the ground, floor or lower 
level” (Lamb et al., 2005).  
1.2.2. Community-dwelling  
This term is used when referring to elderly persons who are not in assisted living 
(including nursing homes, residential care homes, hospitals and other types of 
institutional accommodations). 
1.2.3. Medications  
Medications were grouped according to the British National Formulary, 67th Edition 
[14].  
Cardiovascular medicines: Antihypertensives (A2RA, ACE-I, thiazide diuretics, CCBs 
and β-blockers), vasodilators (α-blockers and nitrates) and antiarrhythmics. 
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Antidiabetics: Biguanides, sulphonylureas, other oral antidiabetics and insulin. 
Central nervous system medications: All classes of psychotropic drugs (TCA, SSRI, 
antipsychotics, anxiolytics and antidepressants) and antiparkinsonian medications. 
Analgesics: NSAIDs, cyclooxygenase-2 inhibitors and narcotic analgesics.  
Other drug classes: PPI, H2RA, thyroid drugs, steroids and cholesterol lowering drugs 
(dyslipidaemics). 
1.2.4. Polypharmacy  
“Regular use of five or more medicines” (Gnjidic et al., 2012; T. Kojima et al., 2012). 
1.2.5. Fall risk increasing drugs 
Fall risk increasing drugs were identified according to the available metaanalysis by 
Bloch et al and Woollcott at al (Bloch et al updated the meta-analysis of Leipzig et al) 
(Bloch et al., 2013; Leipzig et al., 1999a, 1999b; Woolcott et al., 2009)). These included 
cardiovascular agents (α-blockers, β-blockers, CCB, diuretics and nitrates), CNS drugs 
(antipsychotics, sedative hypnotics, benzodiazepines, antidepressants and 
antiparkinsonians), analgesics (NSAIDs), thyroid drugs and antidiabetics. 
1.2.6. Potentially Inappropriate prescriptions:   
“Prescription of a drug where the potential harm outweighs the benefit” (O'Mahony et 
al., 2015). 
1.2.7. Orthostatic Hypotension:  
A sustained reduction in SBP of 20mmHg or DBP of 10 mmHg within 3 minutes of 
standing or head up tilt of at least 60⁰ on a tilt table with reference to supine blood 
pressure (Freeman et al., 2011). 
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1.2.8. Physical Performance Scores 
The cut off point for poorer TUG was defined as ≥13.5seconds, (Shumway-Cook et al., 
2000) poorer FR as ≤18cm (Duncan et al., 1990) and reduced GS as <20kg for women 
while <30kg for men (Peters et al., 2011; Sallinen et al., 2010). 
1.2.9. Multiple FRID 
Multiple FRID was defined as “the consumption of two or more FRID (≥2 FRID)”.  
Should the participant be on two medications which fall within the same category but 
different class, for instance CCB and ACE-I, they would be considered to be on two 
FRID. 
1.2.10. Multiple Antihypertensives 
 
Multiple antihypertensives use was defined as the consumption of two or more 
antihypertensives (≥2antihypertensives) (Benetos et al., 2015). 
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CHAPTER 2: LITERATURE REVIEW 
2.1. Epidemiology of Falls in the Elderly 
Though fall accidents may occur at all ages, the incidence, severity, associated 
injuries and complications increase exponentially with the advancing age (Berry et al., 
2008). This seems rational because falls are generally considered to be a marker of 
frailty and decreased mobility, both of which intensify with increasing age (Soriano et 
al., 2007). The syndrome of falls occurs because of the interplay between multiple 
intrinsic and extrinsic factors occurring within an aging individual. The risk of recurrent 
falls multiplies after the first fall leading to recurrent and injurious falls, and in turn a 
marked decline in functional health, independence (Ambrose et al., 2013; Smee et al., 
2012; Ward et al., 2015) as well as markedly increased mortality only at 1 and 3 years 
after a fall (M. P. Tan et al., 2015). The fear of falling, which occurs in older adults both 
with and without history of falls, further decreases functional independence, social 
participation as well as quality of life thereby starting a vicious spiral of serious and 
recurrent falls (Scheffer et al., 2008). This section, “epidemiology of falls”, deals with 
the literature on incidence, risk factors and consequences of falls among older adults.  
2.1.1. Incidence and consequences of falls in community 
Among community-dwelling older adults, 28-35% of older individuals aged 
over 64 years and 32-42% of those aged over 70 years (WHOGlobalreport, 2007) and  
50% of those over 80 years (Soriano et al., 2007) fall each year while 10-20% of those 
fall recurrently (Tinetti et al., 1988). Every tenth older individual sustains a serious 
injury after a fall. Falls accompanied by injuries e.g. fractures, soft tissue injuries, 
traumatic brain injuries etc. account for 85% of all the injury-related hospital 
admissions, more than 40% of the nursing home admissions (Woolcott et al., 2009) and 
40% of injury related deaths among the older population (WHOGlobalreport, 2007). 
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Therefore, falls make up the leading cause of death in older individuals and these fall 
related death rates have risen sharply over the past two decades (CDC, 2013). Even with 
these figures, the under-reporting of falls is also a problem with evidence that 75–80% 
of all falls without injury are not being reported at all (Fleming et al., 2008). 
Among the older adults who fall, approximately one-half are unable to get up 
and remain on the ground. These “long-lies” lead to dehydration, rhabdomyolysis, 
pressure sores, and pneumonia (Fleming et al., 2008). In addition, 25%–55% older 
adults who fall develop a marked fear of falling, up to 40% restricting their activities of 
daily living (Soriano et al., 2007). This further increases the risk of falls by a decline in 
physical fitness and increase in functional dependence, social isolation and depression. 
Aside from their effects on mobility, independence and quality of life of older adults 
they is also an increase in the burden on hospitals and residential care facilities 
(Alexander et al., 1992). 
Among Asian countries, the incidence of falls in Malaysia appears to be higher, 
one survey study in a primary care clinic in Kualalumpur, Malaysia reported the 
prevalence of falls to be 47%, recurrent falls to be 57% while injurious falls to be 61% 
(Sazlina et al., 2008). The prevalence of falls is 16.9% in males and 24.3% in females 
according to the Korean study (Choi et al., 2014) and  21% in a Taiwanese study (Wu, 
Chie, Yang, Liu, et al., 2013). Falls made up 51.3% of all injury related admissions 
according to one Singaporean study (Wui et al., 2014). According to a systematic 
review the fall rates in China ranged between 14.7% and 34% per annum, while 60% to 
75% of those reported injurious falls with fractures constituting 6% to 8% of all injuries 
(Kwan et al., 2011). 
Falls along with their consequences are responsible for a large part of 
preventable health care costs, the annual costs attributable to falls and fall-related 
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complications have been estimated to be billions of dollars worldwide (Scuffham et al., 
2003). National fall related costs of prevalence-based studies are 0.85–1.5% of total 
healthcare expenditure (Heinrich et al., 2010). Although this data does not take into 
account the long term consequences of falls such as admission to care facilities or 
longer term need for home care, as falls are a strong predictor of placement in a skilled-
nursing facility among older people living in the community (Tinetti et al., 1998). 
Therefore, falls are the primary reason for death and disability, an overall decrease in 
quality of life, increase in hospitalisations and early admissions to nursing homes; the 
burden of falls and their sequel on individuals, society and health care system is 
substantial. 
2.1.2. Risk Factors 
The risk factors associated with falls are categorised into extrinsic and intrinsic 
factors. The intrinsic and hence non-modifiable risk factors include age, gender (Kwan 
et al., 2011; Lehtola et al., 2006; Wu, Chie, Yang, Liu, et al., 2013), history of falls 
(Vieira et al., 2011; Wu, Chie, Yang, Kuo, et al., 2013), gait and balance impairment, 
mobility restriction and multiple comorbidities (Lee et al., 2006).  The likelihood of 
falling and being seriously injured after a fall increases with age due to both 
physiological and pathological changes. Women are 58% more likely than men to suffer 
a nonfatal fall injury (Ambrose et al., 2013).The extrinsic factors considered modifiable 
include environmental hazards i.e. community hazards, home hazards and footwear 
problems. These include poor lightning, slippery floors, loose carpets, and lack of 
bathroom safety equipment etc. (Vieira et al., 2011). Medications are strongly 
associated with falls both through their direct effects and through indirect mediating 
factors (Kwan et al., 2011; Wu, Chie, Yang, Liu, et al., 2013). Medication intake, 
although generally considered modifiable, could be non-modifiable because certain 
medications are necessary for the optimal management of otherwise fatal diseases. A 
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study identified that unlike most other studies, the major causes of falls in Malaysia 
were the intrinsic factors with comorbidities as the major factor followed by mobility 
limitation, sensory deficits and age (Azhar et al., 2013). Most falls are multifactorial, it 
is therefore important to be aware of interactions and synergism between the risk 
factors. The risk of falls increases linearly with the increase in number of risk factors, it 
increased from 8% to 78% with none to four or more risk factors in one year 
prospective study on community dwelling adults aged 75 years and above (Tinetti et al., 
1988).  
Multifactorial falls prevention interventions, which include exercise, vision 
correction, medication review and home hazard management, are considered beneficial 
among fallers residing in the community with history of previous falls (J. T. Chang et 
al., 2004; Costello et al., 2008; M. Tinetti et al., 2010). In addition, studies have also 
highlighted the benefits of single interventions on falls reduction among elderly. 
Campbell et al and Velde et al showed that medication withdrawal may prove 
successful as a single intervention in reducing falls (Campbell et al., 1999; van der 
Velde, Stricker, et al., 2007). Other studies have shown that cardiac pacing among 
fallers with cardioinhibitory carotid sinus hypersensitivity (Kenny, 1999) and cataract 
surgery (Harwood et al., 2005) significantly reduce falls as a single intervention. Some 
studies also suggested that single intervention of comprehensive exercise alone is 
successful in reducing falls (Costello et al., 2008; M. Tinetti et al., 2010). A meta-
analysis of randomised controlled trials amongst community dwelling older persons 
determined that multifactorial fall prevention interventions are more effective for 
individual patients, while for community programmes involving high risk populations, 
targeted single interventions may be beneficial as they are easier with better compliance 
and cost effectiveness (Campbell et al., 2007). 
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2.2. Medication use in older adults  
Older people use more medications due to the age-related increase in prevalence of 
multiple pathologies. This, combined with the physiological changes in drug 
metabolism makes the older people two to three times more likely to experience adverse 
effects of drugs than younger people (Turnheim, 2004). Falls is the commonest adverse 
drug event, accounting for up to 25% of the hospitalizations in elderly patients (Nickel 
et al., 2013). Gurwitz et al evaluated the records of 30,397 Medicare enrolees aged ≥65 
years and reported the incidence of adverse drug events as 50.1 per 1000 person years 
(Gurwitz et al., 2003). Viktil et al found 47% of their older patient sample used five or 
more drugs which was associated with a linear increase in adverse drug events due to 
“drug interactions” (Viktil et al., 2007). In spite of the higher prevalence of adverse 
drug events, the use of medicines among the elderly is increasing with time, a Swedish 
study analysed the number of drugs dispensed for the entire country during 2005-2008 
and found that the prevalence of polypharmacy (≥5 drugs) and excessive polypharmacy 
(≥10drugs) increased by 8.2% and 15.7% respectively during this time span. Moreover, 
the prevalence of excessive polypharmacy displayed a clear age trend, with the largest 
increase for the group of 70 years and above (Hovstadius et al., 2010). A population-
based study of older adults reported that the use of common cardiovascular medications 
increased dramatically with age and the  use of at least three cardiovascular medicines 
increased from 39% to 54% during their five year follow-up period (P. K. Hiitola et al., 
2007). Not only cardiovascular medications but the prescription of psychotropic drugs 
is also increasing, with a 22.2% increase in the prescription of three or more 
psychotropic medications in the past three decades (Rittmannsberger, 2002). 
The age associated changes in physiological mechanisms which alter the 
pharmacodynamics and pharmacokinetics of drugs. The pharmacokinetic changes 
associated with ageing occur as a result of reduction in the renal or hepatic clearance 
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leading to increased serum drug levels and consequent drug toxicity even with the 
prescription of normal recommended adult doses (McLachlan et al., 2012). Nutritional 
status and body composition also affect drug metabolism. As lean body mass may 
decrease by 12-19%, body water content may reduce by 10-15% and total body fat may 
increase by 14-35% in an older person, the plasma levels of drugs primarily absorbed 
by the muscles increase thereby resulting in an increased plasma concentration of those 
hydrophilic drugs (Noble, 2003). The pharmacodynamic changes associated with 
increasing age include decreased responsiveness to β-adrenergic receptor agonists (β-
agonists) and decreased α-adrenergic receptor activity. Moreover, the brain may be 
exposed to higher drug levels due to reduced  effectiveness of the blood brain barrier in 
the elderly (Turnheim, 2004). In addition, the changes in drug handling abilities due to 
the various deficits arising with age e.g. the presence of dementia, may lead to 
medication errors especially among those with complex medication regimens (Nickel et 
al., 2013). With the increase in number of comorbidities and consequently 
polypharmacy, drug-drug interactions and drug-disease interactions also add up to the 
risk of adverse events in older people. 
2.3. Medications and Falls: Fall risk increasing drugs 
The studies performed on the risk assessment of falls have reported use of 
certain medications to be the significant risk factor for falls. These medications are 
termed as “fall risk increasing drugs” (FRID) in the falls literature. Particularly in older 
community dwellers, the drugs related to CNS are ten times more likely to increase falls 
risk through their direct effects of sedation, drowsiness and dizziness (French et al., 
2006). The association of cardiovascular drugs with falls is complex as they are 
considered to mediate via blood pressure changes, orthostatic hypotension and syncope, 
which themselves are independent factors for falls and may or may not co-exist with 
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cardiovascular drugs (Milos et al., 2014; Poon et al., 2005). Hypoglycaemia caused by 
antidiabetic agents is a significant risk factor for falls in the older population (Berlie et 
al., 2010). Recent studies have reported that not only anticholinergic drugs themselves 
but other drugs with anticholinergic activity are also associated with falls through their 
effects on CNS as well as peripheral effects (Kersten et al., 2014). One Singaporean 
study found that elderly hospitalized patients on hypnotic drugs, cough preparations and 
anti-platelets are more likely to fall (Mamun et al., 2009). The systematic review by 
Hartikainen et al including 29 studies stated that the main group of drugs associated 
with an increased risk of falling was psychotropics: benzodiazepines, antidepressants, 
and antipsychotics while antiepileptics and blood pressure lowering drugs were weakly 
associated with falls (Hartikainen et al., 2007). Not only individual drug classes but an 
increased FRID count may also be a potent predictor of falls. Studies have stated that 
older adults with severe falls have increased FRID count which in turn is related with 
the increased number of medications, comorbidities and frailty (Bennett et al., 2014; 
Milos et al., 2014). This increase in FRID  count is associated with an increased risk of 
fall injury in a dose response fashion (Laflamme et al., 2015). However, FRID count 
increases with the increase in total number of medications, therefore the reports have 
suggested that in an older person receiving multiple medications, polypharmacy itself or 
polypharmacy with at least one other FRID may be a strong predictor for falls 
(Richardson et al., 2015; Ziere et al., 2006). Table 2.1 provides a list of available meta-
analysis on the association of individual FRID classes and falls among older adults. 
2.3.1. Antihypertensives 
The drugs used to treat high blood pressure encompass a controversial 
relationship with falls. While 25% of clinicians tend to prescribe less antihypertensives 
to older people as they believe it would do more harm than good (Fisher et al., 2003), a 
meta-analysis by Zang, involving 42 studies concluded that there is no clear evidence 
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for the association between blood pressure lowering medications and serious injurious 
falls (Zang, 2013). Since untreated cardiovascular pathologies can lead to devastating 
outcomes, some studies have actually found cardiovascular medications to be protective 
against falls (Kuschel et al., 2014). The angiotensin system blocking medications are 
considered the safest amongst others for blood pressure lowering therapy and recent 
prospective studies have even found them to be protective against falls among older 
adults (Romero-Ortuno et al., 2013; Wong et al., 2013). 
On the contrary of the above evidence, a meta-analysis on the risk factors of 
falls found antihypertensives to be among the major risk factors for falls (Vieira et al., 
2011). One study found that among all the antihypertensive agents, their older 
participants on diuretics and β-blockers were more likely to experience a fall (Costa-
Dias et al., 2014). However, even the positive association between antihypertensives 
and falls is not simpler and the factors of dosage increment or initiation of a new 
antihypertensive drug may be more of a culprit in increasing the falls risk. According to 
Gribbin et al, although there was no association between antihypertensive medications 
and falls at baseline, fall risk increased with in the first three weeks of prescription of a 
diuretic (Gribbin et al., 2010) while Butt et al found the initiation of antihypertensive 
therapy to be associated with a 43% increased risk of hip fracture (Butt et al., 2012). 
The history of previous falls may be another factor in the complex association between 
antihypertensives and falls. The longitudinal studies by Callisaya et al. and Tinetti et al. 
involving older participants concluded that among those who had recurrent falls at 
baseline a higher intensity antihypertensive treatment was independently associated 
with future serious falls (Callisaya et al., 2014; Tinetti et al., 2014).  
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Table 2.1: Risk of falls and drugs usage among older people: results from published meta-analyses. 
Drug Class Examples Odds ratio (95% confidence interval) 
Bloch et 
al;2013(Bloch et 
al., 2013) 
Woollcott et 
al;2009(Woolcott 
et al., 2009) 
Leipzig 
al;1999(Leipzig 
et al., 1999a, 
1999b) 
Taking drugs(yes/no) 
Polypharmacy 
Consuming any medication 4.24 (3.06–5.88)* 
1.71 (1.50–1.96)* 
- 
- 
- 
- 
Cardiovascular drugs 
Any Antihypertensives 
ACE inhibitors  
β-blockers  
Calcium channel blockers 
Diuretics   
Digoxin  
Type1a antiarrhythmics  
Vasodilators 
 
 
Captopril, Lisinopril, Perindopril 
Propanolol, Atenolol, Metoprolol,  
Nifedipine, Amlodipine, Felodipine 
Furosemide, Spironolactone, Amiloride 
- 
Quinidine, procainamide 
 
α-blockers (Prazosin, Doxazosin) 
Nitrates (Glyceryl Trinitrate, Isosorbide) 
0.78 (0.67–0.90) 
1.10 (1.05–1.16)* 
- 
1.12 (1.04–1.21)* 
1.21 (1.15–1.28)* 
- 
1.48 (1.11–1.99)* 
- 
 
1.12(1.04-1.21)* 
- 
1.24(1.01-1.50)* 
- 
1.14(0.97-1.33) 
- 
- 
- 
1.07(1.01-1.14)* 
- 
- 
1.20 (0.92, 1.58) 
0.93  (0.94, 1.14) 
0.94 (0.77, 1.11) 
1.08 (1.02, 1.16)* 
1.22(1.05, 1.42)* 
1.59(1.02, 2.48) 
 
1.13 (0.95, 1.36) 
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Psychotropics 
Antipsychotics 
 
Sedative hypnotics 
Benzodiazepines 
 Short acting 
 Long acting  
Antidepressants  
 
 
 
 
 
 
Anti-epileptics  
 
Antiparkinsonians 
Typical (Chlorpromazine, haloperidol) 
Atypical (Clozapine, Olanzapine) 
Barbiturate, Methaqualone, Thalidomide 
 
Lorazepam, Alprazolam 
Diazepam, Clonazepam 
Selective Serotonin Reuptake Inhibitors 
(Fluoxetine, citalopram), Selective 
Norepinephrine Reuptake inhibitors 
(Venlafaxine, Duloxetine), Tricyclic 
Antidepressants (Imipramine, 
Desipramine), Non-Tricyclic 
Antidepressants(Mirtazapine, Trazodone) 
Acetazolamide, Carbamazepine, 
Gabapentin, Lamotrigine 
Dopa and Dopa derivative dopaminergic 
agents, Dopamine receptor antagonists 
(Bromocriptine, Pergolide, Pramiprexole) 
1.74 (1.56–1.95)* 
1.37 (1.16–1.61)* 
 
1.53 (1.40–1.68)* 
1.61 (1.35–1.93)* 
- 
- 
1.59 (1.43–1.75)* 
 
 
 
 
 
 
 
 
1.56 (1.28–1.90)* 
 
1.55 (1.21–1.97)* 
1.59(1.37-1.83)* 
 
1.47(1.35-1.62)* 
1.57(1.43-1.72)* 
- 
- 
1.68(1.47-1.91)* 
 
 
 
 
 
 
 
 
- 
 
- 
1.73(1.52-1.97)* 
1.50(1.25-1.79)* 
 
1.54 (1.40, 1.70)* 
1.48  (1.23, 1.77)* 
1.44 (1.09, 1.90)* 
1.32 (1.09, 1.90)* 
1.66 (1.41, 1.95)* 
 
 
 
 
 
 
 
 
- 
 
- 
Analgesics 
Opioids  
NSAIDs  
 
Oxycodone, Hydrocodone, Morphine 
Diclofenac sodium, Ibuprofen, 
Indomethacin, Naproxen 
1.33 (1.07–1.65)* 
1.43 (1.27–1.61)* 
1.25 (1.11–1.42)* 
- 
0.96(0.78-1.18) 
1.21(1.01-1.44)* 
- 
0.97 (0.78, 1.12) 
1.16  (0.97, 1.38) 
Others  
Metabolic and 
endocrine drugs 
 
Laxatives  
 
Sulfonylureas (Gliclazide), Biguanides 
(Metformin), Thiazolidinediones, Insulin  
Thyroid drugs (levothyroxine) 
Lactulose, Bisacodyl 
 
1.39 (1.20–1.62)* 
 
 
2.03 (1.52–2.72)* 
 
- 
 
 
- 
 
- 
 
 
- 
 
Table 2.1 continued 
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2.3.1.1. Does OH explain the possible mechanism of antihypertensives 
associated falls? 
a. Falls and OH 
The possible mechanism by which antihypertensives may be associated with 
falls remains unclear. The Swedish National Board of Health & Welfare classified the 
drugs associated with falls into two categories; the category FRID consisted of opioids, 
and all classes of psychotropics while the category of drugs indirectly related to falls by 
causing or worsening orthostatism consisted mainly of antihypertensives i.e. diuretics, 
β-blockers, CCB, ACE-I, A2RA, α-blockers and vasodilators (Milos et al., 2014). The 
commonest reason for physicians’ reluctance in prescribing effective antihypertensive 
therapy is the belief that antihypertensives lead to OH (Choulerton et al., 2010). It has 
often been assumed that the relationship between antihypertensives and falls may be 
explained by the increased risk of OH in individuals treated with the antihypertensives, 
as the mechanisms of lowering blood pressure through decreased intravascular volume 
(diuretics), reduced cardiac output (β-blockers), vasodilatation (CCB, centrally acting 
agents) are responsible for causing OH as well (Schiffrin, 2010). To date, there has been 
no published study which evaluated the association of medication induced OH with falls 
among older patients (Bradley et al., 2003). However, Vischer reviewed the benefits 
and limitations of hypertension treatment among very old persons and concluded that 
hypertension being a bigger problem for fallers, should be treated efficiently and 
antihypertensive induced OH should not be a reason to not treat hypertension (Vischer, 
2012). Similarly, it remains to be established whether withdrawal or dose adjustment of 
antihypertensive medications alone may be associated with a prospective reductions in 
falls. Such a study, when conducted, should take into account the potential increased 
risk of cardiovascular endpoints which may be associated with the higher or 
uncontrolled in blood pressure levels.  
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Orthostatic hypotension is not a disease in itself, but a physical finding resulting 
from the complex interplay of multiple contributory factors e.g. impairment of the 
autonomic nervous system, decreased intravascular volume, reduced cardiac 
contractility or decreased venous return. Among older adults, in addition, baroreflex-
mediated cardio-acceleration and vasoconstriction declines in efficiency with age and 
when superimposed with hypertension or medications, these effects are exaggerated 
(Bradley et al., 2003). Amongst community dwelling older people, the prevalence of 
OH is 18.2% (Rutan et al., 1992) while among hospitalized older patients it is 44% 
(Coutaz et al., 2012). The prevalence of OH increases with increasing age, ranging from 
31% in  patients aged 75-79 years, 35% in  individuals aged 80-84 years to  40% in  
those aged 85 years or more (P. Hiitola et al., 2009).  
Orthostatic hypotension may present as light-headedness, dizziness, blurred 
vision, and shakiness immediately after standing and may result in falls by causing loss 
of consciousness or postural instability as a result of cerebral hypoperfusion (M. P. Tan 
et al., 2006). However, the exact reproduction of symptoms of falls or loss of 
consciousness is rarely demonstrated in older fallers. Several studies have found strong 
association between OH and frequent falls with medication induced OH being 
responsible for 33% of these falls (Craig, 1994; Rubenstein et al., 1990; Rutan et al., 
1992). In contrast, a later study by Kario et al found no association between OH and 
falls despite demonstrating a significant relationship between lower standing SBP and 
falls (Kario et al., 2001). However, the presence of symptomatic OH may be 
distinctively related to falls instead of the physical finding of OH. In a study by Shibao 
et al, 34% of patients with OH were symptomatic and 83% of these individuals with 
symptomatic OH experienced falls (Shibao et al., 2007).  
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b. Antihypertensives and OH  
Orthostatic hypotension is widely attributed to diseases like hypertension, 
diabetes and parkinsonism (Perez-Lloret et al., 2012) and is also considered to be a side-
effect of medications prescribed for these conditions. Therefore, OH may occur as a 
consequence of medication or an underlying illness or due to combination of both. 
However studies have shown that intensely prescribed antihypertensive therapy to older 
adults could increase the risk of OH. Intensive hypertensive treatment could be 
determined by higher doses of antihypertensive medications, increased number of 
antihypertensive drugs or lowering blood pressure below the recommended target of 
140/90mmHg (Aronow et al., 2011). It has been suggested that the total number of 
blood pressure lowering medications (Verwoert et al., 2008) or the use of at least three 
antihypertensive drugs is a significant predictor of OH (Kamaruzzaman et al., 2010). 
The study by Hiitola et al, reported that OH was only associated with the total number 
of medicines consumed but not with any particular antihypertensive medications or the 
number of cardiac medications (P. Hiitola et al., 2009). However, in Hiitola’s study the 
use of medicines was very high with participants taking up to 23 medications which 
suggest higher number of comorbidities and more likely the comorbidities associated 
with OH. To date, there have been no studies linking the dosage of antihypertensives 
with OH. 
To determine the association of antihypertensives with OH, the effects of 
antihypertensive withdrawal on OH has been evaluated in a handful of limited studies. 
Fotherby et al. withdrew antihypertensive therapy from 47 subjects with a blood 
pressure of 175/100mmHg or less and reported a decrease in prevalence of OH in the 
antihypertensive withdrawal group while the prevalence of OH remained unchanged in 
the group which continued their antihypertensive therapy but only after re-exclusion of 
those with a blood pressure of greater than 175/100mmHg (Fotherby et al., 1994). This 
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suggests that although antihypertensive withdrawal may be beneficial in reducing OH, it 
is not possible in patients with higher blood pressure readings. The antihypertensive 
therapy evaluated in this study consisted mainly of diuretics, CCB and β-blockers, as 
newer antihypertensive agents such as ARB were not yet available at the time of study. 
In another study where all cardiovascular medications (antihypertensives, anti-
arrhythmic and anti-anginal medications) were withdrawn, 78% of subjects reported 
improvements in symptoms of syncope and falls and the physical finding of OH. 
Furthermore, the renewal of medications was not necessary in 70% of the group (Alsop 
et al., 2001). However the criterion for antihypertensive withdrawal was that if the 
patient on antihypertensive therapy had a blood pressure of 120/80mmHg or lower 
suggesting that withdrawal only occurred in individuals with intensive antihypertensive 
therapy. 
Van der Velde et al also found the withdrawal of these culprit drugs to be 
effective in the resolution of OH. In addition, the withdrawal of cardiovascular drugs 
produced significantly larger reductions in OH than psychotropic medications and other 
drugs (van der Velde, van den Meiracker, et al., 2007). The authors mentioned that the 
drugs were only withdrawn if they were duplicative or if withdrawal was considered 
safe, but no clear cut-off values for blood pressure or duplicative classes on 
antihypertensives were mentioned. The above studies citing the reduction in OH with 
the withdrawal of antihypertensive agents did not include longitudinal follow up data on 
cardiovascular end-points or all-cause mortality. We are therefore unable to define the 
benefits of withdrawing antihypertensive agents and to the extent these drugs could 
safely be withdrawn. 
 The association of antihypertensives with OH differs according to individual 
classes of blood pressure lowering medications. Angiotensin converting enzyme 
 22 
 
inhibitors, ARBs and CCB are less likely to be associated with OH as compared to β-
blockers and thiazide diuretics. The “Predictive Values of Blood Pressure and Arterial 
Stiffness in Institutionalized Very Aged Population” (PARTAGE) study reported that β-
blockers had significantly higher impact on OH due to their increased sympathomimetic 
activity, while OH was less common among ARB users (Valbusa et al., 2012). 
Supporting this evidence, the TILDA study reported an association of OH with β-
blockers and α-blockers, while CCB were shown to be protective against OH. Except 
one study in which thiazides were found to be protective (Fisher et al., 2003), studies 
suggest that thiazides are associated with OH (Kamaruzzaman et al., 2010). A 
randomized, double blind trial comparing the use of an ARB and a thiazide diuretic 
with an ARB and a calcium channel blocker found that both combinations were equally 
effective in controlling high blood pressure, but the ARB and thiazide combination 
group was more likely to develop OH (Fogari et al., 2009). 
The evidence from older studies linking blood pressure lowering drugs to 
postural hypotension can be considered relatively out-dated as they were mostly 
performed while patients were on older hypertensive medications such as methyldopa, 
prazosin, thiazide diuretics or propranolol which had more side-effects and a higher 
propensity to cause OH. The newer antihypertensive agents such as ACE-I or ARB 
which have been developed in response to the unsatisfactory side-effects of older 
antihypertensive medications, now have fewer side-effects and better compliance 
profiles (Fogari et al., 2009). There is an urgent need for well-designed studies to 
measure the risk of adverse cardiovascular and mortality outcomes of withdrawal of 
blood pressure lowering therapy on falls and OH. 
The available studies on the association between antihypertensives, OH and falls are 
listed in table 2.2. 
 23 
 
 
c. Antihypertensives, Orthostatic hypotension and Hypertension 
While antihypertensives are used for the treatment of high blood 
pressure/hypertension, a highly prevalent pathology amongst older adults, the literature 
review could not be completed without taking this factor into account. An English study 
involving 3515 older individuals aged ≥64 years found that 81% of their nationally 
representative population fulfilled their criteria for hypertension during at least one time 
point, with 76% of those with untreated hypertension presenting with isolated systolic 
hypertension (Beckett et al., 2008). Isolated systolic hypertension in turn, has been 
found to be strongly associated with OH (Rutan et al., 1992). The increased pulse 
pressure and isolated systolic hypertension which is unique to hypertension in older 
people is presumed to add to the challenges of achieving blood pressure targets in older 
people, as lowering of systolic blood pressure could then lead to unacceptably low 
diastolic blood pressure with the increased potential of  adverse events.  
 
Table 2.2: Summary of Studies Evaluating the Relationship between Antihypertensive 
Medications with Falls and Orthostatic Hypotension. 
 
Reference 
 
 
Participants 
 
Study Design 
 
 
Findings 
Fotherby et al. 
1997 
(Fotherby et 
al., 1997) 
N=74,  ≥ 60 yrs 
Hospital patients  
Cross-Sectional 
study 
Orthostatic hypotension was not 
associated with antihypertensive 
treatment in elderly 
Ooi et al. 2000 
(Ooi et al., 
2000) 
844 people ≥ 65 yrs 
from nursing homes 
Prospective cohort 
study  
OH was not associated with first fall but 
among subjects with history of falls, those 
with orthostatic hypotension had an 
increased risk of recurrent falls [RR=2.1; 
95%CI (1.4-3.1)].  
Kario et al. 
2001 (Kario et 
al., 2001) 
N=266, ≥ 65 yrs 
community dwelling 
Prospective study Lower SBP on standing is associated with 
falls independently but OH is not 
associated with falls. Antihypertensive 
therapy does not increase the falls risk 
[RR=0.58; 95%CI (0.29–1.2)]. 
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Table 2.2 continued 
 
Heitterachi et 
al. 2002 
(Heitterachi et 
al., 2002) 
N=70, age =60-
92yrs  
community dwelling 
Prospective study OH was significantly associated with falls 
[RR=1.71, 95%CI (1.14-2.59)]. 
Antihypertensives were strongly 
associated with OH but not with falls 
[RR=0.91, 95%CI (0.60-1.51)]. Other 
causes of OH need to be evaluated as 
antihypertensives are not related with 
falls. 
Fisher et al. 
2003 
(Fisher et al., 
2003) 
N=119,  >80 yrs  
Residential care 
facilities 
Case control study There was no significant association 
between antihypertensives and OH 
[OR=0.8 CI (0.3–1.7)] and 
antihypertensives and falls [OR=0.8; 
95%CI (0.4–1.6)].  
Poon et al. 
2005 (Poon et 
al., 2005) 
N=342,  ≥ 75yrs, 
geriatric clinic 
Retrospective study Prevalence of OH increased with the 
increase in number of culprit medicines 
including antihypertensives prescribed 
[X2=15.18; p=0.002] and was predictor of 
falls. Study is about the whole culprit 
medication group but among 
antihypertensives thiazides were the most 
frequent used by patients having OH. 
Kamaruzaman 
et al. 2010 
(Kamaruzzama
n et al., 2010) 
N=4286 women, 
age= 60-80 years; 
community dwelling 
Cross-sectional sub 
study of a large 
prospective study 
OH was associated with three or more 
hypertensives [OR=2.24, 95% CI 1.47–
3.40, P < 0.001]. No other 
antihypertensives were associated with 
OH except beta blockers [OR=1.58; 
95%CI (1.19-2.09); p < 0.01]. This 
medication induced OH was not 
associated with falls. 
Gribbin et al. 
2010 
(Gribbin et al., 
2010) 
N=968, >65years 
primary care 
Prospective Case 
control 
study 
Thiazide diuretics were found to increase 
the risk of first fall significantly 
[OR=1.25; 95%CI (1.15–1.36)], no other 
antihypertensive showed any significant 
association with falls. 
Shuto et al. 
2010 (Shuto et 
al., 2010) 
N=349, , >65years  
hospital  
Case-Control study Antihypertensives were strongly 
associated with falls risk [OR=8.42; 
95%CI (3.12-22.72)].  As the patients are 
hospitalized, use of antihypertensive with 
another risk factor like frailty may lead to 
falls. 
Coutaz et al. 
2012 (Coutaz 
et al., 2012) 
N=388,  >65years  
hospital 
Cross- Sectional 
study 
Antihypertensive therapy does not 
increase the risk of falls even in the 
presence of OH. 
Wong et al. 
2013 
(Wong et al., 
2013) 
N=520,  >65years  
community dwelling 
Prospective cohort 
study 
Antihypertensive medications were not 
associated with falls [OR=1.05; CI (0.37–
2.93)]. Angiotensin system blocking 
medicines showed protective effects 
against falls [OR= 0.68; 95%CI (0.48–
0.97)] 
Butt et al. 
2013 
(Butt et al., 
2013) 
N=543,572 , >65yrs, 
population based 
Prospective study New antihypertensive users have 69% 
increased risk of having a fall [RR=1.94; 
95%CI (1.75-2.16)]. This finding was 
consistent for Thiazide diuretics, 
Angiotensin converting enzyme in 
inhibitors, Calcium channel blockers, β-
blockers but not for Angiotensin receptor 
blockers. 
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Table 2.2 continued 
Callisaya et al. 
2014 
(Callisaya et 
al., 2014) 
N=409, age= 60-86 
years, community 
dwelling 
Prospective 
population-based 
cohort study 
Antihypertensives as a group were not 
associated with falls however higher dose 
of antihypertensives was independently 
associated with greater fall risk [RR = 
1.07; 95%CI (1.02–1.11); p = .004). The 
risk was 48% higher in those with more 
than 3 times the daily defined dose 
[RR=1.48; CI (1.06–2.08); p=.02)]. 
Tinetti et al. 
2014 
(Tinetti et al., 
2014) 
N=4961, age 
≥70years,  
community-living  
Prospective 
population-based 
cohort study 
Antihypertensive medications by number 
or class were not associated with serious 
fall injuries but in participants with 
previous falls or injurious falls use of 
high intensity daily defined doses of 
antihypertensives were associated with 
serious fall injuries [HR=2.31; 95%CI 
(1.01-5.29)]. 
Kuschel et al. 
2014 (Kuschel 
et al., 2014) 
N=64399, ≥ 65 
years community 
living 
Case control study Twenty commonly prescribed medicines 
were tested and antihypertensives showed 
a protective effect against falls. The 
protective effect was highest for ACE-
Inhibitors and Calcium channel blockers 
Risks are presented as odds ratio (OR), risk ratio (RR) and hazard ratio (HR) with 95% confidence 
interval (CI). OH=orthostatic hypotension 
While randomized-controlled studies such as the “Hypertension in the Very 
Elderly Trial” (HYVET) have clearly demonstrated significant survival benefits in 
blood pressure treatment even among the very old participants (Beckett et al., 2008), 
opinions between clinicians do differ with respect to the how aggressively hypertension 
should be treated among older patients. Many geriatricians remain sceptical as 
participants of the HYVET study consisted of physically healthy older individuals who 
did not necessarily represent the average older person attending a geriatric service. The 
larger studies on OH and blood pressure control have reported uncontrolled 
hypertension to be markedly associated with OH more than the use of antihypertensive 
therapy. The British women heart and health study (BWHHS) involving 3775 women 
aged 60-80 years, related OH with uncontrolled hypertension by reporting the 
prevalence of OH to be 24% higher among  hypertensive women with a SBP 
>140mmHg than normotensive women (Kamaruzzaman et al., 2010). The observational 
cohort “Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized 
Very Aged Population” (PARTAGE) study involving 994 participants aged ≥80 years 
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also demonstrated the close association of OH with uncontrolled blood pressure by 
concluding that elderly with OH had significantly higher SBP and DBP than those 
without OH. On the other hand, both normotensive older individuals and those with 
well-controlled blood pressure (SBP≤ 140mmHg) had a lower prevalence of OH than 
those with SBP exceeding 140mmHg. The MOBILIZE Boston (Maintenance of 
Balance, Independent Living, Intellect and Zest in the Elderly of Boston) study 
involving 722 community dwelling adults aged 70 years and above showed that both 
OH and the risk of falls is 2.5 times higher in individuals with uncontrolled 
hypertension (≥140/90mmHg)  compared to those with controlled hypertension 
(Gangavati et al., 2011). 
The Irish Longitudinal Study on Ageing (TILDA) research group classified 
orthostatic hypotension into three groups; small drop with fast recovery, medium drop 
with slow recovery and large drop with no recovery. They found that severe OH with 
slow or no recovery was associated with uncontrolled systolic hypertension (Romero-
Ortuno et al., 2013). As previous studies had not evaluated the patterns of blood 
pressure drop in their OH subjects, the significance of the three classifications remains 
unclear. However, the study clearly showed the association of higher blood pressure 
readings with the severity of OH. The mechanism of association between uncontrolled 
hypertension and OH may be that the normotensive individuals and those with 
controlled hypertension have less arterial stiffness, improved baroreflex sensitivity and 
subsequently less OH as compared to individuals with uncontrolled blood pressure 
levels (Berni et al., 2011; Protogerou et al., 2008).  
While the above studies have demonstrated a significant association between 
uncontrolled hypertension and OH, the Austrian Vorarlberg Health Monitoring and 
Prevention Programme involving 3544 community living seniors aged 60 years 
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suggested the lower blood pressure readings or tightly controlled hypertension to be 
associated with falls by showing that the individuals with blood pressure >120/80 
mmHg had a significantly lower risk of falls compared to those with lower blood 
pressures. They reported that an increase in SBP of 10mmHg and DBP of 5mmHg is 
associated with a 9% reduction in falls risk (Klein et al., 2013). The values cited were 
lower than the recommended treatment targets for hypertension (>140/90mmHg) and 
sitting blood pressure was measured without considering postural blood pressure 
changes, suggesting that while controlled hypertension may be necessary to avoid OH 
and falls, a tighter blood pressure control may not be the best option for older adults. 
While, the above body of evidence suggests that OH is more prevalent among 
individuals with uncontrolled or untreated hypertension, there has been no published 
intervention study to date, determining whether effective treatment of hypertension can 
reduce the severity of OH. Among the frail elderly, even a slight drop in postural blood 
pressure may increase the propensity to fall due to the increase in postural instability as 
the  result of cerebral hypoperfusion (P. Hiitola et al., 2009). The available evidence 
therefore suggests that in robust older individuals, aggressive blood pressure lowering 
therapy is beneficial while in individuals with predilection to falls, blood pressure 
lowering therapy may increase the risk of falls in a dose dependent fashion. In frail 
individuals with a history of falls, blood pressure lowering therapy should be initiated 
and monitored cautiously, the withdrawal of antihypertensives among those with blood 
pressure of <140/90mmHg  may reduce the risk of falls in this particular group of older 
adults.  
d. Use of Antihypertensives to Manage Hypertension in Older Patients 
With conflicting evidence on the association between antihypertensives, OH and 
falls, the treatment of hypertension among older adults with history of falls warrants 
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careful attention. Figure 1 consists of a flow diagram on management of hypertension in 
older people based on current guidelines and available evidence. Prior to prescribing 
any blood pressure lowering treatment, the physician should take into account the 
factors of age, presence of other drugs, other existing pathologies and previous history 
of falls. Intensive blood pressure treatment should be prescribed among robust older 
individuals aged less than 80 years. In individuals aged 80 years and over, it is currently 
not advisable to treat high blood pressure aggressively. In individuals with established 
risk factors for falls, aggressive blood pressure lowering treatment should be avoided 
and in individuals previously on antihypertensive treatment with a treatment target of 
less than 140/90mmHg, their treatment targets should be revised to less than 150/90, 
and medication withdrawal considered. Close monitoring is required for the potential 
onset or exacerbation of OH in these individuals, particularly in the first month of 
initiation of therapy. The blood pressure lowering agents ARB, ACE-I and CCB should 
be used preferentially, especially among the high falls risk group, as diuretics and β-
blockers have been found to be associated with OH and falls and should be avoided in 
individuals at the risk of falls. Should any older individual on antihypertensive 
treatment sustain a fall, their blood pressure management should be revised, and 
treatment targets adjusted accordingly.  
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2.3.2. Anticholinergics 
Several drugs prescribed to older adults for their common medical conditions 
have anticholinergic properties; many drugs not usually denoted as anticholinergics as 
well as many over the counter drugs have shown strong anticholinergic activity. The 
prevalence of anticholinergics among the elderly is quite high, prospective 
epidemiological studies among community dwelling older adults have reported the 
prevalence of medications with anticholinergic properties to be  48% in Europe (Fox et 
al., 2011) 50% in America (Carriere et al., 2009) and 52.66 % in New Zealand (Narayan 
et al., 2013). According to prospective studies on nursing homes, 24% of the French 
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while 46.1% of the Italian participants were on atleast one medication with 
anticholinergic activity (Beuscart et al., 2014; Landi et al., 2014). Amitriptyline, 
nortriptyline, oxybutynin (Narayan et al., 2013) and hydroxyzine (Beuscart et al., 2014) 
are the commonly prescribed drugs among the elderly with significant anticholinergic 
potency. 
Anticholinergic drugs are the most widely used inappropriate drugs by older 
population. A cross-sectional study identified that approximately one in ten older adults 
used anticholinergic medications considered as inappropriate, the most frequently used 
inappropriate anticholinergics were cyclobenzaprine, promethazine, amitriptyline, 
hydroxyzine and dicyclomine according to Beers’ criteria (Kachru et al., 2015). 
Anticholinergic burden is associated with poor mobility, functional decline, 
psychomotor slowing, and cognitive impairment and falls (Cao et al., 2008; Landi et al., 
2014; Nebes et al., 2007). Newer studies have related anticholinergic drugs with 
increased hospitalisations (Salahudeen et al., 2014) cardiovascular diseases and 
mortality (Fox et al., 2011; Myint et al., 2015). 
2.3.2.1 Anticholinergic burden and falls 
 
Several studies have linked the anticholinergic activity of drugs to falls among 
older adults (Aizenberg et al., 2002; Dauphinot et al., 2014; Wilson et al., 2011). The 
meta-analysis of eighteen studies determined that a greater use of drugs with 
anticholinergic activity was significantly associated with falls, in particular, olanzapine 
and trazodone were associated with the highest risk of falls (Ruxton et al., 2015). 
However, it may be the cumulative damage from multiple small dose anticholinergics 
rather than single high dose drugs which markedly increased the risk of falls (Parkinson 
et al., 2015). While prescribing a new drug or providing medication reviews the 
collective anticholinergic burden might be overlooked because these drugs belong to 
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different chemical classes or the patient might be taking over the counter drugs that may 
increase the risk of falls extensively. Although studies on the association of 
anticholinergics and falls are performed in different settings using different tools to 
measure anticholinergic effect, they depict a positive association between 
anticholinergics and falls. Table 2.3 gives a summary of studies showing the association 
of anticholinergics with falls using different tools.  
2.3.2.2. Possible mechanisms of anticholinergic associated falls: Gait and 
Balance 
While substantial evidence exists for anticholinergics to be strongly associated 
with falls, there are more than one plausible mechanism behind the association between 
anticholinergics and falls. Anticholinergics are well known for their cognitive 
impairment effects on older adults (Cao et al., 2008; Carriere et al., 2009; Fox et al., 
2011; Landi et al., 2014; Salahudeen et al., 2014) which itself is an independent 
predictor for falls (Harlein et al., 2011; Vieira et al., 2011). They may also lead to falls 
through their immediate effects i.e. mydriasis (leading to blurred vision), dizziness, 
urinary hesitancy, confusion, sedation, and inability to concentrate (Feinberg, 1993). A 
substantial number of studies have shown higher anticholinergic burden of drugs to be 
associated with the negative impact on gait and balance, poor physical performance and 
general functional decline (Cao et al., 2008; L. Han et al., 2008; Landi et al., 2014; 
Nebes et al., 2007; Pasina et al., 2013). Reduced muscle strength and gait and balance 
impairment is a major independent predictor of falls (M. E. Tinetti et al., 2010), most of 
the falls studies have employed TUG and FR as sensitive and specific measures for 
identifying functional performance including dynamic balance and gait disturbances 
among community dwelling adults (Desai et al., 2010; Shumway-Cook et al., 2000). 
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Table 2.3: Association of anticholinergic load of drugs with falls. 
 
Reference 
 
Study 
Design 
 
Participants (n) 
Scale 
Used 
 
Association with Falls 
Aizenberg 
et 
al(Aizenber
g et al., 
2002) 
Case-Control 
Study 
n=482, age≥65 yrs 
Hospital Setting 
ABS ABS score was significantly 
associated with falls (p  <0.05). 
Rudolph et 
al(Rudolph 
et al., 
2008) 
Cross 
sectional 
N=117 
age≥65 yrs 
Primary care 
ARS Higher ARS score wad 
significantly associated with falls 
(1.5; 95% CI, 1.3-1.8 p<0.001) 
Wislon et 
al(Wilson 
et al., 
2011) 
Longitudinal N=602 
age≥70 yrs 
Residential Care  
DBI Incidence rate ratios of falls were 
1.69 (95% CI, 51.22–2.34) for 
low DBI (<1) and 2.11 (95% CI, 
51.47–3.04) for high DBI (≥1). 
Dauphinot 
et 
al(Dauphin
ot et al., 
2014) 
Longitudinal N=337 
age≥65 yrs 
Hospital Setting 
 
DBI Increased DBI during hospital 
stay was associated with falls 
with a hazard ratio, 2.9; 95%CI, 
1.14–7.12 ;p =0.03). 
Landi et 
al(Landi et 
al., 2014) 
Prospective  N=1490 
age≥65 yrs 
Nursing Homes 
ARS Higher score on ARS was 
associated with falls with odd 
ratio 1.26; 95%CI, 1.13-1.41; 
p<0.05 
Salahuddin 
et 
al(Salahude
en et al., 
2014) 
Pharmacoepi
demiological  
study. 
N= 537,387 
age≥65 yrs 
Population based 
9 
published 
scales 
Anticholinergic burden scores 
according to all nine scales were 
significantly associated with falls 
related hospitalizations. 
Yayla et 
al(Yayla et 
al., 2015) 
Cross 
Sectional 
N=563, age≥65 yrs 
Primary Care patients 
ARS Mean number of falls among 
anticholinergic drug users for a 
mean duration of 3.17 years were 
1.14±1.17. 
ABS=Anticholinergic burden scale, ARS=Anticholinergic Risk scale, Drug Burden Index 
Gait and balance is an outcome coordinated by the central nervous system 
involving various systems of the body. The blockade of acetylcholine transmission in 
the CNS has been related to widespread undesired adverse effects, including reduced 
executive and motor functions (Kersten et al., 2014) and overall reduced performance 
on general daily activities (Chew et al., 2008).  Another physiological explanation 
behind the association of anticholinergics with impaired physical function is the high 
sedative load of anticholinergics, generally defined as the cumulative effect of taking 
multiple drugs with sedative properties, leading to both acute and chronic decline in 
mobility and function. In addition, Taipei et al suggested that a higher sedative load was 
associated with significantly impaired balance as well as a longer time required to 
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perform the TUG test (Taipale et al., 2011). Moreover, Buchner his review article stated 
that anticholinergics have an effect on physical performance and activity due to their 
sedative effects leading to weak muscle strength due to disuse atrophy of muscles and 
subsequently causing falls (Buchner, 1997). Even when diverse measurement methods 
are employed, the anticholinergic burden is significantly associated with deterioration in 
physical function as well as gait and balance. Table 2.4 shows the list of studies 
showing the association between anticholinergics and poor functional scores which 
subsequently leads to falls.  
2.3.3. Others: Central Nervous system (CNS) drugs, Analgesics, 
Antidiabetics 
Drugs affecting the CNS are the medications most commonly associated with 
adverse drug events. Older adults on CNS drugs are almost 10 times more likely to fall 
(Costa-Dias et al., 2014), sustain recurrent falls (van Strien et al., 2013)  and fall injuries 
(Kuschel et al., 2014). Among all the CNS drugs, psychotropics are independent risk 
factors for in falls (Lawlor et al., 2003; Souchet et al., 2005) and injurious falls 
(Stenbacka et al., 2002) in a dose dependent manner (C. H. Chan et al., 2013).  
Different studies have identified antianxiety (Shuto et al., 2010; Sterke et al., 2008; 
Tanaka et al., 2008; van Strien et al., 2013) antidepressants (Costa-Dias et al., 2014; 
Kallin et al., 2002; Lawlor et al., 2003; Sterke et al., 2008; van Strien et al., 2013) and 
sedatives/ hypnotics (Lawlor et al., 2003; Shuto et al., 2010; van Strien et al., 2013; Wu, 
Chie, Yang, Kuo, et al., 2013) to be strongly associated with falls. Psychotropic drugs 
contribute to falls through their cardiac side-effects (Mehta et al., 2011) and central 
nervous system effects of  sedation, dizziness, drowsiness and orthostatic hypotension 
(C. H. Chan et al., 2013; Wilson et al., 2011), as they act on receptors both centrally and 
peripherally. Rodriguez et al found that the increase in the serum levels of 
antidepressants is a significant contributor of OH (Rodriguez de la Torre et al., 2001), 
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while in another study 75% of patients reported OH after treatment with antipsychotic 
drugs (Mackin, 2008). Moreover, there is a significant association of psychotropic 
medications and sensorimotor functioning leading to postural instability resulting in 
falls (Lord et al., 1995).  
Table 2.4: Studies showing the effect of anticholinergic load on poor physical 
performance. 
Reference 
 
Study 
Design 
Participan
ts (n) 
 Scale Used Findings on the association of ACB 
with physical function, gait and 
balance 
Taipale et 
al(Taipale 
et al., 
2012) 
Cross 
Sectional  
n=700 
age≥75 yrs 
Community 
dwelling 
TUG, 
Berg Balance 
scale, 
Walking 
speed 
Timed Up and Go test (P = 0.005), slower 
walking speed (P = 0.0003), longer time to 
perform and lower scores on Berg Balance 
Scale (P =0.005) were associated with 
anticholinergic burden. 
Pasina et al 
(Pasina et 
al., 2013) 
Prospective N=1380 
age≥65 yrs 
Hospital 
Setting 
Barthal Index Anticholinergic burden by ARS was 
associated with poor functional 
performance scores for activities of daily 
living. 
Han et al 
(L. Han et 
al., 2008) 
Prospective N=544 men 
age≥65 yrs 
Community 
dwelling 
IADL scale Cumulative anticholinergic exposure across 
multiple medications over 1 year may 
negatively affect executive function in older 
men causing deterioration of activities of 
daily living. 
Landi et 
al(Landi et 
al., 2014) 
Prospective  N=1490 
age≥65 yrs 
Nursing 
Homes 
IADL scale A higher score of anticholinergic burden in 
the ARS scale was associated with a greater 
likelihood of functional decline (described 
as the loss of  ≥1ADL point) 
Nebes et 
al(Nebes et 
al., 2007) 
Cross-
sectional 
N=90 
Mean age= 
72 yrs 
 
simple 
response-time 
task, 
Walking 
speed 
Higher serum anticholinergic activity 
(SAA) was associated with a significant 
slowing in both gait speed and simple 
response time. 
Cao et 
al(Cao et 
al., 2008) 
Cross-
sectional 
N=932 
women 
age≥65 yrs 
Nursing 
Homes 
ADL scale, 
chair stands, 
mobility and 
balance, gait 
speed, grip 
strength 
Anticholinergic drug burden was 
independently associated with greater 
difficulty in four physical function domains 
for balance & mobility difficulty; slow gait; 
chair stands difficulty; weak grip strength; 
upper extremity limitations; and difficulty 
in activities of daily living. 
Bostock et 
al(Bostock 
et al., 
2013)  
Prospective N=271 
Mean age= 
83 yrs 
Hospital 
setting 
BI The use of anticholinergic drugs showed 
independent associations with lower BI, 
shoeing a decreased performance in 
activities of daily living 
Lowry et 
al(Lowry et 
al., 2012) 
Prospective N=362 
age≥65 yrs 
Hospital 
setting 
BI Higher score of anticholinergics and 
sedatives were associated with lower score 
of BI, indicating a decrease in activities of 
daily living 
Lampela et 
al(Lampela 
et al., 
2013) 
Cross-
sectional 
N=621 
age≥65 yrs 
population-
based 
SAA Anticholinergic drug burden was inversely 
associated with activities of daily living and 
instrumental activities of daily living. 
TUG=Timed up and Go, ADL=Activities of daily living, BI=Barthal Index, SAA= Serum Anticholinergic Activity 
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While the persistent use of psychotropics leads to falls and fractures in the 
elderly (Vitry et al., 2010), the start of a new drug (C. H. Chan et al., 2013) or the dose 
increment of an old psychotropic drug may be associated with 3.4 fold increase risk of 
falls (Sorock et al., 2009). Echt et al. supported these findings by demonstrating that the 
start or dose titration of any new psychotropic was significantly associated with falls 
within the first seven days (C. H. Chan et al., 2013; Echt et al., 2013). While SSRI are 
considered safer compared to TCA because of fewer cardiovascular side effects, they 
pose the same increase in the risk of falling in the elderly (Wilcock et al., 2005). In one 
study where 54.7% of participants were using SSRI and 31.6% were taking TCA, SSRI 
were found to be associated with falls instead of TCA, while trazodone, venlafaxine, 
mirtazapine were associated with most adverse outcomes (Coupland et al., 2011). 
Benzodiazepines are considered the culprit medicines for falls, fracture associated falls 
(Formiga et al., 2008; Wahab et al., 2012). The short acting benzodiazepines are 
considered to counter the side effects of the older long acting drugs but the safety 
profile of these newer agents against falls have yet to be firmly established. One study 
showed that short acting benzodiazepines pose the same risk falls as are long acting 
benzodiazepines (van Strien et al., 2013) while another showed that short acting 
benzodiazepines are more likely to cause falls than long acting benzodiazepines when 
taken in same dosages (Shuto et al., 2010; van Strien et al., 2013).  
Drugs prescribed for Parkinson’s disease are also considered to be strongly 
associated with falls by the mechanism of OH and mental confusion (Shuto et al., 2010; 
Tanaka et al., 2008). Muscle relaxants are associated serious falls in elderly patients by 
causing weakness and drowsiness (Coutinho et al., 2008). Narcotic analgesics (Costa-
Dias et al., 2014) and anticonvulsants (Vieira et al., 2011) are also among the drugs 
significantly associated with falls through their CNS effects. 
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Diabetes is one of the commonest pathologies among older adults; antidiabetics 
have shown to increase the risk of falls and their recurrence in some studies (Costa-Dias 
et al., 2014). While a tight glycaemic control is vital in reducing all the diabetes related 
complications as well as falls adults (Schwartz et al., 2008), hypoglycaemia is also 
related to fracture associated falls, the association of antidiabetics with falls may be 
attributed to hypoglycaemia (Johnston et al., 2012). Among oral antidiabetics, 
metformin is indirectly associated with falls by causing vitamin B12 deficiency while 
thiazolidinediones are associated with fracture associated falls due to their effects on 
bone (Wu, Chie, Yang, Kuo, et al., 2013) tissue (Mayne et al., 2010). Insulin therapy 
also significantly increases the risk of falls in older adults (Schwartz et al., 2008).  
2.4. Polypharmacy 
 
There is an extensive body of evidence linking increasing age and adverse drug 
events with polypharmacy. In the absence of consensus definition various authors have 
termed polypharmacy as the total number of medications or use of multiple medications 
(Bushardt et al., 2008); published papers have used varying cut-offs for polypharmacy 
ranging from 2 to 9 medications (Hajjar et al., 2007), with the definition of “use of four 
or five drugs by the patient” most frequently employed in the falls literature (Bushardt 
et al., 2008; Wyles et al., 2005). Existing definitions may or may not include over the 
counter and complementary treatments. Table 2.5 lists the published definitions used to 
define polypharmacy among older adults.  
Polypharmacy in a patient can occur for the treatment of one disease or several 
diseases. Polypharmacy, however, may be necessary in the older population with 
multiple pathologies in view of clear substantiation on improved clinical endpoint for 
diseases effecting mainly older people like ischaemic heart disease, stroke, diabetes and 
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hypertension (Bushardt et al., 2008). In addition, the use of combination therapy is 
considered essential for the standard treatment for conditions like diabetes, tuberculosis 
and AIDS (Aronson, 2006). However, the risk of cumulative side effects and drug 
interactions with multiple medications and multiple pathologies persists, even if an 
older individual is prescribed polypharmacy for clinically justified reasons. 
 
Table 2.5: List of Previously Published Definitions for Polypharmacy. 
Reference Definitions of polypharmacy 
Veehof et al. 
(Veehof et al., 
2000) 
A long-term (240 days a year) simultaneous use of two or more drugs. They 
classified polypharmacy as minor (2-3drugs), moderate (4-5 drugs) and major 
(>5drugs). 
Brager et al. 
(Brager et al., 2005) 
The use of two or more medications to treat the same condition or the use of 
two or more drugs of the same chemical class; or the use of two or more agents 
with the same or similar pharmacologic actions to treat different conditions. 
Ziere et al. (Ziere et 
al., 2006) 
Use of four or more medications with at least one inappropriate/ fall risk 
increasing medication. 
Slabaugh et al. 
(Slabaugh et al., 
2010) 
Simultaneous use of five or more medications occurring for at least one day. 
Hovstadius et al. 
(Hovstadius et al., 
2010) 
The use of multiple drugs with ≥5 drugs was termed as polypharmacy while the 
use of ≥ 10 drugs was termed as excessive polypharmacy occurring within a 
period of three months. 
Kamaruzzaman et 
al. (Kamaruzzaman 
et al., 2010) 
The intake of more medications by a patient than is clinically justified. 
 
The term polypharmacy has also been used interchangeably with inappropriate 
polypharmacy due to prescribing of drugs considered inappropriate for older individuals 
(Bushardt et al., 2008). The presence of polypharmacy leads to an increased risk of 
inappropriate prescribing and inappropriate omission of medications and vice versa 
(Taro Kojima et al., 2012; Steinman et al., 2006). Therefore, some authors have 
employed terms of appropriate or “rational” and inappropriate or “irrational” 
polypharmacy with rational polypharmacy being justified among older people because 
of the existence of multiple pathologies (Brager et al., 2005; Hammond et al., 2013). 
With the advent of evidence-based prescribing for long-term pathologies, however, 
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physicians caring for older individuals often find it impossible to prescribe less than 
four or five medications (Hammond et al., 2013). There is currently inadequate 
evidence on the ratios of the risk of prescribing multiple medications versus the 
potential benefits of prophylactic treatments to inform the determination of a standard 
“cut-off” for polypharmacy among older adults. 
2.4.1.  Prevalence, Risk factors and Consequences 
Polypharmacy is prevalent among the geriatric population, one Italian study on 
older adults reported that 39.4% of their sample was exposed to at least one episode of 
polypharmacy which substantially increased with age and with higher number of 
chronic conditions (Slabaugh et al., 2010). The prevalence was even higher in an 
Austrian study where 58% of their older participants fulfilled the criterion for 
polypharmacy (Schuler et al., 2008). The trend towards polypharmacy is increasing 
with time, the prevalence of polypharmacy and excessive polypharmacy increased by 
8.2% and 15.7% respectively during 2005-2008 in Sweden (Hovstadius et al., 2010) 
while it increased by 17.8% to 60.4% respectively during 1997 to 2012 according to an 
Irish study (Moriarty et al., 2015). A study from New Zealand analyzing the 
pharmaceutical collections maintained by the Ministry of Health from 2005 to 2013, 
found a significant increase in polypharmacy (29.5 vs. 23.4%) and excessive 
polypharmacy (2.1 vs. 1.3%) during this time period (Nishtala & Salahudeen, 2014).  
Old age, female gender and increased number of comorbidities increase the risk 
for polypharmacy (Jokanovic et al., 2015; Nishtala & Salahudeen, 2014; Pan et al., 
2014). Polypharmacy in older people is often viewed in a negative light due to the 
increased risk of adverse events including generalised worsened physical and 
psychological health leading to increased hospital visits (Nguyen et al., 2006; 
Swanenburg et al., 2010).  The consequences of polypharmacy are increased risk of 
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inappropriate prescriptions as well as inappropriate omissions of drugs, drug 
interactions and non-adherence with drugs in older adults with complicated medication 
regimens, cognitive impairment, functional decline, falls, urinary incontinence, 
malnourishment and mortality (Fried et al., 2014; Hajjar et al., 2007; Jyrkka et al., 2009; 
Maher et al., 2014). Polypharmacy, especially inappropriate polypharmacy is also 
associated with increased costs due to drug-related morbidity, dependence and mortality 
(Tamura et al., 2012). 
2.4.2. Polypharmacy and Falls 
Polypharmacy has been considered as a significant risk factor for falls among 
the older population (Wu, Chie, Yang, Liu, et al., 2013) fractures associated with falls  
(S. W. Lai et al., 2010; Pan et al., 2014) and injuries (Baranzini et al., 2009). The falls 
studies have suggested that multiple number of drugs or the cut-off of ≥4 or ≥5 
medications are independently associated with falls, while the falls risk intensely 
increases with the use of 5 or more medications (Baranzini et al., 2009; Buatois et al., 
2010; Freeland et al., 2012; Tromp et al., 2001). Hammond et al. stated that there 
appears to be a stronger link between falls and the type of medications taken e.g. FRID, 
rather than polypharmacy on its own (Hammond et al., 2013).The reason that the risk of 
falls increases linearly with the increase in the number of medicines is the increase in 
FRID associated with polypharmacy which predisposes an older person to falls 
(Swanenburg et al., 2010).  
Different tools have been developed by the researchers to assess adverse events 
due to polypharmacy among older people. The “GerontoNet Score” can predict the 
increased risk of adverse drug events with the increase in score which includes number 
of comorbidities, number of drugs, heart failure, renal failure, liver disease and previous 
adverse drug reactions (Onder et al., 2010). Similarly, the Medication Regimen 
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Complexity Index (MRCI) can assess the complexity of medication regimen depending 
on dosage of drugs (McDonald et al., 2013). However, FRID differ from those drugs 
associated with adverse drug events among older people, there being no published tool 
to assess the risk of falls by taking into account the presence of polypharmacy, FRID, 
other risk factors for falls and concomitant illness.  
The published studies uniformly demonstrate significantly increased risk of falls 
with polypharmacy despite the variable definitions used. In a longitudinal survey of 
diabetic people, the users of four or more prescription medications were twice as likely 
to fall than those who consumed one or two prescription medications (E. S. Huang et 
al., 2010). The longitudinal study Concord Healthy and Ageing in Men Project 
(CHAMP) study suggested the use of five or more medications to be associated with the 
increased risk of falls (Gnjidic et al., 2013). One hospital based study including patients 
≥60 years explained the pathway of polypharmacy associated falls by reporting that 
polypharmacy increases the prevalence of drug-drug interactions and FRID, both of 
which are strongly associated with falls and this association is stronger in case of frail 
than robust older adults (Bennett et al., 2014). Table 2.6 summarises the findings of 
available studies relating polypharmacy with falls. 
2.5. Potentially Inappropriate Prescriptions (PIP)  
The increase in number of medicines is not only associated with adverse drug 
reactions, but also increases the risk of inappropriate prescribing by the physicians 
(Mamun et al., 2004). However, studies have established that the number of 
medications is not as important as the number of potentially inappropriate drugs 
(Schuler et al., 2008; Tamura et al., 2012). A systematic review of 19 studies concluded 
that one in five prescriptions issued to elderly persons in primary care is inappropriate. 
Medications with largest rate of PIP were propoxyphene, doxazosin, diphenhydramine 
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and amitriptyline (Opondo et al., 2012). Among older adults, medicines are considered 
“inappropriate” if  they are prescribed at inappropriately higher doses or for longer time 
periods than recommended and if the choice of drugs is inappropriate i.e. when the risk 
of treatment potentially outweighs the benefits or when it can potentially interact with 
any existing pathology or drug, if prescribed while contraindicated, or if duplication 
therapy exists (O'Mahony et al., 2008; Wyles et al., 2005). It also includes non-
compliance or the omission of medications in the presence of a valid indication (M. 
Chan et al., 2001).  
In one study on inappropriate prescribing, unnecessary drugs were found to be 
prescribed in 36.3% of all patients, drugs to avoid (Beers criteria) in 30.1%, duplication 
in 7.6%, wrong dosage in 23.4% and possible drug-drug interactions in 65.8% (Schuler 
et al., 2008). In another study involving community dwelling seniors aged ≥ 65years 
who consumed five or more medications daily, 65% were using one or more 
inappropriate medications, 57% were taking medicines which were ineffective, not 
indicated or therapeutically duplicative while 37% were on drugs considered 
inappropriate according to the Beers’ criteria (Steinman et al., 2006). It is agreed that 
the adverse events and consequent emergency department visits due to inappropriate 
prescribing are the most potentially avoidable/preventable events (M. Chan et al., 2001; 
Nickel et al., 2013; Opondo et al., 2012). The reason is that they are due to drugs 
already considered to be inappropriate for elderly or due to recognised drug-drug 
interactions and hence the risk of prescribing those drugs is already known (Juurlink et 
al., 2003). Due to higher incidence of hospitalisations and higher use of unnecessary 
medications, PIP is associated with greater health care utilization rates and costs 
(Akazawa et al., 2010).   
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Table 2.6: Summary of Studies on the Association between Polypharmacy and Falls 
among the Older Population. 
Reference 
 
Study 
Design 
Participants (n) Polypharmacy 
definition 
Falls risk* 
≥ 4 drugs/day 
Tromp et 
al;2001(Trom
p et al., 2001) 
Prospective n=1285; ≥65 yrs 
Community 
dwelling 
≥4 drugs/day Falls [OR=1.3; CI (1.0-1.7); p<0.05] 
Recurrent falls [OR=1.5; CI (1.0-2.3); 
p<0.05] 
Ziere et al; 
2006(Ziere et 
al., 2006) 
Cross-
sectional  
 
n=6928  
Median age 70.6 yrs 
Community 
dwelling 
≥4 drugs/day 3 drugs/day [OR=1.4; CI (1.1-2)]  
4 drugs/day + 1 falls risk[OR=1.6; CI 
(1.1-2.1)]  
Buatois et al; 
2010(Buatois 
et al., 2010) 
Prospective n=1618; ≥ 65 yrs 
Community 
dwelling 
≥4drugs/day OR=1.66; CI (1.06–2.60); p=0.025 
Freeland et 
al;2012(Freel
and et al., 
2012) 
Longitudinal n=118;  ≥65yrs 
Community 
Dwelling 
≥4 drugs/day OR=1.14; CI (1.02-1.27); p=0.02 
each additional medication= 14%  
fall risk 
Mizukami et 
al;2013(Mizu
kami et al., 
2013) 
Cross-
sectional 
n=602; ≥ 65 yrs 
Community 
Dwelling 
≥4prescription 
drugs/day 
OR=2.6; CI (1.1-6.6); p < 0.05 
Wu et al; 
2013(Wu, 
Chie, Yang, 
Liu, et al., 
2013) 
Cross- 
sectional  
n=671;  ≥65yrs 
Community hospital 
≥4 drugs OR=2.08; CI (1.17-3.70); p<0.05 
≥5 drugs/day 
Nishtala et 
al;2014(Nisht
ala, Narayan, 
et al., 2014) 
Cross-
sectional 
n=537387; ≥ 65 yrs 
Community 
Dwelling 
≥5 drugs/day RR=1.792 ; CI (1.659–1.936); p<0.05 
Kojima et 
al;2012(T. 
Kojima et al., 
2012) 
Longitudinal n=17276; ≥65yrs 
Community 
Dwelling 
≥5 drugs/day No. of drugs [OR=1.30; CI (1.08-1.57); 
p <0.05]  
≥5/day[OR=4.5; CI (1.7-12.2); 
p<0.0005] 
Gnjidic et 
al;2012(Gnjid
ic et al., 2012) 
Longitudinal 
 
n=1705;  >70yrs 
Community 
dwelling 
≥5 drugs/day  OR=1.7; CI (1.03-1.12); p=0.002 
Number of Medications 
Formiga et 
al;2008(Formi
ga et al., 
2008) 
Cross-
sectional  
n=1225; ≥65yrs 
Hospital based 
No. of 
prescription drugs 
OR=1.123; CI (1.069-1.181); p=0.0001 
Corsinovi et 
al;2009(Corsi
novi et al., 
2009) 
Longitudinal  
 
n=62;  ≥65 yrs 
Geriatric hospital 
No. of 
medications 
RR=1.226; β=0.204; CI (1.22-1.340); 
p<0.001 
OR=Odds ratio; RR= Relative Risk; CI= 95% Confidence Interval  
Ϯ OR & RR are reported for risk of falls occurrence unless otherwise specified 
 
 
Prevalence studies in older people in Ireland have shown rates of prescription of 
one or more PIP as 22% in the primary care setting, 35% in acute hospital care and 60% 
in nursing home care using the STOPP criteria (O’Mahony et al., 2010). A Serbian 
study involving older primary care patients with one or more prescribed medications, 
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found the prevalence of PIP as 27.3% while patients with more than four prescriptions 
had a higher risk for PIP (Vezmar Kovacevic et al., 2014). The prevalence of PIP in 
hospitalized Taiwanese elderly was 63.8% while in the community health centre was 
27.5% according to Beers criteria (H.-Y. Lai et al., 2009; Lin et al., 2011). A 
retrospective community Japanese study involving 6628 adults aged ≥65 years, reported 
that 43.6% were prescribed at least one PIP according to Beers criteria (Akazawa et al., 
2010).  
So far, the most convincing evidence for PIP exists for  psychotropic medications 
which are commonly inappropriately prescribed to the elderly over past 50 years 
(Dell’osso et al., 2013). An analysis of 2.5 million Medicare beneficiaries living in 
nursing homes showed that 27.6% of residents were receiving at least one psychotropic 
drug with only 41% compliance to the available prescribing guidelines while the 
remaining 60% were being prescribed these medications without proper indications, as 
duplicative drugs with different trade names or in inappropriate doses (Briesacher et al., 
2005). Long-acting benzodiazepines are the most common PIP among the 
psychotropics, other classes of PIP identified according to studies are, antihistamines, 
muscle relaxants/ antispasmodics and anticholinergics (Akazawa et al., 2010; H.-Y. Lai 
et al., 2009; Lin et al., 2011; Vezmar Kovacevic et al., 2014). 
A Malaysian study identified 23.7% of PIP among their participants according to 
STOPP criteria while 32.7% according to Beers criteria. The common PIP identified 
were nifedipine, chlorpheniramine and diphenhydramine, antihistamines, duplication of 
drug classes, glibenclamide and anticholinergic agents. Higher number of medications 
and longer stay at nursing home were identiﬁed as predictors of PIP for both Beers and 
STOPP criteria (Chen et al., 2012).  None of the study on the prevalence of PIP has 
been performed among older community residents or hospitalised elderly. 
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While Beers’ criteria has been widely used in the international literature, various 
other tools have also been developed to assess the inappropriateness of prescribing 
amongst older adults e.g. IPET (Improving Prescribing in the Elderly Tool), MAI 
(medication appropriateness index) and STOPP/START, the prevalence of PIP varies 
according to the applied criterion. Caution should be exercised in applying these criteria 
developed in other regions where medication availability in the local market may be 
limited. Therefore, the criteria with more categories and a higher percentage of local 
market drug availability tend to detect more PIP (C. B. Chang et al., 2011). 
Recent literature has shown STOPP to be superior to Beers’ criteria in detecting 
PIP among older adults in all health care settings, although there were some differences 
across settings (Conejos Miquel et al., 2010). Prospective data showed that STOPP 
criteria detected adverse drug effects that were causal or contributory to acute 
hospitalisation in older people 2.8 times more frequently than Beers’ criteria 
(O’Mahony et al., 2010). A systematic review of 19 studies involving older adults 
having at least one inappropriate medication found that 78.9% of studies were 
conducted in the USA, 73.7% of those used Beers criteria while the rest used Zhan, 
which is derived from on Beers criteria (Guaraldo et al., 2011). However Beers’ criteria 
has limited application outside the US settings, a systematic review found that the 
STOPP criteria is not only more sensitive but it has also been used to review the 
medication profiles in Europe, Asia and North America amongst community dwelling, 
acute care and long-term care older patients (Hill-Taylor et al., 2013). One prospective 
hospital study on 744 adults aged >65 years and regular intake of drugs found that 
STOPP identified almost twice the number of hospital admissions (11.5%) as compared 
to Beers’ criteria (6%) (Gallagher et al., 2008). 
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2.5.1. Potentially Inappropriate Prescriptions and Falls 
Studies involving older adults using one or more medications at baseline have 
identified that elderly with PIP have a significantly increased risk of falls, however, 
none of the studies have assessed the association between PIP and recurrent falls. While 
PIP is significantly associated with adverse drugs events among older adults, table 2.7 
shows the list of those studies which found that some classes of FRID are the 
commonest PIP among older adults. 
2.6. Role of Comorbidities in fallers with Chronic and Multiple 
medications 
Medications are prescribed in response to a disease, the prevalence of diseases 
among the older population is higher with around 92% of all older adults having at least 
one chronic disease (Sibley et al., 2014), 60% of hospital patients have at least one 
comorbidity and 37% have two or more. Multimorbidity, the coexistence of two or 
more chronic conditions also becomes prevalent with increasing age with 84% of adults 
aged over 65 years having two or more chronic conditions as compared to 35% of those 
aged 45 to 65 years (Page et al., 2010). A population-based study identified that 67% of 
the older adults had multimorbidity, which increased with age, from 50% for persons 
under age 65 years to 62% for those aged 65–74 years and 81.5% for those aged ≥85 
years (Salive, 2013). Multimorbidity is strongly associated with the risk of adverse drug 
events among older people (Evans et al., 2005; Salive, 2013), the existence of three or 
more comorbidities increases the risk for having a severe adverse drug event by 2.9–
12.6-fold (Page et al., 2010). Moreover, multimorbidity is associated with elevated risk 
of death, disability, poor functional status, poor quality of life (Salive, 2013).  
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Table 2.7: Studies showing PIP and drugs associated with falls among older adults. 
Reference 
 
Study 
Design 
Participants 
(n) 
PIP Criteria Association with Falls 
Eager et 
al(Egger et 
al., 2006) 
retrospectiv
e cross-
sectional 
study 
800 patients 
aged > or =65 
years Hospital 
patients 
Beers criteria This was largely because of a higher 
prescription rate of platelet aggregation 
inhibitors in combination with low-
molecular-weight heparins and 
benzodiazepines in patients with a history of 
falls and syncope.  
Berdot et 
al(Berdot et 
al., 2009) 
Prospective
, 
Multicentre 
n=6343; ≥ 65 
yrs 
Non-
institutionalized 
elderly selected 
by electoral 
roles 
Beer’s criteria PIP users had an increased risk of falling 
which was due to long-acting 
benzodiazepines (OR=1.4; 95%CI, 1.1–1.0), 
other psychotropics (OR, 1.7; 95%CI 1.7–
2.7) medication with anticholinergic 
properties (OR = 1.6; 95%CI, 1.2–2.1). 
Fiss et al 
(Fiss et al., 
2011) 
Prospective n=744; ≥65 yrs, 
Community 
dwelling, 
regular intake of 
drugs. 
Beer’s criteria The intake of PIP was associated with falls 
(φ: 0.1074; P= 0.0244). 
Dalleur et al 
(Dalleur et 
al., 2012) 
cross-
sectional 
study 
hospital302 
 frail older 
persons 
STOPP  PIMs (prevalence 48%) mainly involved 
benzodiazepines, aspirin and opiates. PIP 
related admissions were associated with falls. 
Liu et al 
(Liu et al., 
2012) 
 65 years and520 
records of 
elderly medical 
ward inpatients 
STOPP and 
START 
36.2% of the population had at least one PIP. 
Benzodiazepines, neuroleptics and first 
generation antihistamines were commonest 
PIP associated with falls.  
Wahab et 
al(Wahab et 
al., 2012) 
Prospective n=100; Mean 
age=65 yrs; 
Hospital patients 
STOPP criteria PIP were associated with falls, the most 
frequently encountered PIM was opiates 
prescribed in patients with recurrent falls 
(12.3 %), followed by benzodiazepines in 
fallers (10.1 %). 
Borensetein 
et al 
(Borenstein 
et al., 2013) 
Cross-
sectional  
n=214; Mean 
age=75 yrs; 
Hospital patients 
Beer’s criteria PIP were associated with falls  (OR = 3.05; 
95% CI = 1.19, 7.83)  
Frankenthel 
et 
al(Frankenth
al et al., 
2013) 
Prospective n=382; ≥ 65 yrs; 
taking atleast 
one medication; 
Geriatric 
Hospital 
STOPP/START The increased PIP was significantly 
associated with falls (OR: 1.16, 95 % CI 
1.021–1.32) 
Ailabuni et 
al 
(Ailabouni 
et al., 2015) 
Cross-
sectional 
N=102 , ≥65 
years; 
residential care 
homes  
STOPP criteria Antipsychotics, opiates and benzodiazepines 
accounted for approximately 50% of the PIP 
exposures and were associated with a 
medium/high falls risk.  
Manias et al 
(Manias et 
al., 2015) 
Cross-
sectional 
study 
65 years and 
over hospital100 
STOPP criteria 92 PIP were detected in 54 patients. The 
commonest PIP  
medications that adversely affected 
individuals who were 
prone to falls. 
San-Jose et 
al (San-Jose 
et al., 2015) 
prospective
multicentre 
study 
hospitals aged 
85 years and 
over 336patients 
Beers and 
STOPP criteria 
47.2% of had at least one Beers-listed PIM, 
63.3% at least one STOPP-listed PIM. Use of 
benzodiazepines in patients who are prone to 
falls (18.3%)  
Increase in multimorbidity is significantly related with falls, the risk of falls 
increases linearly with the increasing number of comorbidities from low to moderate 
and high (Calderón-Larrañaga et al., 2012). The data from the Canadian community 
health survey involving 16,357 adults aged ≥65 years reported that both the number and 
pattern of chronic conditions were related to falls. The fall risk was significantly greater 
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in individuals with one, two, four, five and six or more chronic conditions as compared 
to those with none disease (Sibley et al., 2014). Studies have identified that 
cerebrovascular, chronic obstructive airways and renal disease, osteoporosis, diabetes, 
hypertension, Parkinson’s disease and stroke dementia, depression, and malignancy are 
significantly related with falls (Johal et al., 2009; Jorgensen et al., 2014; Lee et al., 
2006; Sibley et al., 2014; Tilling et al., 2006). The presence of these falls related 
comorbidities also increase the incidence of hip and humeral fractures after the fall 
(Jorgensen et al., 2014)  
The possible mechanism for the association between comorbidities and falls is 
the age related decline of functional performance due to the increase in number of 
diseases (Guo et al., 2003). Another reason behind this association is that the increased 
consumption of treatment drugs which follows these illnesses. However, this 
association is complex as it is difficult to determine whether falls could be attributed to 
physical illness or polypharmacy, in fact, the multifactorial nature of falls dictates that it 
to be a combination of both as well as additional factors (Coimbra et al., 2010). It is 
only possible to attribute falls to a medicine alone should that particular drug be 
inappropriately prescribed or when falls occur within few days after starting or 
changing a medicine and subsequent discontinuation of the culprit drug then results in 
resolution of falls symptoms (Sorock et al., 2009). However, even in these cases, other 
established risk factors may be existing, and the introduction of the culprit drug may 
simply tip the balance. In a cross-sectional study among hospitalized elderly patients 
where mean number of diseases was 7.7, the existence of multimorbidities actually led 
to polypharmacy (Mizokami et al., 2012).  
There have been few studies on the association of falls with simultaneous 
existence of polypharmacy and polymorbidity. In a cross-sectional survey of 4050 
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women aged 65-79 years, Lawlor et al argued that as multiple pathologies and multiple 
medications co-exist, it’s the number of chronic diseases rather than the number of 
medications  that is associated with increased risk of falls (Lawlor et al., 2003). A cross-
sectional study, including community-dwelling older adults reported that medical 
morbidity contributed significantly to falls instead of the number of medications (M. A. 
Han et al., 2013). The longitudinal study by Kojima et al, however, found 
polypharmacy to be an independent risk factor for falls and not polymorbidity (T. 
Kojima et al., 2012). A Spanish study involving 733 residents aged ≥65years suggested 
that the risk of falls increases when polypharmacy it coexists with multimorbidity of a 
minimum three diseases (Damian et al., 2013). The study by Lee et al involving 
community-dwelling men and women aged ≥65 years reported that although 
medications are associated with falls and recurrent falls this association is mediated 
through the underlying medical diagnoses and neuromuscular impairment (Lee et al., 
2006). 
2.7.  Impact of Medication Withdrawal Interventions on falls 
A study from Netherlands analysing pharmacotherapy of 102 home-dwelling older 
patients (≥75 years, using ≥4 medicines continually) reported that 98% of their 
prescriptions could be modified with the use of regular medication reviews 
(Denneboom et al., 2006). From the above review it can be deducted that instead of 
number of medications, the type of medications i.e. FRID or anticholinergics and 
inappropriate medications play a significant role in falls. The reason behind the 
association of polypharmacy and falls is the increased prevalence of all three 
medication related falls risk factors i.e. FRID, anticholinergics and PIP along with 
polypharmacy. Reducing unnecessary prescriptions improves drug compliance and 
patients’ quality of life, reduces medication errors as well as adverse drug events which 
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translates into cost-savings through the reduction of medication and hospitalisations 
costs (Frankenthal et al., 2014). The American Geriatrics Society/British Geriatric 
Society Joint Falls Prevention Guidelines 2010, now advocate careful medication 
reviews for all older fallers (AGS/BGSguidelines, 2011). However, few trials including 
high risk fallers at baseline have positively demonstrated a reduction in the risk of falls 
with the withdrawal of culprit medications or reduction of dose burden (van der 
Cammen et al., 2014). 
One systematic review concluded that polypharmacy withdrawal was shown to 
improve cognitive function but it had no significant effect on falls prevention (van der 
Cammen et al., 2014). The medication withdrawal trials on PIP have also shown 
positive results for deprescribing. A study reviewed the drugs of 10,364 adults aged ≥65 
years and successfully reduced inappropriate medications from 66.7%. to 31.3% during 
the 6-month follow-up, the highest rate of discontinuation was observed for 
anticholinergics (Starner et al., 2009). One systematic review including 31 trials 
concluded that while some medications can be safely withdrawn, withdrawal of 
diuretics was unsuccessful primarily when heart failure was present medications (Iyer et 
al., 2008). 
The evidence for longer term benefit of medication withdrawal is only 
demonstrated by a few studies evaluating the withdrawal of psychotropic medications 
(Iyer et al., 2008). However contrarily, one systematic review including 22 quantitative 
studies on PIP reduction concluded that interventions to reduce inappropriate 
prescribing of antipsychotic medications might be effective but for the shorter term 
(Thompson Coon et al., 2014). Among other drug trials, the available evidence shows 
the benefits of psychotropic withdrawal as an effective intervention on falls reduction, 
as adverse drug events due to these medications are more common and easily  
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preventable than non-psychotropic medicines (Rothschild et al., 2007). 
Table 2.8: Effect of Medication Withdrawal Interventions on Falls among older adults. 
 
Based on currently available literature on the adverse effects of polypharmacy, 
FRID and PIP, we can deduce that regular review of medications is advisable among 
older patients who are receiving multiple regularly prescribed medications. The 
medication review among fallers should consider the risk factors of falls as well as 
presence of comorbidities first followed by assessment of inappropriate drugs. 
Reference 
 
Study 
Design 
Participants (n) Intervention Association with Falls 
Campbell 
et al 
(Campbell 
et al., 
1999) 
RCT n=93; ≥ 65 yrs; 
Community 
participants, 
taking 
psychotropics 
Gradually 
withdrew 
psychotropics 
Psychotropic withdrawal led to a 
66% reduction in falls rate during 
44 weeks of follow up. But it was 
difficult to achieve permanent 
withdrawal as 47% of the 
participants from the medication 
withdrawal group in a study started 
taking their withdrawn medications 
again only after one month of 
completion of trial 
Velde et 
al(van der 
Velde, 
Stricker, et 
al., 2007) 
Prospectiv
e 
n=139; ≥65 yr; 
Geriatric 
Outpatients;  ≥1 
fall in past year 
FRID i.e. 
psychotropics, 
cardiovascular 
drugs, 
analgesics, 
antidiabetics & 
anticholinergics 
The risk of fall for overall drug 
withdrawal was reduced (HR, 0.48; 
95% CI; 0.23, 0.99), however 
cardiovascular drugs showed 
highest fall risk reduction during 
three months of follow up.  
Iyer et al 
(Iyer et al., 
2008) 
Systemati
c review  
n=8972; ; ≥65 yrs; 
Hospital patients 
Psychotropic 
drug 
Withdrawal 
Withdrawal of psychotropic 
medications was associated with a 
reduction in falls. 
Salonja et 
al 
(Salonoja 
et al., 
2012) 
Prospectiv
e 
n=528 ; ≥65 yrs, 
Community 
dwelling, at least 
one fall 
Withdrew 
psychotropics 
Withdrawal of psychotropics, 
especially benzodiazepines played 
an important role by lowering the 
risk of falls during the year.  
Van der 
Cammen 
(van der 
Cammen et 
al., 2014) 
Review n=382; ≥ 65 yrs; 
atleast one 
medication; 
Geriatric Hospital 
Psychotropic 
drug 
Withdrawal 
Withdrawal of psychotropics 
reduced fall rate 
Frankenthe
l at al 
(Frankenth
al et al., 
2014) 
RCT n=359;  ≥65 yrs 
Chronic care 
geriatric facility. 
Withdrew drugs 
according to 
STOPP/START 
criteria 
The average number of falls in the 
intervention group dropped 
significantly (P = .006). 
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Unnecessary or duplicative medicines should be withdrawn and medications necessary 
for disease management should be replaced with safer alternatives or dose titrated. The 
withdrawal of inappropriate drugs and anticholinergics could achieve the dual benefits 
of both decreasing the number of drugs and hence the risk from culprit medicines. Table 
2.8 shows the available studies for the effect of medication withdrawal on falls among 
older adults. However, in all those studies the long-term effects of withdrawal on end 
organ damage, quality of life and survival rates have not been evaluated, in spite of their 
beneficial effects on falls reduction.  
 
2.8.  Summary  
The elderly have the highest prevalence of falls and multiple comorbidities; they 
are the highest users of medications and respond differently to drugs than do younger 
people. With the literature review concluded, we can identify some clear problems for 
the elderly fallers. While plenty of studies have listed the positive association between 
medications and falls, there are certain methodological problems in determining the 
exact contribution of drugs to falls and more importantly the contribution of untreated 
diseases on falls if those drugs are deprescribed. Attributing the cause of an older 
person falling to polypharmacy or a single medication or inappropriate prescribing 
alone is difficult because of various confounding variables, some of which are listed 
above. Because of the difficulty in measuring the effects of the drugs themselves, many 
studies used a simple count of drugs for polypharmacy and FRID; polypharmacy and 
FRID co-exist and overlap and the comparison between polypharmacy and FRID count 
associated with falls is also non-existent, which would be helpful in focussed 
medication reviews for older fallers. The review also identified that in spite of certain 
drugs being widely accepted as culprits for falls, none of the studies have involved their 
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mechanisms or mediators to get a clearer picture of this triad of medications, 
comorbidities and falls. A research on this would also help in retaining the drug 
necessary for disease management while improving the mediator in reducing falls. The 
prescription of drugs among elderly fallers is a challenging situation because of the fine 
line between the benefit of drug for the disease it is prescribed and it’s higher dose or 
number resulting in serious recurrent falls. However, interestingly, the existence of PIP 
although widely mentioned in the literature to be responsible for serious and 
preventable adverse drug events has never been evaluated among the sample of 
recurrent fallers.  The evaluation of PIP with a criteria may provide firm basis for the 
deprescribing of certain drugs which may reduce the risk of future falls.  The studies on 
medication withdrawal also have limitations of being feasible for frail older adults with 
history of falls and multiple serious comorbidities and whether they are applicable and 
beneficial for longer term.  In spite of the higher risk of falls among Malaysian elderly, 
no study exists on the association between medications and falls in this region. There is 
a need for additional research and documentation about the association of medication 
and their correlation to falls among the urban community dwellers in Malaysia. 
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CHAPTER 3: METHODOLOGY 
3.1.  Study design and setting 
This study has two arms: Cross sectional arm involving case control 
comparisons between faller and nonfaller groups and longitudinal arm where fallers 
were randomised to interventions or non-interventions and then followed prospectively 
for a period of 12 months to record falls. The sample of fallers was included from a 
single centred randomized-controlled trial of individually-tailored multifactorial 
intervention for older Malaysian fallers residing in the community, known as 
“Malaysian Falls Assessment and Intervention Trial (MyFAIT)”. It was based in a large 
teaching hospital in Kuala Lumpur, the detailed protocol for MyFAIT protocol is 
published elsewhere (P. J. Tan et al., 2014). The study was approved by University of 
Malaya Medical Centre Ethics Committee (925.4). Written and Informed consent was 
then obtained from all study participants. 
3.2.  Sample:  
3.2.1. Inclusion and Exclusion Criteria of participants 
The inclusion criteria for fallers recruited into MyFAIT was age  ≥65 years, with 
two or more falls or one injurious fall (Injuries classified according to ICD-10 
definition) in the previous year because these factors are shown to be strongly 
associated with the amplified risk of future falls high risk of future falls 
(AGS/BGSguidelines, 2011; Ambrose et al., 2013; Wu, Chie, Yang, Kuo, et al., 2013). 
The participants aged 65 years and older with no history of falls over the past year were 
recruited as “control subjects” for case control comparisons.  
Exclusion criteria (for both cases and controls) were a clinical diagnosis of 
dementia (ICD-10 definition), severe physical disabilities (unable to stand) and major 
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psychiatric illness or psychosis. The participants with dementia were excluded because 
the previous falls studies including dementia patients have yielded inconclusive results, 
suggesting that separate interventions should be conducted for individuals with 
dementia.  
3.2.2. Sample Size  
The sample size of 352 participants (cases and controls) was calculated for an 
unmatched case-control study with 95% confidence interval and 80% power (α = 0.05) 
to detect an effect size of 0.30 which is small to medium effect size (G*Power 3.1.9.2.).  
For the prospective intervention study, the sample size of 208 participants was 
calculated, 104 in each arm, which will provide 80% power to detect a 40% reduction in 
the number of individuals who experience falls to 30% in the intervention group 
assuming that without intervention, 50% of individuals will experience a subsequent fall 
(Close et al., 1999) 
3.2.3. Mechanism of recruitment 
Fallers were the participants who were discharged from the primary care clinics, 
geriatric medicine clinics and the emergency department of the hospital due to falls. 
Non-fallers were the volunteer participants recruited through media and word-of-mouth 
advertising from the hospital catchment area.  
The reporting of case control study follows the STROBE Statement along with 
references to STROBE and the broader EQUATOR guidelines (Simera et al., 2010) 
while the CONSORT statement is used as a guideline to design the flow of participants’ 
progress through the prospective study arm. 
3.3.  Data Collection 
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Both the fallers (cases) and nonfallers (controls) were invited to attend the “falls 
clinic” for the baseline assessment and evaluation which lasted approximately 2 hours 
per participant. The assessment was performed for all the participants by a team 
comprising of geriatricians, psychiatrist, ophthalmologist, physiotherapist and 
researchers who have received training in administration of all assessment items. The 
non-fallers (controls) only received baseline assessment necessary for case control 
analysis, while the fallers were subjected to randomisation into intervention and control 
groups afterwards by a computer-generated random number sequence. The intervention 
group were subjected to individualized treatment programs by the geriatrician while the 
non-intervention group continued to receive conventional care by their respective 
medical practitioners. The prescribed treatment in MyFAIT was targeted at six specific 
treatment modalities: medication review intervention, falls education, exercise 
intervention, home hazards intervention, cardiovascular intervention and visual 
intervention. 
Falls diaries with daily entries were used to record falls occurrences, and were 
returned monthly for one year from randomization. These diaries were written in the 
three main languages of Malaysia; Malay, English and Mandarin, due to varying 
cultural and educational backgrounds. Prompts were provided in the falls diaries, which 
include how and when a fall occurred, or if there were injuries sustained after their fall. 
Participants were contacted every 2 months by telephone calls to encourage complete 
diary returns.  
3.3.1. Basic Demographics 
A structured history was obtained from all participants which included enquiry 
regarding (i) basic sociodemographics (ii) detailed falls history i.e. occurrence, time and 
mechanism, related symptoms and the complications of falls. 
 56 
 
3.3.2. Comorbidity Assessment 
The participants were interviewed by a geriatrician for comorbidity assessment which 
included self-reported medical history. This was recorded into standardised form under 
categories which included diabetes, hypertension, any respiratory disorder, arthritis, 
osteoporosis, hearing disorders, depression, thyroid diseases, eye diseases (cataract, 
glaucoma) and vascular diseases (diagnosis of myocardial infarction, angina, stroke, 
transient ischemic attack or peripheral vascular disease). 
3.3.3. Medication assessment 
Patients were asked to bring in their written prescriptions and actual medications to 
their appointments in order to collect a comprehensive list of prescribed and over the 
counter medicines. A careful list of medicines, as well as their doses and duration of use 
was obtained via face-to-face interviews using a standardised case record form. 
Medications were grouped according to the British National Formulary, 67th Edition 
(BNF, 2014). Topical and herbal medications were not considered in the analysis.  
 
3.3.4. Assessments during the visit 
1. Height and weight were recorded. 
2. Blood pressure readings were obtained in the supine position followed by three 
minutes of standing using an oscillometric blood pressure device (Omron HEM-
7200) (the details are described in chapter 5).  
3. Physical strength and balance performance scores were assessed using TUG, FR 
and GS according to standard procedures (the details are described in chapter 6) 
(P. J. Tan et al., 2014).  
4. Other assessments performed were: visual assessment by visual acuity, contrast 
sensitivity, and binocular vision; 12-lead electrocardiogram (ECG); 
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psychological and quality-of-life assessments using psychometric 
questionnaires. Complete cardiovascular and neurological assessments were also 
performed by the geriatricians according to the disease history and 
symptomatology of participants. 
3.3.5. Data Processing and Statistical Analysis 
The Statistical Package for Social Science (SPSS) software version 21.0 (Chicago, 
IL,USA) was used for statistical analysis. The data was collated into the database at the 
time of assessment, and entered in SPSS after cleaning and organisation.  
a. Univariate Analysis: The frequencies were expressed as mean (± standard 
deviation) or median (interquartile range) for continuous data and evaluated for 
normal distributions. The comparisons were then made between fallers and non-
fallers using the independent t-test for parametric and Mann-Whitney U test for 
non-parametric variables. Categorical data were expressed as frequencies with 
percentages in parentheses with differences between groups expressed as odds 
ratios with 95% confidence intervals; statistical significance was tested with the 
Chi-squared test.  
b. Multivariate Analysis: Because our goals was to examine the effect of 
controlling for multiple chronic conditions on the association between falls and 
specific class of medications, the method for multivariate analysis for specific 
variables is described in the respective chapters. 
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CHAPTER 4: THE CONSUMPTION OF TWO OR MORE FALL RISK INCREASING 
DRUGS RATHER THAN POLYPHARMACY IS ASSOCIATED WITH FALLS 
 
4.1.  Introduction: 
 
Polypharmacy as well as FRID are regarded as well documented factors for falls 
(Gnjidic et al., 2012; Kojima et al., 2011; Milos et al., 2014; van der Velde, Stricker, et 
al., 2007). The commonly adopted practice of merely counting drugs as polypharmacy 
is arguably no longer relevant to evidence-based prescribing, as polypharmacy in 
individuals with multiple chronic conditions is often inevitable. Moreover, while 
polypharmacy includes the total medication count of a patient, some older adults may 
be using less risk drugs than others making counting of total medication impossible to 
calculate falls risk. The presence of polypharmacy therefore may not necessary imply 
increased falls risk if medications associated with higher risk of falls are avoided. 
Polypharmacy increases the risk of FRID use which is responsible for previously 
established association between polypharmacy and falls, while polypharmacy without 
the presence of FRID may not be associated with falls, hence the term “polypharmacy” 
may not be valid for fallers. But none of the studies have demonstrated that it might be 
the FRID count and not the total medication count/ polypharmacy which are associated 
with falls. We hypothesized that the established association between polypharmacy and 
falls among older people is attributable to the use of multiple FRID.  
4.2.  Objective 
 
We conducted a case-control study comparing individuals at high risk of falls with non-
fallers to determine the relationship between polypharmacy and FRID with the risk of 
recurrent and injurious falls among community dwelling older adults. 
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4.3.  Methodology 
The setting, participants, baseline demographics, medication collection assessment as 
described in chapter 3. 
Statistical Analysis: After the univariate analysis as described in chapter 3, potential 
confounders were identified from comparison of basic characteristics between fallers 
and non-fallers and were adjusted for in subsequent models using multivariate logistic 
regression methods and the differences between groups were expressed as odds ratios 
with 95% confidence intervals. A p-value of <0.05 was considered statistically 
significant. 
4.4.  Results 
 
4.4.1. Recruitment and baseline demographics 
A total of 442 participants who attended the “falls clinic” were assessed initially. 
Eighty four participants were excluded based on whether they did not meet the 
inclusion criteria or fulfilled exclusion criteria or had missing data. Data on 358 
participants, 202 fallers and 156 non-fallers was analysed; the baseline demographics 
are summarized in Table 4.1. Fallers were significantly older than non-fallers and were 
significantly more likely to have diabetes, vascular disorders and eye diseases. Fallers 
had significantly lower SBP but were not significantly more likely to have OH as 
compared to non-fallers. The scores of physical performance i.e. TUG, FR and GS were 
significantly poorer among fallers.  
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Table 4.1: Baseline characteristics of fallers and non-fallers. 
Basic characteristics (N=358) Fallers† n=(202) Non-Fallers‡ (n=156) p-value 
Age (years), mean ± SD 75.2(±7.1) 72.2(±5.5) <0.001*** 
Male Gender, n(%) 65(32.2) 51(32.7) 0.923 
Body Mass Index (kg/m2), 
 mean ± SD 
24.2(±3.7) 24.5(±4) 0.481 
Smoker, n(%) 7(3.5) 7(4.5) 0.612 
Alcohol, n(%) 15(7.4) 15(9.6) 0 .452 
Medical History, n(%) 
Diabetes 69(34.2) 30(19.2) 0.002** 
Hypertension  115(56.9) 77(49.4) 0.173 
Respiratory disorders  9(4.5) 6(3.8) 0.791 
Arthritis  44(21.8) 40(25.6) 0.378 
Osteoporosis  19(9.4) 15(9.6) 0.936 
Hearing disorders  14(6.9) 7(4.5) 0.332 
Depression  6(3.0) 2(1.3) 0.231 
Thyroid diseases  13(6.4) 16(10.3) 0.192 
Eye diseases  95(47) 52(33.3) 0.009** 
Vascular diseases  41(20.8) 18(11.5) 0.032* 
Blood Pressure 
Supine SBP, mean ± SD 130(24.8) 135.6(20.3) 0.04* 
Supine DBP, mean ± SD 66.2(15) 66.6(15.0) 0.78 
OH, n(%) 52(15.7) 28(17.9) 0.09 
Physical Performance, n(%) 
TUG ≥ 13.5s 101(50) 31(21.8) <0.001 
FR ≤ 18cm 59(29.2) 13(8.3) <0.001 
Reduced RGS 149(73.8) 85(54.5) <0.001 
Reduced LGS 157(77.7) 96(61.5) 0.001 
    
SD=standard deviation, Data presented are mean (SD) for continuous and number (%) for categorical data. Vascular 
disease=diagnosis of myocardial infarction, angina, stroke, transient ischemic attack or peripheral artery disease. Grip strength 
reduced; <20kg women, <30kg men 
***p≤.001, **p≤.01, *p≤.05  
†Recurrent or injurious falls in the past 12-months 
‡No falls in the past 12 months 
 
4.4.2. Medications among participants 
Medication intake was significantly greater among fallers, with 85.7% of fallers 
and 64.7% of non-fallers using at least one drug (OR=3.0; 95%CI, 1.8-4.9; p≤0.001). 
Use of biguanides, sulfonylureas, α-blockers, A2RA, anti-anginals, PPI, NSAID and 
dyslipidemics were found to be significantly associated with falls following univariate 
analysis. Non-steroidal anti-inflammatory drugs were the only class of medications 
which remained associated with falls after adjustment for age, gender and comorbidities 
(Table 4.2).  
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Table 4.2: Medications among Fallers and Non-fallers 
Drug use 
(N=358) 
Fallers 
(n=202 )  
Non-
Fallers  
(n= 156 ) 
OR 
(95%CI) 
OR† 
(95%CI) 
OR‡ 
(95%CI) 
Fall Risk Increasing Drugs 
Cardiovascular drugs, n(%) 
α-blockers 20(9.9) 6(3.8) 2.8(1.1-7.1)* 0.1(0.8-5.5) 2.7(0.9-7.7) 
β-blockers 39(19.3) 24(15.4) 1.3(0.8-2.3) 1.1(0.7-2.1) 1.2(0.7-2.3) 
ACE-inhibitors 33(16.3) 23(14.7) 1.1(0.6-2.1) 1.0(0.6-1.8) 0.9(0.5-1.7) 
A2RAs 37(18.3) 15(9.6) 2.1(1.1-4.0)* 1.7 (0.9-3.4) 1.6(0.8-3.2) 
Calcium channel 
blockers 
64(31.7) 40(25.6) 1.4(0.8-2.1) 1.1(0.7-1.7) 1.3(0.6-1.7) 
Diuretics 27(13.4) 14(9.0) 1.6(0.8-3.07) 1.6(0.8-3.2) 1.6(0.8-3.4) 
Nitrates 8(4.0) 4(2.6) 1.5(0.5-5.3) 1.0(0.3-3.5) 0.9(0.2-3.4) 
Anti-anginal agents 14(6.9) 3(1.9) 3.8(1.1-13.5)* 2.7(0.8-10.0) 2.2(0.6-8.8) 
Analgesics n(%) 
NSAID 71(10.4) 3(1.9) 5.9(1.7-20.2)** 6.2(1.8-21.5)** 6.2(1.7-22.1)** 
CNS Medicines 
Benzodiazepines 10(5) 4(2.6) 1.9(0.6-1.4) 1.3(0.3-4.5) 1.3(0.3-4.8) 
Antidepressants 7(3.5) 3(1.9) 1.8(0.4-7.1) 1.6(0.3-6.5) 1.6(0.3-6.8) 
Antiparkinsonians 9(4.5) 5(3.2) 1.4(0.4-4.2) 1.4(0.4-4.2) 1.2(0.3-2.9) 
Endocrine Medicines 
Thyroid medications 9(4.5) 8(5.1) 0.7(0.3-2.2) 0.73(0.3-2.0) 0.82(0.3-2.6) 
Anti- diabetic drugs, n(%) 
Insulin 8(4.0) 4(2.6) 1.5(0.5-5.3) 1.9(0.6-6.6) 1.1(0.3-4.0) 
Biguanides 41(20.3) 14(9.0) 2.5(1.4-4.9)* 2.5(1.3-4.8)** 1.7(0.7-4.1) 
Sulfonylureas 35(17.3) 9(5.8) 3.4(1.6-7.3)** 3.1(1.4-6.7)** 2.2(0.9-5.6) 
DPP4I 13(6.4) 6(3.8) 1.7(0.6-4.6) 1.5(0.57-4.3) 1.0(0.3-2.8) 
Other antidiabetics 2(1.0) 0(0.0) n/a n/a n/a 
      
Drugs Other than Fall Risk Increasing Drugs, n(%) 
H2RA 4(2) 3(1.9) 1.0(0.2-4.6) 2.5(0.9-7.7) 0.66(0.1-3.4) 
PPI 16(7.9) 4(2.6) 3.2(1.1-9.9)* 2.4(0.8-7.7) 2.9(0.9-9.4) 
Dyslipidaemic agents 103(51.0) 63(40.4) 1.5(1.0-2.3)* 0.91(0.2-4.1) 1.3(0.9-2.1) 
Steroids 6(3.0) 3(1.9) 1.3(0.3-5.5) 1.4(0.8-2.6) 0.63(0.1-2.9) 
**p≤0.01, *p≤0.05; OR= Odds Ratio; CI= Confidence Interval, DPP4I=Dipeptidyl Peptidase 4 Inhibitors, PPI=Proton pump 
Inhibitors, H2RA=Hydrogen2 receptor antagonists, NSAIDs Non-steroidal anti-inflammatory drugs, CNS= Central Nervous system, 
FRID=fall-risk increasing drugs 
†adjusted for age alone, ‡ Each model is adjusted for age, gender, BMI, Comorbidities (Diabetes, Hypertension, Depression, Thyroid 
diseases, Eye diseases, vascular disease) 
 
4.4.3. Polypharmacy versus FRID 
Table 4.3 displays the results of univariate analyses exploring the relationship 
between polypharmacy and FRID with falls. There was a significant correlation 
between increased number of prescribed drugs with the increased FRID count (r=0.84, 
p≤0.001). The use of ≥2FRID was significantly associated with polypharmacy (OR, 
27.2, 95%CI, 13.4-55.1; p≤0.001). Both polypharmacy as well as FRID count were 
significantly associated with falls (Table 4.3).  
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Table 4.3: Medication count and FRID count among fallers and nonfallers. 
 
***p≤0.001, **p≤0.01, *p≤0.05; OR= Odds Ratio; CI= Confidence Interval, FRIDS= fall-risk increasing drugs, Polypharmacy=5 or 
more prescription drugs, 
ϯ ≥2 FRID excluded (n=183), ‡Polypharmacy excluded (n=240) 
 
 
The use of one FRID only was not associated with falls but ≥2FRID were 
significantly associated with falls (OR, 2.9; 95%CI,1.9-4.5.; p≤0.001). After adjusting 
for age and comorbidities, the significant association between polypharmacy and falls 
was attenuated (OR, 1.6; 95%CI, 0.9-2.8; p=0.07) while the use of ≥2FRID remained 
significantly associated with falls (OR, 2.9; 95%CI, 1.6-5.1; p ≤0.001) (Table 4.4, 
Model 1). After additional adjustment for physical performance scores (TUG, FR and 
GS) and blood pressure, ≥2FRID instead of polypharmacy remained an independent 
predictor for falls (Table 4.4, Model 2). Furthermore when individuals with ≥2FRID 
were excluded, the presence of polypharmacy was also not associated with falls among 
the remaining participants (Table 4.4, Model 3). Conversely, when participants with 
polypharmacy were excluded, the use of ≥2 FRID remained significantly associated 
with falls (OR, 3.1; 95%CI,1.4-6.8; p=0.003) (Table 4.4, Model 4).  
 
 
 
 
 
Drug use 
(N=358) 
Fallers 
(n= 202 )  
Non-Fallers  
(n= 156 ) 
OR(95%CI) P value 
Medication Count 
No. of prescribed drugs, median(IQR) 4(4) 2(4) - <0.001*** 
Polypharmacy, n(%) 81(40.1) 36(23.1) 2.23(1.4-3.6) 0.001** 
FRID Count 
No, of FRID, median(IQR) 2(3) 1(2) - <0.001*** 
1 FRID, n(%) 35(17.3) 37(23.7) 0.7(0.4-1.1) 0.132 
≥2 FRID, n(%) 122(60.4) 53(34.0) 2.9(1.9-4.5) <0.001*** 
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Table 4.4: Logistic Regression Models for Falls against polypharmacy and ≥2 FRID. 
 
 Polypharmacy ≥2 FRID 
 Adjusted OR 
(95%CI) 
p-
value 
Adjusted OR 
(95%CI) 
p-value 
Model 1‡ 
All Participants (n=358) 1.6(0.9-2.8) 0.073 2.9(1.6-5.1) ≤0.001*** 
Model 2◊ 
All Participants (n=358) 1.6(0.9-2.9) 0.102 2.8(1.4-5.3) 0.001** 
Model 3 
≥2 FRID excluded (n=183) 1.1(0.3-4.2) 0.841 - - 
Model 4     
Polypharmacy excluded 
(n=240) 
- - 3.1(1.4-6.8) 0.003** 
***p≤0.001, **p≤0.01, *p≤0.05; OR= Odds Ratio; CI= Confidence Interval, FRIDS= fall-risk increasing drugs, ‡ Each model is 
adjusted for age, gender, BMI, Comorbidities (Diabetes, Hypertension , Depression, Thyroid diseases, Eye diseases Vascular 
diseases; 
◊
 Each model is adjusted for age, gender, BMI, Comorbidities (Diabetes, Hypertension , Depression, Thyroid diseases, 
Eye diseases ,Circulatory diseases), Supine blood pressure, Timed up and go, Functional reach and Grip strength. 
 
4.5  Discussion 
 
The association of polypharmacy with falls was attenuated while ≥2FRID 
remained an independent factor for falls in the final adjusted models. The individual 
FRID classes of antihypertensives, antidiabetics or central nervous system drugs which 
have previously been considered to be strongly associated with falls (A. Huang et al., 
2012) were not associated with falls. Non-steroidal anti-inflammatory drugs were 
significantly associated with falls after multivariate adjustment for age, gender and 
comorbidities. The use of ≥2FRID remained a significant predictor for falls even when 
individuals with polypharmacy were excluded, while polypharmacy was not associated 
with falls when individuals with ≥2FRID were excluded. Our findings therefore suggest 
that the previous assumptions that polypharmacy is associated with falls can be 
explained by increased risk of multiple FRID which correlated strongly with 
polypharmacy.  
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Traditional assumptions exist about the association between different drug 
classes with the increased risk of falls, however, it is confounded by the association 
between inevitable medication use with increasing age and comorbidities. Therefore, as 
the prevalence of multiple chronic conditions increases with age,(Salive, 2013) the use 
of medications also increases with one in every fourth older adult taking five or more 
prescription medicines (Linjakumpu et al., 2002). Our results demonstrating that 
polypharmacy is not associated with falls after adjustments for comorbidities are 
consistent with Lawler et al’s findings suggesting  that amongst multiple chronic 
conditions and polypharmacy, multiple comorbidities were independent predictors of 
falls (Lawlor et al., 2003).  
The presence of polypharmacy, however, increases the likelihood of multiple 
FRID use. Our study therefore suggests that the increase in risk of falls linked to 
multiple drug use in previous studies is attributable to the use of multiple FRID. Our 
findings are similar to that found in a study conducted in a hospital setting by Bennett et 
al who reported that the number of FRID on the patients’ prescriptions on discharge was 
associated with a greater risk of recurrent falls (Bennett et al., 2014). Similarly another 
study by Milos et al (Milos et al., 2014) suggested that fallers in their study were on 
significantly more FRID than non-fallers.  
Ziere et al (Ziere et al., 2006) and Richardson et al (Richardson et al., 2015) 
evaluated falls risk associated with polypharmacy along with FRID and reported that 
the inclusion of at least one FRID with polypharmacy predisposes an older adult to 
falls. However as both the above mentioned studies included middle aged and elderly 
cohorts, the findings among older adults were compared to those of middle aged 
individuals. As the use of CNS medications increases with age and is an established 
factor for falls, the main FRID in both studies were CNS drugs. In our study, involving 
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community dwelling adults, although CNS drugs or other individual drug class was not 
significantly associated with falls, the combined use of ≥2FRID increased the falls risk, 
regardless of the presence of polypharmacy. 
Velde et al (van der Velde, Stricker, et al., 2007) demonstrated that the 
withdrawal of FRID reduced the risk of falls over a short follow-up period of two 
months in an intervention study involving 139 patients attending the geriatrics 
outpatient department. The main FRID withdrawn in this study were sedatives, 
antihypertensives and analgesics. However, it cannot be determined whether it was 
possible to sustain FRID withdrawal for a longer duration of time among the older 
adults with multiple chronic conditions. According to a systematic review, only the 
withdrawal of psychotropic medications amongst all other drugs has been effective in 
reducing falls (van der Cammen et al., 2014) but Campbell et al claimed that medication 
withdrawal among geriatric patients, though achievable, may not be sustainable for the 
longer term (Campbell et al., 1999). While cautious medication review is now 
considered an integral part of multifaceted falls interventions (AGS/BGSguidelines, 
2011), our study provides the evidence to support current opinions that the traditional 
approach of merely reducing the total number of medications consumed may no longer 
be applicable. In the management of chronic diseases, the use of multiple medications 
may no longer be avoidable in order to effectively reduce the risk of future occurrence 
of adverse outcomes which may outweigh the risk of falls (Gage et al., 2005). Future 
studies should now evaluate whether the approach of reducing FRID alone without 
taking into account polypharmacy may be sustainable for longer durations as well as 
effective in reducing falls risk without increasing the risk of other adverse health 
outcomes.  
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The significant association between multiple FRID and not individual FRID 
with falls suggests that the increased risk of falls may be due to either the cumulative 
burden of FRID or drug-drug interactions between individual FRID. The study by 
Wilson et al reported a cumulative increased load of two FRID classes; sedatives and 
anticholinergics, calculated by using a drug burden index, to be significantly associated 
with an increased risk of falls (Wilson et al., 2011). Similarly, a population based 
longitudinal study by Callisaya et al reported that an increased daily dose of 
antihypertensives, which is considered a FRID drug class, increases the risk of falls 
among older adults (Callisaya et al., 2014). While our study is in agreement with these 
findings and suggests that the use of multiple FRID is associated with recurrent or 
injurious falls in older adults, it remains to be established, whether the risk of falls can 
be reduced by avoiding multiple FRID taking into account the loss of benefit of 
secondary prevention of other chronic conditions.  
To our knowledge this was the first study to suggest the use of FRID with a cut 
off of ≥2FRID predicts increased risk of recurrent or injurious falls rather than 
polypharmacy in isolation, while the presence of polypharmacy in the absence of 
multiple FRID use is not associated with recurrent or injurious falls. Our collection of 
medication data by face-to-face interviews and cross-checking of patients’ prescriptions 
as well as medication packages minimized the risk of missing or erroneous medication 
data. Our cross-sectional design, however, is a limitation with regards to the ability to 
assign causation between FRID and falls, and our reliance on retrospective falls recall 
may be subjected to recall bias. This study, however, firmly paves the ground for the 
direction of future studies on effective medication management for the secondary 
prevention of falls. The ability to identify an alternative approach rather than relying on 
avoidance of polypharmacy entirely among fallers with a narrow band of five or more 
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medications is vitally important, as polypharmacy is now considered inevitable with 
evidence-based management of chronic diseases.  
4.6  Conclusion 
 
Our study has found that the use of ≥2FRID is associated with increased risk of 
recurrent and injurious falls, while the use of individual FRID in isolation or the 
presence of polypharmacy itself unlike previous studies was not significantly associated 
with recurrent or injurious falls. Our findings have important implications for effective 
risk reduction in the management of chronic diseases where the avoidance of 
polypharmacy may then deprive the patient of effective prophylactic treatment.  Future 
studies should seek to confirm whether avoidance or withdrawal of multiple FRID 
among high risk fallers reduces further falls risk with consideration for other adverse 
outcomes if secondary prophylaxis is withheld in the interest of fall prevention.  
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CHAPTER 5: THE ASSOCIATION OF ANTIHYPERTENSIVES WITH POSTURAL 
BLOOD PRESSURE AND FALLS AMONG SENIORS RESIDING IN THE 
COMMUNITY: A CASE CONTROL STUDY 
5.1 Introduction 
 
Among FRID, after the CNS drugs, antihypertensives are the most commonly 
reported ones to be independently associated with falls among older adults (Gribbin et 
al., 2010; Leipzig et al., 1999b) in a dose dependent manner (Callisaya et al., 2014; 
Tinetti et al., 2014). However, there are studies reporting no association or negative 
association of antihypertensives with falls, making it compulsory to explore the possible 
mechanism through which antihypertensives could lead to falls. 
Orthostatic hypotension is considered a commonly documented adverse effect of 
antihypertensive treatment (Heitterachi et al., 2002) with studies demonstrating α-
blockers, β-blockers and diuretics to be frequently associated with OH (Gribbin et al., 
2010; Romero-Ortuno et al., 2013). It is therefore assumed that antihypertensive therapy 
results in falls through the side-effects of OH or hypotensive episodes (Craig, 1994; 
Rubenstein et al., 1990). However, these studies have evaluated fallers unilaterally 
without the inclusion of a control population.  
Available large studies (Callisaya et al., 2014; Tinetti et al., 2014) on the 
association between antihypertensives with falls have employed medication databases 
or cohort study information which did not include postural blood pressure 
measurements. Furthermore, previous studies had not considered evaluating the 
triangular relationship between antihypertensive use, postural blood pressure changes 
and the risk of falls. We hypothesized that postural blood pressure drop is a mediating 
factor for falls associated with antihypertensive use. Therefore, the objectives of this 
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study were to examine the associations of antihypertensives with postural blood 
pressure drop among older individuals with and without a history of falls, and 
subsequently employing statistical modelling to evaluate the role of postural blood 
pressure changes in falls associated with antihypertensive use.  
5.2 Methodology 
 
The setting, participants, baseline demographics, medication collection 
assessment as described in chapter 3. 
5.2.1. Blood pressure lowering drugs were divided into the following main classes: 
ACE-I, A2RA, β-blockers, CCB, thiazide diuretics and α-blockers. Combination drugs 
were separated into their respective discrete classes (e.g. Diovan HCT which contained 
Valsartan and Hydrochlorothiazide was classified into both A2RA and thiazide diuretic 
groups and counted as 2 antihypertensive medications).  
5.2.2. Baseline Measurements 
Participants were interviewed by a geriatrician and an established diagnosis of 
hypertension was recorded if the participant reported physician diagnosed hypertension 
and/or was on existing blood pressure lowering therapy, regardless of the recorded 
blood pressure at the time of assessment.  
5.2.3. Blood Pressure Measurements 
Blood pressure was measured at the falls clinic between the hours of 1.00 pm to 
4.00pm and participants were advised to take their regular prescribed medications on 
the day of assessment. One recumbent reading was obtained after 10 minutes of supine 
rest. Three standing readings were obtained at 1 minute, 2 minutes and 3 minutes after 
assuming the erect posture. All blood pressure measurements were obtained with an 
automated blood pressure machine (Omron HEM-7200). Orthostatic hypotension was 
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diagnosed if a systolic blood pressure drop of 20mmHg or greater or diastolic blood 
pressure drop of 10 mmHg or greater was observed within three minutes of standing 
according to the consensus definition (Freeman et al., 2011). Minimal standing SBP 
was the lowest recorded SBP measurement amongst the three BP recordings obtained at 
1, 2 and 3 minutes after assuming the erect posture.  
5.2.4. Statistical Analysis 
For categorical outcomes of OH and falls, multivariate logistic regression 
methods were used to control for potential confounders. As minimal SBP was a 
continuous variable, independent t test was applied to test statistical significance and 
mean differences in minimal SBP were adjusted for confounders using linear regression 
methods. A p-value of <0.05 was considered statistically significant. Statistical 
modelling using binary logistic regression analysis method was employed to determine 
the mediation effects of postural blood pressure changes on falls associated with 
antihypertensive use. This was determined by examining the associations by step-wise 
adjustment of potential confounders. If the independent variable (antihypertensive use) 
was no longer statistically significant after the addition of a new variable (OH or 
minimal standing SBP) within the model, then the new variation was considered a 
potential mediator for the relationship between the independent variable and dependent 
variable.  
5.3.  Results 
5.3.1. Recruitment and baseline demographics 
A total of 442 participants were assessed initially. Eighty participants were 
excluded as they either did not meet the inclusion criteria or fulfilled exclusion criteria. 
Blood pressure data was incomplete for four individuals, who were then excluded from 
the analyses. Data on medication and blood pressure measurements from a total of 358 
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participants which included 202 fallers and 156 non-fallers were subsequently analyzed.  
Fallers were significantly older than non-fallers and they had significantly more 
comorbidities, with diabetes, eye diseases and circulatory diseases being significant 
among fallers. There was no significant difference between fallers and non-fallers with 
regards to gender, body mass index, hypertension, osteoporosis, depression, thyroid 
diseases and other chronic conditions (Table 5.1).  
Table 5.1: Comparison of Baseline Characteristics of Fallers and Non-fallers . 
Characteristics Fallers† 
(n=202) 
Non-Fallers‡ (n=156) p-value 
Age (Years), mean ± SD 75.2 ±7.1 72.2(±5.5) <0.001*** 
Male Gender, n(%) 65(32.2) 51(32.7) 0.92 
Body Mass Index (kg/m2), 
mean ± SD 
24.2 ±3.7 24.5(±4.0) 0.48 
Smoker, n(%)  7(3.5) 7(4.5) 0.61 
Alcohol, n(%) 15(7.4) 15(9.6) 0.45 
Medical History, n(%) 
Diabetes 69(34.2) 30(19.2) 0.002** 
Hypertension 115(56.9) 77(49.4) 0.17 
Respiratory disorders 9(4.5) 6(3.8) 0.78 
Arthritis 44(21.8) 40(25.6) 0.37 
Osteoporosis 19(9.4) 15(9.6) 0.93 
Hearing disorders 14(6.9) 7(4.5) 0.33 
Depression 6(3) 2(1.3) 0.47 
Thyroid diseases 13(6.4) 16(10.3) 0.18 
Eye diseases 95(47) 52(33.3) 0.009** 
Circulatory diseases 41(20.8) 18(11.5) 0.03* 
Neoplasm 4(2) 9(5.8) 0.05* 
No. of co-morbidities, mean ± SD 2.3(±1.6) 1.8 (±1.5) 0.01** 
Min SBPa (mmHg). mean ± SD 128(±27.3) 135.7(±24.7) 0.01** 
Min DBPb (mmHg), mean ± SD 67(±16.7) 69.8(±17.3) 0.13 
SD=standard deviation 
***p≤.001, **p≤.01, *p≤.05 
†Recurrent or injurious falls in the past 12-months 
‡No falls in the past 12 months 
aMinimal standing SBP was the lowest recorded reading of SBP amongst the three standing 
bMinimal standing DBP was the lowest recorded reading of DBP amongst the three standing 
measurements 
5.3.2. Blood Pressure Measurements 
Table 5.2 summarises the supine and erect blood pressure measurements of the 
participants. In the supine position, the systolic blood pressure (SBP) of fallers was 
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significantly lower than non-fallers, which was no longer significant following 
adjustment for age and comorbidities. After assuming the upright posture, there was no 
significant difference in standing SBP measurement at 1 min, but SBP at 2 and 3 
minutes were significantly lower among fallers than non-fallers. These remained 
significant after adjustment of age and number of comorbidities. There was no 
significant difference in supine and standing diastolic blood pressure (DBP) at any time 
point between fallers and non-fallers. There was no significant difference in the 
prevalence of OH [fallers, 52(25.7) vs. nonfallers, 28(17.9); p=0.08] between the two 
groups using the pre-defined criteria; however mean minimal SBP during standing was 
significantly lower in fallers (Table 5.1).  
Table 5.2: Postural Blood Pressure Measurements Among Fallers and Non-Fallers. 
  
SBP=systolic blood pressure, DBP=diastolic blood pressure; OH= orthostatic hypotension; CI= 
Confidence Interval 
***p≤0.001, **p≤0.01, *p≤0.05 
†Recurrent or injurious falls in the past 12-months 
‡No falls in the past 12 months 
§adjusted  for age and number of comorbidities using linear regression 
 
 
  
Blood 
Pressure 
Fallers† 
(n=202 ) 
Non-
Fallers‡ 
(n=156) 
Mean 
Difference 
(95%CI) 
Unadjuste
d  
p-value 
Adjusted 
Mean 
Difference§ 
(95%CI) 
Adjuste
d p-
value§ 
Supine (mmHg),  mean (±SD) 
Baseline 
SBP  
130(24.8) 135.6(20.3) 4.6(0.05-9.2) 0.04* 4.5(0.23 to 
9.2) 
0.06 
Baseline 
DBP 
66.2(15) 66.6(15.0) 0.4(-2.6 to 3.5) 0.78 0.73(-2.4-3.9) 0.65 
Standing (mmHg),  mean (±SD)  
SBP at 1 
min 
134.2(27.9) 139.6(26.5) 5.3(-0.33 to 
11.1) 
0.06 5.3(-0.56 to 
11.2) 
0.07 
SBP at 2 
min 
139.1(26) 146.2(24.0) 7.1(1.7-12.3) 0.009** 7.7(2.3-13.2) 0.006** 
SBP at 3 
min 
139.1(27) 146.5(24.2) 7.3(1.9-12.8) 0.008** 7.6(2.1-13.3) 0.007** 
DBP at 1 
min 
71.1(17) 72.2(18.2) 1.6(-2.0 to 5.3) 0.37 0.32(-3.3 to 
4.1) 
0.86 
DBP at 2 
min 
72.8(17) 75.2(16.2) 2.4(-1.1 to 5.9) 0.17 1.1(-2.4 to 4.6) 0.54 
DBP at 3 
min 
72.8(16.2) 75.7(15.3) 2.8(-0.47 to 6.1) 0.09 1.3(-1.9 to 4.6) 0.43 
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5.3.3. Antihypertensive Medications and Falls 
Among the total sample, 126 fallers and 77 non-fallers were taking at least one antihypertensive drug (OR=1.7; 95%CI, 1.1-2.5; p=0.01). With 
univariate analyses of individual classes of antihypertensives, α-blockers and A2RA were associated with falls. However, this finding was no 
longer significant following adjustment for age difference alone (Table 5.3). Fallers were significantly more likely to be on two or more 
antihypertensives following univariate analysis (OR=1.97; 95%CI, 1.2-3.1; p=0.005), but this was not statistically significant after adjustment 
for age and number of co-morbidities (OR=1.6; 95% CI, 0.95-2.6; p=0.07) (Table 5.3).  
Table 5.3: The Association between Antihypertensive Classes and Falls, Orthostatic Hypotension and Min SBP.  
 Falls Orthostatic Hypotension Minimal SBP 
Antihypertensives  Unadjusted 
OR(95%CI) 
Adjusted  
OR§ (95%CI) 
Unadjusted 
OR(95%CI) 
Adjusted 
OR§ (95%CI) 
Mean differencec 
(95%CI) 
Adjusted mean 
differenceϮ (95%CI) 
α-blockers 2.7(1.1-7.0)*** 2.2(0.82-5.81) 1.9(0.83-4.5) 1.83(0.75-4.4) 13.5(3.6 to 23.4)*** 14.1(3.3 to 24.8)*** 
β-blockers  1.3(0.75-2.3) 0.98(0.54-1.8) 1.5(0.81-2.7) 1.28(0.67-2.5) 3.7(-3.5 to11.0) 3.7(-3.3 to 11.4) 
ACE-I  1.1(0.63-2.0) 1.1(0.61-2.1) 1.3(0.69-2.5) 1.29(0.65-2.6) 0.05(-8.2 to 8.3) 0.59 (-8.3 to 7.2) 
A2RA 2.1(1.1-4.0)*** 1.7(0.9-3.5) 1.2(0.6-2.3) 1.09(0.53-2.2) 3.1(-4.3 to10.5) 3.7(-4.3 to 11.7) 
CCB 1.3(0.84-2.1) 1.0(0.63-1.73) 0.98(0.56-1.7) 0.86(0.48-1.5) -0.77(-6.7 to 5.2) -0.53(-6.9 to 5.8) 
Diuretics  1.5(0.78-3.1) 1.5(0.78-3.2) 2.2(1.1-4.4)* 2.2(1.1-4.4)*** -1.3(-10.7 to 8.1) -1.1(-9.9 to 7.7) 
Nitrates  1.6(0.46-5.3) 0.89(0.24-3.2) 1.7(0.52-6.1) 1.6(0.45-5.8) -6.0(-21.3 to 9.2) -5.8 (-21.5 to 9.9) 
Any antihypertensive  1.7(1.1-2.5) 1.4(0.94-2.3) 1.5(0.93-2.6) 1.6(0.8-3.3) 4.4 (-1.1 to 9.9) 4.4(-1.2 to 10.2) 
≥2 antihypertensives  1.97(1.2-3.1)** 1.6(0.95-2.6) 1.5(0.85-2.5) 1.37(0.79-2.3) 2.8(-3.1 to 8.8) 3.4(-3.0 to 9.9) 
ACE-I, Angiotensin converting enzyme inhibitors; A2RA, angiotensin II receptor antagonists; CCB, calcium channel blockers; 
***p≤0.001, **p≤0.01, *p≤0.05; OR= Odds Ratio; CI= Confidence Interval 
§adjusted  for age and number of comorbidities using binary logistic regression. 
Ϯ adjusted  for age and number of comorbidities using linear regression
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5.3.4. Antihypertensives versus Orthostatic Hypotension and Minimal 
standing SBP 
Regardless of the history of falls, individuals with OH were significantly more 
likely to be on diuretics even after adjustment for age (p=0.02), but no significant 
decrease in minimal SBP was observed with diuretic use. While the use of α-blockers 
is associated with significantly lower minimal standing SBP (p=0.01), OH was not 
associated with α- blocker use. The antihypertensive classes of β-blockers, CCB, ACE-
I and A2RA were not associated with OH or decreased minimal standing SBP. There 
was no significant difference in the number of anti-hypertensives used between 
individuals with and without OH. Similarly the minimal standing SBP did not differ 
with number of antihypertensives (Table 5.3). 
5.3.5. Multivariate Analyses 
Multivariate analysis was employed to determine the influence of OH and 
minimal standing SBP on the relationship between the antihypertensive use and falls 
(Table 5.4). Model 1 confirms that the relationship between the use of any 
antihypertensive drug and falls was unattenuated by the presence of OH, while Model 2 
confirms that the presence of OH did not alter the significant association between the 
use of 2 or more antihypertensives and falls. Model 3 denotes that both the use of any 
antihypertensive and minimal standing SBP were independently associated with falls 
and Model 4, similarly indicated that the use of two or more antihypertensives and 
minimal standing SBP were also independently associated with falls. Model 5 indicates 
that minimal standing SBP remained an independent predictor for falls despite the 
inclusion of age or comorbidities in the model.  
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Table 5.4. Logistic Regression Models to Determine the Influence of Postural Blood 
Pressure Changes on the Relationship between Antihypertensives and Falls. 
 
OR=odds ratio, CI=confidence interval, Min SBP=Minimal systolic blood pressure  
***p≤0.001, **p≤0.01, *p≤0.05 
5.4. Discussion 
Our case-control study uniquely examined the relationships between BP lowering 
therapy with recurrent or injurious falls and postural blood pressure variations. 
Treatment with medications from any antihypertensive drug class was not associated 
with falls; instead use of multiple antihypertensives exhibited significant association 
with falls, which was only attenuated by the age and number of comorbidities. 
Orthostatic hypotension, according to the existing consensus definition, was not 
associated with the risk of recurrent or injurious falls. Minimal standing SBP, however, 
was significantly lower among fallers as compared to controls. The increased risk of 
falls observed with antihypertensive use was not mediated by OH or minimal standing 
Models Adjusted OR (95%CI)  p-value R2 
Orthostatic Hypotension and Antihypertensive Use 
Model 1   0.03 
Any hypertensive 1.6(1.1-2.5) 0.02*  
Orthostatic hypotension 1.5(0.89-2.5) 0.12  
    
Model 2   0.04 
≥2 antihypertensives 1.9(1.2-3.1) 0.008**  
Orthostatic hypotension 1.5(0.9-2.6) 0.12  
    
Minimal SBP and Antihypertensive Use 
Model 3   0.04 
Any hypertensive 1.6(1.1-2.5) 0.02*  
Min SBP (per mmHg) 0.99(0.98-0.99) 0.02*  
Model 4   0.05 
≥2 antihypertensives 1.9(1.2-3.2) 0.007 **  
Min SBP (per mmHg) 0.99(0.08-0.99) 0.02*  
Model 5   0.102 
Age (per year’s increase) 1.1(1.0-1.1) 0.001***  
No. of comorbidities 1.0(0.91-1.2) 0.45  
≥2 antihypertensives 1.5(0.91-2.6) 0.10  
Min SBP  
(per mmHg increase) 
0.99(0.98-0.99) 0.01**  
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SBP, but was influenced by the inevitable age differences between our fallers and non-
faller controls.   
By opting to select cases from individuals with recurrent or injurious falls and 
controls from those with no history of falls in the previous year, we excluded those 
with a history of only one non-injurious fall in the previous year. As the risk factors for 
one time fallers and recurrent fallers (two or more) differ, it is the recurrent faller who 
would benefit to the greatest extent from fall prevention efforts and from the negative 
outcomes associated with multiple falls (AGS/BGSguidelines, 2011; Ambrose et al., 
2013; Fletcher et al., 2002), therefore this study only focused on the latter group of 
older adults. 
Although orthostatic hypotension has formerly been reported as a risk factor of 
falls (Craig, 1994; Ooi et al., 2000; Rubenstein et al., 1990), this study suggests that it 
is the presence of a lower SBP while standing rather than the presence of OH alone that 
determines the risk of recurrent or injurious falls. A recent meta-analysis demonstrated 
that in spite of lower cardiovascular morbidity and mortality among older hypertensive 
adults on antihypertensive therapy than those without treatment, mild treatment was 
effective for all ages over 65years and strict SBP control presented no added advantage 
(Goeres et al., 2014). Our study superimposes this report by suggesting that use of 
antihypertensives is only beneficial with mild consumption whereas a strict SBP 
control, may present higher risk for falls. While the prevalence of hypertension 
increases markedly with age (van Rossum et al., 2000), age-related decline in blood 
pressure is also prominent in older adults, which is the marker of poor or deteriorating 
health (Hakala et al., 1998) and may be associated with syncope (Yiu et al., 2006) and 
recurrent falls (Heitterachi et al., 2002). One longitudinal study found that among older 
adults, the changes in blood pressure are related to health, with a rise of 1.5mmHg per 
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year among healthy elderly while a drop among the older adults with multiple co-
morbidities and this co-morbidity related drop was more prominent with SBP than 
DBP (Starr et al., 1998). The prevalence of lower SBP while standing among our 
fallers might then be explained by the significant number of comorbidities. 
Furthermore, the report by Odden et al suggested that frail older adults might benefit 
from slightly higher blood pressure, to overcome age-related loss of vascular elasticity 
and sustain perfusion of vital organs (Odden et al., 2012). Of note, the difference in 
standing SBP among our fallers was only observed if standing SBP was measured at 
2minutes and beyond. Our findings support that of Kario et al who reported that 
individuals with a history of falls and a standing SBP below 140 mmHg had an 
increased risk of falling(Kario et al., 2001). Before further conclusions can be drawn, 
prospective evaluation of the relationship between minimal standing SBP at 2 or 
3minutes and falls occurrence is warranted, in order to develop a clear cut-off for 
minimal standing SBP or an accurate predictive score while taking into account 
minimal standing SBP, age, history of recurrent and injurious falls alongside other 
potential predictors for falls. 
 Our study has provided a deeper insight into the link between postural blood pressure 
and antihypertensives among older fallers. The measurement of standing SBP may 
represent a useful parameter in determining how aggressively SBP should be treated 
among geriatric population, with increasing age and history of falls currently being the 
only available decision aid(James et al., 2014). Our findings contradict those of a 
previous study that various classes of antihypertensives are associated with falls (Wong 
et al., 2013) and choosing one class over the other may reduce the risk of falls. On the 
contrary, our results indicate that the use of two of more antihypertensives regardless of 
class of medication might be associated with high risk of falls.  
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Callisaya et al (Callisaya et al., 2014) stated that increased antihypertensive burden, 
calculated by the ingested dose of each antihypertensive divided by the recommended 
maximal daily dose, increases the risk of falls, independent of drug classes. While our 
study supports this finding, it suggests that the simple method of counting number of 
antihypertensives may also be effective in predicting falls risk. The association of 
multiple antihypertensives with falls was attenuated with age adjustment, as reported 
by Gu and colleagues (Gu et al., 2006) that the use of multiple antihypertensives 
increases with increasing age. A multicentre longitudinal study found that lower SBP 
along with use of two or more antihypertensives significantly contributed to mortality 
among their institutionalized octogenarians (Benetos et al., 2015). Although we did not 
find the association of use of two or more antihypertensives with SBP but as the 
authors suggested that the safety of using multiple antihypertensives in elderly patients 
with lower SBP “raises a cautionary note”, our findings do suggest that 2 or more 
antihypertensives and lower standing SBP are independently linked with falls and if 
they co-exist they may amplify falls risk. 
While orthostatic hypotension was related with uncontrolled blood pressure as 
suggested by the findings of the British Women Heart and Health study (BWHHS), the 
number of antihypertensives and use of β-blockers were not associated with OH in our 
study. Instead, diuretic use was linked with OH, unlike that reported by the 
BWHHS(Kamaruzzaman et al., 2010). In addition, using currently agreed definitions 
for OH, there was no significant relationship between OH and falls. While this suggests 
that the use of multiple blood pressure lowering agents may be associated with higher-
risk of future falls through currently unexplained mechanisms, it also suggests that the 
diagnostic criteria for OH may require revision(Frith et al., 2014). 
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To our knowledge, our study was the first to include the evaluation of postural blood 
pressure measurements, antihypertensive use and falls in the same participants. The 
limitations of the study are as follows. As a case-control study, it was unable to 
determine any causal relationship between antihypertensive therapy and falls, which 
will be a subject of a future prospective study which, however, requires larger sample 
sizes for adequate statistical power. Falls in our study were identified through 
retrospective recall, the prospective study will therefore need to consider the use of fall 
diaries to minimize recall bias(Ganz et al., 2005).  
5.5. Conclusion 
Individuals with a history of at least two falls or one injurious fall, had significantly 
lower standing SBP obtained 2-3 minutes after assuming the upright posture rather than 
immediately. Orthostatic hypotension was not associated with recurrent or injurious 
falls. While falls were also associated with the regular use of two or more 
antihypertensive drugs as compared to non-faller controls, this was not mediated by 
minimal standing SBP, challenging previous assumptions that antihypertensive are 
linked to falls through their blood pressure lowering effects. A prospective study 
evaluating actual falls outcome with regards to blood pressure changes among older 
individuals prescribed antihypertensive therapy is now warranted to accurately identify 
factors associated with increased risk of falls, which will be invaluable for effective 
blood pressure lowering among the older population. 
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CHAPTER 6. ANTICHOLINERGIC BURDEN IS ASSOCIATED WITH RECURRENT 
AND INJURIOUS FALLS IN OLDER INDIVIDUALS 
 
6.1. Introduction: 
The drugs with anticholinergic activity are the most widely prescribed FRID 
among older adults (Carriere et al., 2009; Fox et al., 2011). In addition, recent studies 
have reported the anticholinergic cognitive burden (ACB) of drugs to be associated 
with poor mobility, functional decline, psychomotor slowing (Cao et al., 2008; Fox et 
al., 2014; Landi et al., 2014; Nebes et al., 2007) as well as falls among older adults 
(Aizenberg et al., 2002; Dauphinot et al., 2014; Wilson et al., 2011). However, studies 
have not evaluated the anticholinergic effects of drugs among community-dwelling 
older people at particularly high risk of recurrent falls. Furthermore, previous studies 
had not, evaluated mobility and balance performance in relation to the use of 
anticholinergic drugs in a single study. We hypothesized that the use of drugs with 
ACB leads to falls through their effects on mobility and balance. Therefore, the 
objective of this study was to examine the association between ACB of drugs with falls 
and subsequently employing statistical modelling to evaluate the mediating effects of 
mobility and balance on anticholinergic associated falls among community dwelling 
older adults. 
6.2. Methodology 
The methodology of study population and recording of basic characteristics, 
medication recording (chapter 3) and blood pressure have been explained earlier 
(chapter 4).  
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6.2.1. Physical function 
The Timed-Up and Go (TUG) and Functional Reach (FR) tests were conducted 
to provide indicators of gait speed and balance respectively. The TUG test is 
considered as an appropriate clinical tool to measure functional mobility among older 
adults (Herman et al., 2011). For TUG, the participants were instructed to walk a 
distance of 3-metres at their normal pace, from and back to a seated start position, on a 
46cm high arm-chair. Functional reach was defined as the distance between arm’s 
length and maximal forward reach achieved using a fixed base of support (Duncan et 
al., 1990). The participants were instructed to stand with their feet shoulder width apart 
next, and to raise their arm at 90°, parallel to the wall. A one-metre ruler was placed at 
shoulder (acromion) height, parallel to the participant’s arm and the distances were 
recorded at the location of the 3rd metacarpal. After noting down the initial reach, the 
final distance was recorded (in centimetres) as the participants leaned forward without 
stepping or losing the balance. The difference between the two measurements was 
recorded as the FR of the participant.  
Participants were instructed to grip the Jamar dynamometer with maximal 
strength with their dominant hand, followed by their non-dominant hand while seated 
and elbows bent at 90°. Three readings for each hand were obtained, the average of 
which was considered as the final grip strength. All the above tests were demonstrated 
with one trial run. Shoes were kept on for these tests and walking aids were allowed for 
TUG if required. 
6.2.2. Anticholinergic Burden 
The total anticholinergic burden for each participant was calculated using the 
validated Anticholinergic Cognitive Burden(ACB) Scale (Fox et al., 2011).The drugs 
were classified as having absent, possible or deﬁnite anticholinergic properties . The 
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total ACB was then calculated using the formula; Total ACB =[number of score1 
anticholinergic drugs]+[number of score2 anticholinergic drugs*2]+[number of score 3 
anticholinergic drugs*3]. We categorized patients’ ACB status into 2categories (no 
ACB=total score 0; positive ACB= total score≥1) for comparison of characteristics 
between the no ACB and positive ACB fallers and non-fallers. 
6.2.3. Statistical Analysis 
The continuous data of TUG, FR and GS were dichotomized to form binomial 
variables (poorer TUG ≥13.5sec and poorer FR ≤18cm, reduced GS≤ 20kg for women, 
≤30kg for men). A p-value of <0.05 was considered statistically significant. Statistical 
modelling using logistic regression methods was employed to determine the mediation 
effects of TUG and FR on falls associated with ACB. This was determined by 
examining the associations by step-wise adjustment for potential confounders. If the 
independent variable (ACB score) was no longer statistically significant after the 
addition of a new variable (TUG or FR) in the model with falls as the dependent 
variable, then the new variable was considered a potential mediator for the relationship 
between the independent variable and dependent variable (falls). Potential confounders 
were identified from comparison of basic characteristics between fallers and non-fallers 
and were adjusted for in subsequent models. However, as numerous medical conditions 
with potential collinearity were significantly different between groups, we adopted the 
approach of adjusting for the number of comorbidities, instead of individual 
comorbidities, to address multicollinearity.  
6.3. Results 
6.3.1. Recruitment and baseline demographics 
Four hundred and twenty eight participants, 263 fallers and 165 non-fallers 
were recruited into the study. Fallers were significantly older with significantly more 
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comorbidities and more medications. Diabetes, visual problems, hypertension, hearing 
disorders and circulatory diseases were significantly increased among fallers. The 
measures of gait and balance i.e. TUG and FR were significant for falls but not upper 
limb strength i.e. GS (Table 6.1).  
Table 6.1: Characteristics and Anticholinergic Cognitive Burden Among Fallers and 
Non-fallers. 
Characteristics Fallersa 
(n=263) 
Nonfallersb 
(n=165) 
Mean 
difference/OR 
(95% CI) 
P valuec 
Age, mean(±SD) 75.3(7.3) 72.13(5.5) 3.1(1.8-4.4) <0.001 
BMI, mean(±SD) 23.75(4.1) 24.13(4.0) 0.4(0.3-1.2) 0.33 
     
Characteristics Fallersa 
(n=263) 
Nonfallersb 
(n=165) 
OR(95% CI) P valued 
Male, n(%) 84(31.9) 55(33.3) 1.0(0.7-1.6) 0.76 
Smoking, n(%) 15(5.7) 7(4.2) 1.3(0.5-3.4) 0.50 
Alcohol, n(%) 23(8.7) 17(10.3) 0.8(0.4-1.6) 0.59 
     
Medical History 
Diabetes, n(%) 95(36.1) 29(17.6) 2.6(1.6-4.2) <0.001 
Visual problems, n(%) 132(50.2) 51(30.9) 2.2(1.5-3.3) <0.001 
Hypertension, n(%) 155(58.9) 74(44.8) 1.7(12-2.6) 0.004 
Circulatory diseases, n(%) 45(17.1) 14(8.1) 2.2(1.2-4.2) 0.01 
Hearing disorders, n(%) 28(10.6) 7(4.2) 2.6(1.1-6.3) 0.01 
Neoplasm, n(%) 6(2.3) 10(6.1) 0.36(0l.1-1.1) 0.04 
Arthritis, n(%) 68(25.9) 38(23.0) 1.1(0.74-1.8) 0.51 
Osteoporosis, n(%) 25(9.5) 16(9.7) 0.97(0.5-1.8) 0.94 
Asthma, n(%) 18(6.8) 9(5.5) 1.2(0.5-2.9) 0.56 
Thyroid disorders, n(%) 17(6.5) 15(9.1) 0.69(0.3-1.4) 0.31 
     
Orthostatic Hypotension, 
n(%) 
62(23.6) 29(17.6) 1.4(0.88-2.3) 0.14 
     
Physical Performance Scores, n(%) 
TUG ≥ 13.5s 134(51) 34(20.6) 3.9(2.5-6.2) <0.001 
FR ≤ 18cm 78(29.7) 13(7.9) 4.8(2.6-9.1) <0.001 
Reduced RGS  201(76.4) 89(53.9) 2.7(1.7-4.2) <0.001 
Reduced LGS 212(80.6) 101(61.2) 2.9(1.8-4.6) <0.001 
     
Total ACB Score, n(%) 
ACB≥1 75(28.5) 29(17.6) 1.8(1.1-3.0) 0.01 
SD=standard deviation; OR= Odds ratio; CI Confidence Interval 
ACB= Anticholinergic cognitive Burden; TUG= timed up and go, FR=functional reach 
LGS= grip strength in left hand; RGS=grip strength in right hand; Reduced Grip strength ≤20kg women, ≤30kg men 
aRecurrent or injurious falls in the past 12-months, bNo falls in the past 12 months, cStudent’s t-test, dChi-squared test;  
 
6.3.2. Anticholinergic Burden Score and Falls 
Seventy five (28.5%) fallers and 29(17.6%) non-fallers had an ACB score of 
≥1, which was significant for falls (OR, 1.8; 95%CI; 1.1, 3.0; p=0.01) (Table 1). When 
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the characteristics of participants with an ACB score ≥ 1 and those with ACB score of 
0 were compared, age, gender, number of co-morbidities and use of medicines, poorer 
TUG and poorer FR were statistically significant for ACB score ≥ 1 while grip 
strength, baseline blood pressure or prevalence of orthostatic hypotension did not show 
any association (Table 6.2). 
Table 6.2: Characteristics of sample population according to the anticholinergic 
cognitive burden score. 
 
Total participants 
N=458 
ACB=0 
n=324 
ACB≥1 
n=71 
Mean Difference 
/OR(95%CI) 
p-valuea 
Age mean(SD) 73.3(6.6) 76.5(7) 3.2(1.6-4.6) 0.0001 
Systolic blood pressure, mean(SD) 130(22) 132(22) 1.8(-3.1 to 6.7) 0.45 
Diastolic blood pressure, 
mean(SD) 
67(15) 67(14) 0.14(-3.1 to 3.3) 0.93 
     
Total participants 
N=458 
ACB=0 
n=324 
ACB≥1 
n=71 
OR 
(95%CI) 
p-valueb 
Falls (yes) n(%) 188(58) 75(72.1) 1.8(1.1-3.0) 0.01 
     
Gender (Male) 95(29.3) 44(42.3) 0.56(0.35-0.89) 0.01 
Smoking n(%) 15(4.6) 7(6.7) 1.4(0.58-3.7) 0.39 
Alcohol n(%) 26(8) 14(13.5) 1.7(0.89-3.5) 0.09 
Orthostatic Hypotension n(%) 68(21) 23(22.1) 1.1(0.62-1.8) 0.80 
     
TUG ≥ 13.5s, n(%) 110(34) 58(55.8) 2.4(1.5-3.7) 0.0001 
FR ≤ 18cm, n(%) 53)16.4) 38(36.5) 2.8(1.7-4.7) 0.0001 
Reduced Rt GS, n (%) 210(64.8) 80(76.9) 1.6(0.95-2.7) 0.07 
Reduced Lt GS, n(%) 231(71.3) 82(78.8) 1.3(0.78-2.4) 0.25 
     
No of comorbidities  Median(IQR) 2(2) 2(2) n/a 0.0001
c
 
No of medications◊ Median(IQR) 2(4) 5(4) n/a 0.0001
c
 
     
TUG= timed up and go, FR=functional reach, GS=grip strength, Grip strength reduced <20kg women, <30kg men 
◊
Calculated after excluding the drugs in ACB scale, aStudent’s t-test, bChi-squared test , cMann Whitney U test. 
 
 
Subgroup analysis was performed by investigating the ACB score separately 
according to the faller and non-faller groups. Age and number of co-morbidities were 
significantly associated with a positive ACB score in both groups. Timed up and go 
performance was significantly poorer among ACB positive subgroups in both fallers 
and nonfallers while FR performance was only poorer among the fall participants with 
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positive ACB score. Grip Strength was not statistically significant between those with 
or without positive ACB score (Table 6.3). 
Table 6.3: Subgroup analysis of participants as fallers and nonfallers according to the 
ACB score. 
Characteristics Fallers† (n=263) Nonfallers‡ (n=165) 
 ACB=0 
n=188 
ACB≥1 
n=75 
P value ACB=0 
n=136 
ACB≥1 
n=29 
P value 
Age, mean(±SD) 74.7)7.2) 76.8(7.5) 0.03a 71.4(5.2) 75.6(5.8) <0.001a 
Number of 
comorbidities, 
median (IQR) 
2(3) 3(2) 0.004b 1(2) 2(3) 0.01b 
Measures of upper limb and lower limb strength, n(%) 
TUG ≥ 13.5s 86(45.7) 48(64) 0.009c 24(17.6) 10(34.5) 0.04c 
FR ≤ 18cm 43(22.9) 35(46.7) 0.0001c 10(7.4) 3(10.3) 0.61c 
Reduced RGS 138(73.4) 63(84) 0.19c 72(52.9) 17(58.6) 0.69c 
Reduced LGS  147(78.2) 65(86.7) 0.20 84(61.8) 17(58.6) 0.58c 
Type of Falls n(%) 
Indoor 109(58.3) 45(59.2) 0.89c - - - 
Outdoor 107(57.2) 43(56.6) 0.92c - - - 
Injuries 87(46.5) 43(56.6) 0.13c - - - 
Medication use◊ 
Number of drugs
◊ 
Median(IQR) 
 
3(4) 
 
5(5) 
 
0.0001b 
 
1(3) 
 
4(3) 
 
0.0001b 
Antihypertensives 
n(%) 
93(49.5) 62(82.1) 0.0001c 46(35.1) 22(83.2) 0.0001c 
Analgesics n(%) 50(26.7) 40(52.6) 0.0001c 17(12.6) 9(30) 0.02c 
Psychotropics n(%) 10(5.3) 18(23.7) 0.0001c 4(3) 4(13.3) 0.01c 
Antidiabetic drugs 
n(%) 
53(28.3) 26(34.2) 0.34c 13(9.6) 8(26.7) 0.01c 
Antiparkinsonians 
n(%) 
2(1.1) 5(6.6) 0.01* c 1(0.7) 1(3.3) 0.24c 
Blood pressure (BP) mean(±SD) 
Systolic BP 
mean(±SD) 
125.6(21.6) 132.3(24.7) 0.03a 135.2(20.1) 133.4(19.2) 0.66a 
Diastolic BP 
mean(±SD) 
66.4(14.1) 67.8(13.7) 0.45a 67.4(15.1) 64.3(13.1) 0.31a 
OH n(%) 44(23.4) 18(24) 0.92c 24(17.6) 5 (17.2) 0.95c 
◊Calculated after excluding the drugs with ACA; astudent’s t test, bMann Whitney U test, cChi squared test 
 
 
6.3.3. Multivariate Analyses 
The unadjusted models show that both an ACB score of 1 or greater and GS are 
independent predictors of falls (models 1 and 2) but the association between ACB ≥1 
and falls was attenuated and became non-significant with the insertion of TUG and FR 
into the models (models 3 and 4). After adjusting for age and gender, ACB ≥1 was no 
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longer significant with GS (models 5&6) and remained non-significant by the presence 
of TUG and FR (models 7&8).The similar results were observed after adjusting of age, 
gender and number of co-morbidities (models 9, 10,11,12). The association between 
TUG, FR, GS and falls remained significant after adjusting for age, gender and number 
of comorbidities (Table 6.4). 
Table 6.4: Logistic Regression Models to Determine the Influence of Timed up and Go 
and Functional Reach on ACB associated Falls. 
 
 Unadjusted 
models 
Adjusted for age 
and gender 
Adjusted for age, gender 
and number of 
comorbidities  
 Model 1 Model 5 Model 9 
Reduced RGS 2.6(1.7-4.1)*** 2.1(1.3-3.4)** 1.9(1.2-3.1)** 
ACB >=1 1.7(1.1-2.9)* 1.5(0.9-2.6) 1.4(0.8-2.4) 
    
 Model 2 Model 6 Model 10 
Reduced LGS 2.8(1.7-4.6)*** 2.3(1.4-3.8)** 2.1(1.3-3.5)** 
ACB >=1 1.8(1.1-2.9)* 1.5(0.9-2.6) 1.4(0.85-2.4) 
 
 Model 3 Model 7 Model 11 
TUG ≥13.5s 3.7(2.4-5.9)*** 3.1(1.9-5.0)*** 2.8(1.7-4.6)*** 
ACB >=1 1.4(0.88-2.4) 1.3(0.81-2.2) 1.3(0.76-2.1) 
 
 Model 4 Model 8 Model 12 
FR≤18cm 4.5(2.4-8.5)*** 3.7(1.9-7.1)*** 3.4(1.8-6.6)*** 
ACB >=1 1.4(0.89-2.4) 1.3(0.8-2.2) 1.2(0.7-2.1) 
***p≤0.001, **p≤0.01, *p≤0.05 
ACB=anticholinergic cognitive burden; TUG=timed up and go; FR=Functional Reach; RGS=right grip strength; LGS=left grip 
strength 
Model 1,2,3,4 adjusted separately for TUG or FR or RGS or  LGS;  
Model 5,6,7,8 adjusted age and gender and (TUG or FR or RGS or LGS) 
Model 9,10,11,12 adjusted for age, gender, number of comorbidities and (TUG or FR or RGS or LGS) 
 
 
 
6.4. Discussion 
In this study, we found that the use of any ACB drug was significantly 
associated with falls and increased age along with poorer dynamic balance and gait 
speed. Grip strength was significantly associated with falls but not with a positive ACB 
score. The significant association between a positive ACB score and falls was 
attenuated when controlled for TUG and FR but not by GS, thus suggesting that TUG 
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and FR are the potential mediating factors through which anticholinergic medications 
may precipitate falls.  
Nearly half of our participants (46.1%) were on at least one medication with 
anticholinergic activity, which is similar to that reported by other studies (Carriere et 
al., 2009; Fox et al., 2011; Landi et al., 2014). Using the Anticholinergic Burden Scale, 
Aizenberg and colleagues were the first to report that higher anticholinergic activity 
was significantly associated with increased rate of falls(Aizenberg et al., 2002). Two 
studies have used the Drug Burden Index (DBI), to assess the association of falls with 
the cumulative load of sedatives and anticholinergic drugs in different settings 
(Dauphinot et al., 2014; Wilson et al., 2011). Wilson et al found increased DBI to be 
independently associated with falls prospectively among institutionalized older people 
(Wilson et al., 2011). Dauphinot et al demonstrated a significant increase in the risk of 
falls among older adults with increased DBI during their hospital stay (Dauphinot et al., 
2014). However, sedatives alone are considered as independent predictors of falls 
among older adults (Woolcott et al., 2009) and drugs with anticholinergic activity 
include beta-blockers, colchicine, ranitidine and other commonly prescribed drugs to 
older adults, and not merely psychotropics. A recent meta-analysis of eighteen studies 
involving different ACB scales, found ACB to be associated with falls along with 
cognitive impairment and all-cause mortality (Ruxton et al., 2015). 
Our results suggest that falls associated with ACB medications are potentially 
mediated by the deterioration in lower limb function measured with TUG and FR. The 
TUG test is a composite measure of response time, limb girdle strength, gait initiation, 
gait speed and dynamic balance, widely used as a screening test for gait and balance 
disorders in research and clinical practice (AGS/BGSguidelines, 2011). Functional 
reach is a convenient measure of dynamic balance. Landi et al analysed a population of 
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1490 nursing home residents and reported that a higher score in the anticholinergic risk 
scale was associated with a greater likelihood of functional decline, poor physical 
performance and a higher rate of falls (Landi et al., 2014). Our findings are further 
supported from the study by Nebes et al, who examined the cumulative anticholinergic 
load of older community residents by testing their serum anticholinergic activity 
(Nebes et al., 2007). Although they excluded the participants with impaired cognition 
and psychiatric illnesses or taking any psychotropic medications at baseline, they found 
that elevated serum anticholinergic activity was significantly associated with the slow 
gait speed and response time. Furthermore, a recent metaanalysis reported that five of 
their eight included studies reported a decline in physical function among users of 
anticholinergics (Fox et al., 2014). 
Anticholinergics are well known for their cognitive effects in older adults (Cao 
et al., 2008; Carriere et al., 2009; Fox et al., 2011; Fox et al., 2014; Landi et al., 2014; 
Salahudeen et al., 2014) and cognitive impairment itself is an independent risk factor 
for falls (Harlein et al., 2011). The study by Herman et al added a new dimension to the 
existing knowledge about cognition and TUG by stating that the transferring and 
turning component of TUG might be utilizing intact cognitive resources (Herman et al., 
2011).The mediating effects of TUG in our population can be explained by  TUG being 
affected by the cognitive effects of anticholinergic activity thus leading to falls. An 
interesting study by Cao et al reported that anticholinergic drug burden was 
independently associated with cognitive impairment and deterioration of all four 
domains of physical function leading to balance difficulty, mobility difficulty, slow 
gait, difficulty with chair stands, weak grip strength and upper extremity limitations 
(Cao et al., 2008). Our study has also found ACB associated functional decline to be a 
mediator for falls by evaluating gait speed and limb girdle strength using TUG test and 
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balance limitations using FR test. There is insufficient evidence in the literature to 
explain the mechanisms behind the particular role of FR and ACB associated falls.  
Grip strength, which is a widely known marker of general frailty and 
sarcopenia, although related to falls, was not associated with ACB. The lack of 
association between ACB and GS supports our early hypothesis that anticholinergics 
adversely affect physical function not by reducing overall strength, but through its 
central effects which dictates reaction time, speed and functional balance. The 
antimuscarinic activity of anticholinergic drugs inhibits receptors in the forebrain, 
particularly in the basal ganglia, groups of nerve cells responsible for the coordination 
of movement. This cholinergic blockade in the brain is responsible for decline in motor 
and executive function (Nebes et al., 2007). Furthermore, normal ageing is 
accompanied by an increased sensitivity to the blockade of the muscarinic receptors 
and increased permeability of blood brain barrier (Kersten et al., 2014) thus enhancing 
the anticholinergic effects of medications, leading to significant deterioration in 
physical function and consequently leading to falls. 
Our selected participants were at high risk of future falls with their history of 
injurious or recurrent falls (AGS/BGSguidelines, 2011). The ACB score although 
lower was still statistically significant, suggesting that medications with mild 
anticholinergic properties, among high risk fallers exacerbate their risk of falls. 
Similarly the impact of age and comorbidities on ACB score and falls is also 
comparable to previous studies (Carriere et al., 2009; Feinberg, 1993), because the 
number of comorbidities tends to increase with age along with the medications 
prescribed for the treatment of diseases. Different methods have been used by 
researchers to assess the anticholinergic activity of prescribed medications including: 
the anticholinergic risk scale, anticholinergic burden scale, drug burden index and 
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measuring serum anticholinergic activity. The measure of serum anticholinergic 
activity is the gold standard to measure the ACB burden of drugs and ACB scale is 
based on the affinity of drugs for muscarinic receptors of drugs and scored according to 
their clinical relevance (Ruxton et al., 2015). The study by Pont et al found that the 
ACB scale is the most reliable and clinically relevant among other available scales 
(Pont et al., 2015). A study conducted using nine anticholinergic scales found that the 
ACB scale identified not only the highest exposure to anticholinergic medications in 
the population but was also most likely to predict adverse outcomes of clinical 
interest(Salahudeen et al., 2014). The ACB scale is more sensitive than other available 
scales in detecting adverse outcomes, according to the meta-analysis by Ruston et al, 
with per unit increase in the ACB scale doubling the odds of all-cause mortality, which 
was not the case with any other scales (Ruxton et al., 2015). 
Our study was the first to explore the association of drugs with anticholinergic 
properties and falls using the ACB scale in the community setting and was also the first 
to relate measures of mobility with ACB associated falls. However, as it was a cross 
sectional study, causal relationships could not be established. Hence a future 
adequately powered prospective study is warranted to consolidate this association. Falls 
were recorded retrospectively and therefore may be subject to recall bias. In additional, 
future studies should also include adequately sensitive assessments of higher mental 
function as well as lower limb function.  
6.5. Conclusion 
Our study suggests that ACB is associated with reduced lower limb function 
leading to falls among older adults. The TUG and FR are therefore potentially useful 
tools to assess the adverse anticholinergic activity of medications on older individuals, 
and may be useful risk indicators prior to the prescription of medications with 
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anticholinergic activity. In addition to medication review and withdrawal interventions, 
it would be interesting to explore whether concomitant physiotherapy which improves 
TUG and FR may reduce ACB induced falls risk. Consolidated evidence from the 
prospective and intervention studies is now required to further explore this association.  
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CHAPTER 7: ASSOCIATION OF INAPPROPRIATE PRESCRIPTIONS WITH FALLS 
AMONG COMMUNITY DWELLING OLDER ADULTS 
7.1. Introduction  
The increase in total number of medications/polypharmacy and FRID among 
older individuals is linked to the increased risk of potentially inappropriate 
prescriptions (PIP)(Weng et al., 2013). While, numerous studies have described the 
association between polypharmacy and falls, few studies have studied the relationship 
between PIP and falls, particularly in the context of secondary prevention among older 
individuals at high risk of falls(A. Zia et al., 2015b). Potentially inappropriate 
prescriptions are drug prescriptions in which potential harm from established relative 
contra-indications, interactions and side-effects outweigh the expected benefit of the 
prescribed drug, particularly where safer alternatives are available(Frankenthal et al., 
2013). Several criteria have been developed to detect PIP among older adults. These 
include the Beer’s criteria, medication appropriateness index (MAI), inappropriate 
prescribing in elderly tool (IPET) and the Screening Tool for Older Person’s 
Prescriptions (STOPP) criteria. The MAI detects the overall prescribing quality in ten 
different domains e.g. indication, effectiveness, cost; but does not provide guidance on 
the appropriateness of specific medications(Hanlon et al., 1992).The Canadian tool 
IPET, consisting of a list of 14 most prevalent prescriptions, has only been used in 
Canada and in a solitary Irish study outside Canada(Page et al., 2010). The Beer’s 
criteria, a list of 30 drugs to be avoided in the elderly regardless of the diagnosis, has 
dominated the international literature. However, the Beer’s criteria is limited by lack of 
sensitivity, missing drug-drug interactions and duplicate drug classes. Furthermore, 
there is no evidence for subsequent reduction of adverse drug events following 
adjustment of inappropriate prescriptions detected by the Beer’s criteria. Its 
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applicability outside the United States is also questionable due to the non-availability 
of certain drugs in other countries named in the Beer’s criteria (Wahab et al., 2012).  
The newer STOPP criteria has evidence of good inter-rater reliability, inclusion 
of both American and European medications(Page et al., 2010) and is documented to 
detect almost 2.8 times more adverse drug events than Beer’s criteria(O’Mahony et al., 
2010). It has been recently been upgraded to STOPP2 (O'Mahony et al., 2015). 
However, STOPP or STOPP2 have never been employed in the detection PIP among a 
community-dwelling sample of older fallers. This study, therefore, aimed to determine 
the association between PIP identified by STOPP2 and falls in community dwelling 
older adults and to identify factors associated with PIP among older individuals with 
recurrent and injurious falls.  
7.2. Methods 
The methodology for setting, participants and collection of baseline 
demographics, medication assessment, blood pressure readings, orthostatic 
hypotension, gait and balance (TUG, FR and GS) have been explained earlier. 
7.2.1. Criteria for Potentially Inappropriate Prescriptions 
The STOPP (screening tool of older person’s potentially inappropriate 
prescriptions) criteria was formulated and validated by a panel of 18 experts in geriatric 
pharmacotherapy in 2006(Gallagher et al., 2008). It consisted of 65 criteria arranged 
according to physiological systems and medical diagnosis i.e. cardiovascular system, 
central nervous system, musculoskeletal system, urogenital system, endocrine system, 
duplicate drugs, falls risk increasing drugs and analgesics. Based on expanding 
evidence based therapeutics, STOPP was upgraded by a 19 member expert panel to 80 
criteria, known as STOPP2 (O'Mahony et al., 2015). The new STOPP categories 
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created were antiplatelet/anticoagulant drugs, renal function drugs and drugs that 
increase anticholinergic burden. We used version 2 of the STOPP to detect 
inappropriateness of prescribing based on the medical history and medication use of 
fallers and non-fallers.  
7.2.2. Statistical Analysis:  
After the univariate analysis, multiple group comparisons were performed using 
logistic regression with dummy variables. The total prescriptions issued to participants 
were assessed and analysed according to faller and non-faller groups. For further 
analysis, participants were grouped into PIP=0 versus PIP≥1. Potential confounders for 
the risk of falls according to significant differences in basic characteristics i.e. age, 
gender, blood pressure, polypharmacy and comorbidities were adjusted for using 
multivariate logistic regression and the differences between groups were expressed as 
odds ratios (OR) with 95% confidence intervals(CI). A p-value of <0.05 was 
considered statistically significant. The best predictor model for increased risk of falls 
using PIP as an independent variable was also obtained. A further exploratory 
multivariate analysis was performed after the exclusion of non-fallers, to determine the 
predictors of PIP among fallers.  
7.3. Results: 
7.3.1. Recruitment and Baseline Demographics  
We recruited 428 participants, 263 fallers and 165 non-fallers into the study. 
Fallers were significantly older, and had significantly more comorbidities than non-
fallers. Diabetes, visual problems, hypertension, hearing disorders and circulatory 
diseases were significantly increased among fallers. Fallers and non-fallers were on a 
median (interquartile range) of 4(4) and 2(3) drugs respectively (p≤0.001). The 
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measures of gait and balance i.e. TUG, FR and grip strength were also as significantly 
poorer among fallers (Table 7.1).  
Table 7.1: Basic Characteristics of the whole population. 
Characteristics Fallersa  
(n=263) 
Nonfallersb 
(n=165) 
OR(95% CI) or mean 
difference (95%CI) 
P valuec 
Age, mean(±SD) 75.3(7.3) 72.13(5.5) - <0.001d 
Male, n(%) 84(31.9) 55(33.3) 1.0(0.7-1.6) 0.76 
Smoking, n(%) 15(5.7) 7(4.2) 1.3(0.5-3.4) 0.50 
Alcohol, n(%) 23(8.7) 17(10.3) 0.8(0.4-1.6) 0.59 
BMI, mean(±SD) 23.75(4.1) 24.13(4.0) - 0.33d 
Marital Status, n(%) 
Single 
Married 
Widowed 
 
14(8.1) 
124(75.2) 
27(16.4) 
 
19(7.2) 
186(70.7) 
58(22.1) 
 0.16 
Living Alone, n(%) 12(7.3) 21(8) 1.1(0.52-2.3) 0.78 
Living with Spouse, n(%) 92(55.8) 138(52.5) 0.87(0.59-1.2) 0.51 
Living with Children, n(%) 80(48.5) 133(50.6) 1.1(0.73-1.6) 0.67 
Medical History 
No of comorbidities  
Median(IQR) 
2(2) 2(2) n/a <0.001*** 
Diabetes, n(%) 95(36.1) 29(17.6) 2.6(1.6-4.2) <0.001** 
Visual problems, n(%) 132(50.2) 51(30.9) 2.2(1.5-3.3) <0.001** 
Hypertension, n(%) 155(58.9) 74(44.8) 1.7(12-2.6) 0.004** 
Circulatory diseases, n(%) 45(17.1) 14(8.1) 2.2(1.2-4.2) 0.01 
Hearing disorders, n(%) 28(10.6) 7(4.2) 2.6(1.1-6.3) 0.01* 
Neoplasm, n(%) 6(2.3) 10(6.1) 0.36(0.1-1.1) 0.04* 
Arthritis, n(%) 68(25.9) 38(23.0) 1.1(0.74-1.8) 0.51 
Osteoporosis, n(%) 25(9.5) 16(9.7) 0.97(0.5-1.8) 0.94 
Asthma, n(%) 18(6.8) 9(5.5) 1.2(0.5-2.9) 0.56 
Thyroid disorders, n(%) 17(6.5) 15(9.1) 0.69(0.3-1.4) 0.31 
Medication History 
No of medications◊ 
Median(IQR) 
4(4) 2(3) n/a <0.001*** 
Polypharmacy, n(%) 36(21.8) 111(42.2) 2.6(1.7-4.1) 0.001 
Blood Pressure 
Systolic blood pressure, 
mean(SD) 
134.8(20.3) 127.5(22.7) n/a 0.001** 
Diastolic blood pressure, 
mean(SD) 
66.8(14.8) 66.8(13.9) n/a 0.98 
Orthostatic Hypotension, 
n(%) 
62(23.6) 29(17.6) 1.4(0.88-2.3) 0.14 
Physical Performance Scores, n(%) 
TUG ≥ 13.5s 134(51) 34(20.6) 3.9(2.5-6.2) <0.001*** 
FR ≤ 18cm 78(29.7) 13(7.9) 4.8(2.6-9.1) <0.001*** 
Reduced grip strength 215(81.7) 101(61.2) 2.9(1.8-4.6) <0.001*** 
Potentially Inappropriate Prescriptions 
PIP=1 59(22.4) 38(23) 1.5(0.9-2.4) 0.09 
PIP= 2 47(17.9) 14(8.5) 3.2(1.6-6.2) <0. 
001*** 
PIP≥ 3 50(19.0) 9(5.5) 5.4(2.5-11.5) <0. 
001*** 
     
PIP≥1 156(59.3) 61(37) 2.5(1.6-3.7) <0. 
001*** 
***p≤0.001, **p≤0.01, *p≤0.05 
SD=standard deviation; OR= Odds ratio; CI Confidence Interval 
TUG= timed up and go, FR=functional reach, Reduced Grip strength ≤20kg women, ≤30kg men 
aRecurrent or injurious falls in the past 12-months; bNo falls in the past 12 months 
cChi-squared test unless otherwise indicated; dStudent’s t-test 
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OH= Orthostatic Hypotension, SBP=systolic blood pressure, DBP=diastolic blood pressure, TUG=timed up and go, FR=functional 
reach, circulatory diseases= as any history of myocardial infarction, angina, stroke, TIA, or peripheral artery disease.  
PIP=potentially inappropriate prescriptions 
7.3.2. Potentially Inappropriate Prescriptions among Participants   
We detected a total of 223 PIPs among our population according to STOPP2. 
The presence of PIP were significantly associated with falls (OR,1.8; 95%CI, 1.4-2.2; 
p<0.001). When we dichotomised PIP into no PIP and PIP≥1, 156(59.3%) of fallers 
and 61(37%) of non-fallers had at least one PIP (OR= 2.5; 95%CI; 1.6-3.7; p≤0.001) 
(Table 7.1). 
The most common PIP among our sample were drugs for the endocrine system: 
sulphonylureas with a long duration of action (57 prescriptions). This was followed by 
the use of beta-adrenergic receptor blockers among diabetics with hypoglycemic 
episodes (30 prescriptions). The use of two or more drugs with anticholinergic 
properties (23 prescriptions) was also higher (see appendix 7.A for complete list).  
7.3.3. Univariate Analysis for Factors Associated with Potentially 
Inappropriate Prescribing 
The subanalysis for comparison of characteristics among fallers and nonfallers 
with no PIP and PIP≥1 showed that both groups with PIP≥1 were significantly more 
likely to be older, and had more comorbidities and medications. They were also 
significantly more likely to be diabetic and hypertensive, and were more likely to have 
OH and poorer TUG score among both fallers and non-fallers. Fallers with PIP≥1, in 
addition were more likely to be female, as well as have a preponderance of eye and 
circulatory diseases, and poorer FR score (Table 7.2).  
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 Fallers (n=263) Non-Fallers (n=165) 
 No PIP 
(n=107) 
≥1 PIP 
(n=156) 
OR(95%CI) p-value No PIP 
(n=104) 
≥1 PIP 
(n=51) 
OR(95%CI) p-value 
Falls n(%) 
Indoor Falls 60(56.1) 94(60.3) 1.1(0.72-1.9) 0.49 - - - - 
Outdoor Falls 59(55.1) 91(58.3) 1.1(0.69-1.8) 0.60 - - - - 
Injurious Falls  49(45.8) 81(51.9) 1.2(0.78-2.1) 0.32 - - - - 
Basic Demographics 
Age, 
mean(SD) 
73.8(7.2) 76.3(7.2) 1.0(1.0-1.1)§ 0.004** 71.4(4.8) 73.2(6.3) 1.0(1-1.1) 0.05* 
Gender (Male), n(%) 26(24.3) 58(37.2) 0.5(0.3-0.9) 0.02* 33(31.7) 22(36.1) 0.82(0.42-1.6) 0.56 
Smoker, n(%) 7(6.5) 8(5.1) 0.7(0.27-2.1) 0.62 2(1.9) 5(8.2) 4.5(1-24.2) 0.05* 
Alcohol, n(%) 10(9.3) 13(8.3) 0.8(0.4-2.1) 0.77 9(8.7) 8(13.1) 1.5(0.58-4.3) 0.36 
BMI, 
mean(SD) 
23.2(4.2) 24.1(3.9) 1.0(0.99-1.1) 
§ 
0.06 23.8(4.3) 24.5(3.5) 1.0(0.96-1.1) 0.32 
Comorbidities, 
median(IQR) 
2(3) 3(3) - <0.001*** 1(3) 2(1) - <0.001*** 
Diabetes, n(%) 0(0) 95(60.9) 0.4(0.5-0.4) <0.001*** 0(0) 29(47.5) 0.2(0.1-0.3) <0.001*** 
Hypertension, 
n(%) 
47(43.9) 108(69.2) 2.8(1.7-4.7) <0.001*** 32(30.8) 42(68.9) 4.9(2.5-9.8) <0.001*** 
Thyroid disease, 
n(%) 
8(7.5) 9(5.8) 0.7(0.3-2.0) 0.58 7(6.7) 8(13.1) 2.1(0.71-6.1) 0.16 
Eye disease, n(%) 42(39.3) 90(57.7) 2.1(1.2-3.4) 0.003** 29(27.9) 22(36.1) 1.4(0.74-2.8) 0.27 
Circulatory disease, n(%) 10(9.3) 35(22.4) 2.8(1.3-5.9) 0.006** 7(6.7) 7(11.5) 1.7(0.59-5.4) 0.29 
Arthritis, n(%) 25(23.4) 43(27.6) 1.2(0.71-2.2) 0.44 22(21.2) 16(26.2) 1.3(0.63-2.7) 0.45 
Neoplasm, n(%) 2(1.9) 4(2.6) 1.3(0.24-7.6) 0.71 7(6.7) 3(4.9) 0.7(0.17-2.8) 0.63 
Asthma, n(%) 7(6.5) 11(7.1) 1.1(0.40-2.8) 0.87 4(3.8) 5(8.2) 2.2(0.578-8.6) 0.23 
Table 7.2: Characteristics of sample population according to PIP score. 
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§ mean difference with 95% confidence interval.  
Δ
p value calculated by using Mann Whitney U test; ***p≤0.001, **p≤0.01, *p≤0.05 
OH= Orthostatic Hypotension, SBP=systolic blood pressure, DBP=diastolic blood pressure, TUG=timed up and go, FR=functional reach, circulatory diseases= as any history of 
myocardial infarction, angina, stroke, TIA, or peripheral artery disease. 
 
Medication count,  median(IQR) 2(4) 5(4) - <0.001Δ*** 0(2) 4(4) - <0.001Δ*** 
Polypharmacy n(%) 16(15) 95(60.9) 8.8(4.7-16.4) <0.001*** 9(8.7) 27(44.3) 8.3(3.-19.6) <0.001*** 
Blood Pressure 
SBP, mean(SD) 124.3(19.7) 129.8(24.4) 1.0(0.99-1.0) 0.26 135.1(18.5) 134.4(18.4) 1.0(0.08-1.0) 0.65 
DBP, 
mean(SD) 
65.5(13.7) 67.7(14.1) 1.0(0.98-1.0) 0.49 67.8(14.1) 65(15.8) 0.98(0.96-1.0) 0.20 
OH n(%) 18(16.8) 44(28.2) 1.9(1.05-3.5) 0.03* 13(12.5) 16(26.2) 2.4(1.1-5.6) 0.02* 
Physical Performance Scores 
TUG≥13.5s, , n(%) 38(35.5) 96(61.5) 2.8(1.6-4.7) <0.001*** 14(13.5) 20(32.8) 3.0(1.4-6.5) 0.004** 
FR≤ 18cm, , n(%) 21(19.6) 57(36.5) 2.3(1.3-4.1) 0.004** 5(4.8) 8(13.1) 2.9(0.9-9.3) 0.06 
Reduced grip strength, , n(%) 84(78.5) 131(84) 1.4(0.7-2.9) 0.26 58(55.5) 43(70.5) 1.6(0.8-3.2) 0.17 
Table 7.2 continued  
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7.3.4. Multivariate Analysis (Table 7.3)   
Multivariate logistic regression was first used to adjust for potential confounders; PIP 
remained an independent predictor of recurrent and injurious falls (Model 1). Moreover, 
PIP, age, blood pressure, and poorer TUG and FR formed the best predictor model for 
recurrent and injurious falls (R2= 0.276) (Model 2). Subsequently, when control 
participants were excluded; polypharmacy, TUG and OH were independent predictors 
of PIP among fallers (R2=0.329) (Model 4). 
Table 7.3: Multivariate Analysis to Determine Association of PIP with Falls and Factors 
Associated with Potentially Inappropriate Prescribing Among Fallers. 
 
Falls (N= 428, fallers=263, nonfallers=165) PIP (fallers, n=263) 
Characteristi
cs 
OR(95%CI)
ϯ 
P value 
R2 Characteristics OR(95%CI)
ϯ 
P value R2 
Model 1   
0.3
15 
Model 3   0.699 
Age 1.0(0.9-1.1) 0.17  Age 1.0(0.9-1.1) 0.79  
Gender 1.4(0.8-2.4) 0.17  Gender 0.7(0.3-1.7) 0.54  
Diabetes 1.2(0.6-2.5) 0.59  Diabetes 0.9(0.4-2.7) 0.99  
Hypertension 0.8(0.5-1.4) 0.55  Hypertension 1.1(0.5-2.6) 0.71  
Eye diseases 1.8(1.1-3.0) 0.02*  Eye diseases 1.2(0.5-2.8) 0.53  
Hearing 
disorders 
0.9(0.3-2.6) 0.91 
 Circulatory 
diseases 
0.6(0.2-1.7) 0.82  
Circulatory 
diseases 
1.2(0.5-2.6) 0.59 
 Polypharmacy 4.7(1.8-11.7) 0.001**  
SBP at rest 0.9(0.8-0.9) 
<0.001**
* 
 
TUG≥ 13.5s 
1.4(0.6-3.3) 0.39  
DBP at rest 1.0(1.0-1.1) 0.01*  FR≤ 18cm 1.5(0.6-3.7) 0.35  
TUG≥ 13.5s 2.0(1.1-3.5) 0.01* 
 Orthostatic 
hypotension 
9.9(4.1-23.5) <0.001*
** 
 
FR≤ 18cm 3.5(1.6-7.5) 0.001**      
Reduced grip 
strength 
1.6(0.9-2.9) 0.09 
     
PIP 1.4(1.0-1.8) 0.03*      
Model 2   
0.2
76 
Model 4   0.329 
Age 1.0(1.0-1.1) 0.03* 
 Polypharmacy 8.4(4.4-16.1) <0.001*
** 
 
SBP at rest 0.9(0.8-0.9) 
<0.001**
* 
 TUG≥ 13.5s 2.3(1.2-4.1) 0.003**  
DBP at rest 1.0(1.0-1.1) 0.02* 
 Orthostatic 
hypotension 
8.4(4.4-16.1) 0.001**  
TUG≥ 13.5s 2.1(1.2-3.6) 0.004**      
FR≤ 18cm 3.5(1.6-7.2) 0.001**      
PIP 1.5(1.1-1.9) 
<0.001**
* 
     
***p≤0.001, **p≤0.01, *p≤0.05, ϯ analysed using binary logistic regression. TUG=timed up and go, 
FR=functional reach 
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7.4. Discussion 
The presence of at least one PIP identified with STOPP2 was independently 
associated with falls in our cross-sectional study. Both fallers and non-fallers with PIP 
were older with more comorbidities, more medications and poorer gait and balance than 
those with no PIP. Older age, low blood pressure, deterioration in TUG and FR as well 
as PIP remained independent predictors for falls in the final model. Moreover, instead 
of age and gender, the presence of polypharmacy, OH and impaired TUG were 
independently associated with PIP among fallers.  
The commonest PIP identified were linked to diabetes treatment, as our 
population had a higher proportion of individuals with diabetes which is explained by 
the high prevalence of diabetes among the South Asian population(Gujral et al., 2013). 
The preponderance of long acting sulfonylureas detected in our study is comparable to 
that reported by two previous Malaysian studies conducted in nursing homes, using the 
STOPP criteria(Al Aqqad et al., 2014; Chen et al., 2012). Hypoglycaemia due to 
hypoglycemics is a significant risk factor for falls in the older population (Berlie et al., 
2010) which could worsen with long acting hypoglycemics. However, the inappropriate 
prescription of oral hypoglycemics is considered to be one of the most preventable 
adverse drugs events (Pretorius et al., 2013). The use of β-blockers among diabetics 
with frequent hypoglycaemia is considered inappropriate, as it could lead to masking of 
hypoglycemic symptoms by diminishing the adrenergic counter action of low blood 
glucose levels e.g. diminished occurrence of tremor and heart pounding(Sawicki et al., 
2001). However, the frequent use of inappropriate medications for diabetes 
management among our sample may also be influenced by  the limited availability of 
drugs in both government and private clinics (Hussain, 2008). Community based clinics 
currently dispense their own medications, with the issues of pharmacy dispensing 
currently being hotly debated. 
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The association between anticholinergic medications and falls has been reported 
in several studies previously (Berdot et al., 2009; Landi et al., 2014; A. Zia et al., 2016). 
Ageing is accompanied by increased sensitivity to the blockade of muscarinic receptors 
and increased permeability of the blood brain barrier, thereby enhancing the central 
nervous system effects of anticholinergic drugs. This cholinergic blockade in the brain 
is associated with reduced executive and motor functions and poorer gait and balance 
thus leading to an increased risk of falls (A. Zia et al., 2016). The complete avoidance 
of anticholinergic medications, however, is not always possible as many prescription 
and over-the-counter medications contain anticholinergic properties (Landi et al., 2014). 
Older individuals with a history of recurrent and injurious falls were more likely 
to have at least one PIP compared to individuals without falls, this finding is consistent 
with that reported by several other studies (Berdot et al., 2009; Borenstein et al., 2013; 
Frankenthal et al., 2013, 2014; McMahon et al., 2014). These studies were mainly 
cross-sectional and were conducted in hospitals or institutions. An Irish study reported 
the prevalence of PIP among older fallers presenting to the emergency department to be 
53% according to STOPP(McMahon et al., 2014). Two prospective cohort studies 
performed among hospitalised older adults showed a significant association of PIP with 
falls using the Beer’s criteria (Borenstein et al., 2013) and STOPP criteria(Frankenthal 
et al., 2013). In addition, one randomised controlled trial in a long-term geriatric care 
facility revealed a significant reduction in falls following medication review 
intervention using the STOPP criteria (Frankenthal et al., 2014). However, we were 
only able to locate one study performed in a community sample. This French 
longitudinal study observed that users of PIP had a significantly increased risk of falling 
with a 32% prevalence of PIP among their cohort at baseline according to STOPP 
criteria (Berdot et al., 2009). Our proportion of individuals on PIP was comparable to 
the Irish study but higher than the French study, as we recruited high risk older adults 
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with recurrent or injurious falls at baseline. Our study was therefore the first to evaluate 
the use of the STOPP2 criteria in a community-dwelling population, and has potentially 
important implications in the direction of future intervention studies evaluating 
objective methods of conducting medication reviews for the secondary prevention of 
falls.  
The predictors of PIP were poorer TUG, OH and polypharmacy. A poorer TUG 
score among fallers with PIP could be explained by the higher anticholinergic burden as 
the commonest PIP, since higher anticholinergic burden is associated with functional 
decline and poorer scores of TUG as a result (Landi et al., 2014; A. Zia et al., 2016). 
The association of OH with PIP could be explained by the higher proportion of fallers 
with diabetes mellitus, as OH is frequent among diabetics due to the complication of 
cardiovascular autonomic neuropathy (Gaspar et al., 2016).The occurrence of 
polypharmacy and hence PIP among fallers was high which is comparable studies 
linking PIP with polypharmacy(McMahon et al., 2014; Weng et al., 2013). While 
falling should trigger a medication review as a part of comprehensive assessment, the 
avoidance of polypharmacy entirely is not possible due to evidence based disease 
management (Pretorius et al., 2013).Therefore, avoidance of inappropriate 
polypharmacy during medication reviews according to some defined criteria could be 
helpful in falls risk reduction(A. Zia et al., 2015b). Hamilton et al also concluded in 
their prospective study that PIP according to the STOPP criteria are the significantly 
avoidable serious adverse drug events (Hamilton et al., 2011) which may also prove 
beneficial for high risk older fallers. 
As our study was conducted in the unique setting of community-dwellers in a 
middle-income developing country of South-East Asia, the generalizability in the global 
context may be limited. As alluded to earlier, the availability of medications in 
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healthcare facilities in our setting is limited, for instance, unlike in previous studies, 
benzodiazepines which have always been considered to be strongly associated with falls 
(Berdot et al., 2009; McMahon et al., 2014), were less commonly prescribed in our 
study. The use of narcotic analgesics and tranquilizers in our setting is highly regulated 
in response to the high prevalence of recreational drug use in this region. However, as 
few studies on PIP have been conducted in South-East Asia and other developing 
countries, and none among the fallers, our study has conversely added important 
insights into PIP in alternative settings.   
Our study has useful clinical and research implications for medication review 
among fallers. The inclusion of PIP rather than just withdrawal of drugs labelled as 
“falls-risk increasing drugs” during medication reviews may be a more advisable 
strategy since many  are appropriately prescribed for secondary prophylaxis of chronic 
diseases and their withdrawal could lead to unacceptable increases in risks of adverse 
outcomes(A. Zia et al., 2015b). Our study therefore paves the ground for future 
prospective intervention studies to assess the effectiveness of STOPP2 as a tool in the 
prevention of recurrent or severe falls. 
7.5. Conclusion 
 
PIP is significantly associated with falls according to STOPP2. The use of 
STOPP2 as an objective tool during medication reviews may be beneficial in the 
assessment and prevention of falls among older adults. Future intervention studies are 
now required to evaluate the role of STOPP2 in the prevention of falls among older 
adults.  
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CHAPTER 8: EFFECT OF MEDICATION REVIEW INTERVENTION AMONG 
OLDER COMMUNITY DWELLING FALLERS IN MALAYSIA 
8.1. Introduction 
Previous studies have suggested that polypharmacy is an independent variable 
for falls in older people, while newer studies showed that in an older person receiving 
multiple medications, polypharmacy itself or polypharmacy with at least one other 
FRID may be a strong predictor for falls (Richardson et al., 2015; Ziere et al., 2006). 
The latest studies however suggest that a stronger link exists between falls and the type 
as well as number of FRID taken rather than polypharmacy on its own (Hammond et 
al., 2013). The studies by Milos et al and Bennet el at showed that severe falls and fall 
injuries were associated with FRID use among the older adults in a dose response 
fashion (Bennett et al., 2014; Laflamme et al., 2015; Milos et al., 2014).  
Among older community dwellers, the FRID related to CNS effects are more 
likely to increase falls risk (French et al., 2006) followed by cardiovascular drugs 
(Milos et al., 2014; Poon et al., 2005), antidiabetics (Berlie et al., 2010) and the drugs 
with anticholinergic activity (Kersten et al., 2014). The systematic review by 
Hartikainen et al including 29 studies stated that the main group of drugs associated 
with an increased risk of falling was psychotropics: benzodiazepines, antidepressants, 
and antipsychotics while antiepileptics and blood pressure lowering drugs were weakly 
associated with falls (Hartikainen et al., 2007). Therefore, these FRID should ideally be 
avoided in all older fallers. 
The Falls Prevention Guidelines now advocate careful medication reviews for 
polypharmacy reduction and FRID withdrawal among older adults presenting with falls 
(AGS/BGSguidelines, 2011). Studies have shown that the single intervention of 
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medication review and withdrawal for FRID could prove beneficial for falls reduction 
among older fallers [3,4]. Among older adults with polypharmacy and risk drugs, 
medication withdrawal not only reduces falls but may also improve drug compliance 
and patients’ quality of life as well as reduce medication errors (Frankenthal et al., 
2014). However, while medication review has been advocated in the management of 
falls by international guidelines, very few trials including fallers at baseline have 
positively demonstrated a reduction in the risk of falls with the withdrawal of culprit 
medications or reduction of dose burden (van der Cammen et al., 2014).  
8.2. Objective 
The objective of this study was to prospectively assess whether it is feasible and 
effective to perform fall prevention medication reviews and a subsequent FRID 
withdrawal, swapping with safer alternatives or dose reduction among community 
dwelling older fallers living in a middle income country. 
8.3. Methodology 
The setting, participants and baseline demographics methodology has been 
described in chapter 3. This study was aimed to be a pilot study for a future larger 
randomised controlled trial to determine the feasibility and effectiveness of medication 
review intervention among fallers. 
8.3.1. Medication Assessment and Review 
After obtaining medication data according to procedure mentioned in chapter 3 
and recording it according to British National Formulary, 67th Edition (BNF, 2014), 
FRID were identified according to the metaanalysis by Bloch et al and Woollcott at al 
(Bloch et al., 2013; Woolcott et al., 2009).  
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All the participants in the intervention arm and receiving ≥1FRID received careful 
medication review by the geriatrician. The prescription and dosage of medication was 
compared against their medical conditions, other risk factors of falls as well as existence 
of low blood pressure at the time of the blood pressure testing. The medication review 
consisted of deprescribing of unnecessary or duplicative medications or dose reduction 
or swapping with safer alternatives of those medications which could not be completely 
omitted.  
8.3.2. Statistical Analysis  
Continuous data were evaluated for normal distributions and comparisons were 
made using the independent t-test or Mann-Whitney U where appropriate. Categorical 
data were expressed as frequencies and the statistical significance was determined with 
the Chi-squared test. To determine the effectiveness of the intervention, we conducted a 
survival analysis using time to first fall as a dependent variable, for which the Kaplan-
Meier method was used. To determine the relationship between the intervention time to 
first fall and time to second fall, a Cox regression analysis was conducted. A p-value of 
<0.05 was considered statistically significant.  Sample size calculations for this study 
had been described in a previous section (Section 3.2.2) 
8.4. Results 
8.4.1. Participants and Baseline Demographics  
Two hundred and four fallers matched our inclusion criteria; 106(52.2%) fallers 
were randomised to the non-intervention arm and 98(47.8%) in the intervention arm.  
The diaries return rate in non-intervention arm was 71(66.4%) while intervention arm 
was 66(66.3%). The participants who were lost to follow up were excluded from the 
final analysis i.e. n=35 from the non-intervention group and n=32 from the intervention 
 107 
 
group. The analysis was performed for the remaining 66 participants in the intervention 
group and 71 participants in the non-intervention group (Flow chart 8.1). 
Due to randomisation, no differences in the age, gender, BMI, number of 
comorbidities or any medical condition was observed between the intervention and the 
non-intervention groups (Table 8.1). There were no significant differences in individual 
FRID use at baseline between the intervention and non-intervention groups (Table 8.2). 
8.4.2. Medication Review Assessment 
Medication review was given to the entire intervention group (n=66), it was 
possible to withdraw, swap or reduce dosage in 21(31.8%) of the 66 fallers in the 
intervention group; 13 antihypertensives were stopped, 2 were swapped with safer 
alternatives (alfuzocin was swapped with tamsulosin and nifedipine was switched with 
amlodipine) while 6 antihypertensives were reduced in dosage due to the lower blood 
pressure. Figure 2 shows the survival curve, no statistically significant differences were 
found (log rank test = 1.94; p=0.16). Fig 3 shows the statistical curve for intervention 
and time to second fall, no significance was observed.  Table 8.3 provides the results of 
the Cox proportional hazard model; there was no difference in the time to first fall 
(Hazard ratio for time to first fall= 0.90; 95%CI, 0.51-1.50; p=0.71), and time to second 
fall (Hazard ratio for time to first fall= 0.90; 95%CI, 0.51-1.50; p=0.71) between the 
intervention and non-intervention groups. 
8.5. Discussion 
This substudy of a randomised controlled trial demonstrated that although a 
significant number of fallers were on falls risk drugs; they were provided careful 
reviews of all their regular medications in the effort to reduce consumption of FRID, it 
was possible to withdraw, reduce dosage or swap drugs in a very small proportion of 
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intervention group. No difference was observed in the time to first fall between the 
intervention and the non-intervention groups after one year of follow up. 
Our results are in consistency with other studies which reported that either FRID 
cannot be reduced or it did not show a significant reduction in falls (Casteel et al., 2011; 
Sjoberg et al., 2013; Weber et al., 2008) but are opposed to other studies with beneficial 
effect on falls reduction (Campbell et al., 1999; Frankenthal et al., 2014; Salonoja et al., 
2012; van der Velde, Stricker, et al., 2007). There are few possible reasons for the small 
number of withdrawals than expected, as well as non-effective medication withdrawal 
intervention.  The use of psychotropics among our sample was very small due to their 
government controlled availability in this region and the relatively low acceptance of 
psychiatric treatment (Hussain, 2008). The medication withdrawal trials, in general, 
have shown psychotropic withdrawal to be an effective intervention for falls reduction 
(Rothschild et al., 2007). Out of four studies (two prospective and two RCT) 
demonstrating the effect of medication withdrawal on falls reduction; three have shown 
that the withdrawal of psychotropics led to a significant reduction in falls (Campbell et 
al., 1999; Frankenthal et al., 2014; Salonoja et al., 2012). However, although the RCT 
by Campbell et al showed that withdrawal of psychotropics led to a 66% reduction in 
falls rate during their 44 weeks of follow up, it was difficult to achieve permanent 
withdrawal as 47% of the participants from the withdrawal group started taking 
medications only after one month of completion of trial (Campbell et al., 1999). The 
prospective study by Velde et al was the only one to report benefits of cardiovascular 
drug withdrawal among other FRID on falls reduction during the three months follow 
up period (van der Velde, Stricker, et al., 2007). The authors included high risk fallers 
(≥1 fall in the past year) but intervention was performed amongst those participants 
with higher number of comorbidities and hence a higher FRID use at baseline. We, on 
the contrary, tested the potential effectiveness of careful medication review through a 
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randomized-controlled design with the intention of eliminating potential bias. Many 
previous studies did not always randomize or were uncontrolled, and hence were 
inherently biased. Despite this, international guidelines have been drawn from the poor 
quality evidence available previously. 
Another reason for non-feasibility of medication modification after review may be 
that the high risk fallers have higher number of comorbidities at baseline and FRID 
include treatment for serious diagnoses (cardiovascular drugs) or symptom 
management. Among these older adults, their attending physicians may already have 
considered and tried different drug treatment strategies and hence the geriatrician may 
be less inclined to change drugs taken for these purposes. Moreover, it should be noted 
that the follow up periods for the above mentioned studies with successful medication 
intervention is short and longer term effects of withdrawal on end organ damage, 
quality of life and survival rates have not been evaluated. This suggests that the shorter 
term fall reduction benefit of medication withdrawal might pose a bigger harm to the 
overall health and quality of life of an older adult. Because of this caution of longer 
term threat, our geriatrician was able to withdraw only a few medications among 
patients with lower blood pressure or postural drop in blood pressure only and not the 
ones necessary for the effective management of hypertension, stroke, diabetes or other 
noncommunicable diseases.  
Another reason for negative outcomes may be that we did not use any criteria for 
inappropriate medication withdrawal or anticholinergic medication withdrawal. We did 
not choose this approach because none of the previous falls studies on medication 
withdrawal have used any criteria. The medication withdrawal trials according to 
inappropriate medication usage have also shown positive results with the highest 
withdrawal rate seen with anticholinergics (Starner et al., 2009; Thompson Coon et al., 
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2014), but they have never been used among a sample of older adults with falls. The 
RCT by Frankenthal et al included adults aged 65 and older on at least one medication 
who were then randomized to receive usual pharmaceutical care or undergo medication 
intervention according to STOPP/START criteria. They found that the intervention 
group had reduced number of medications, lesser falls and decreased cost due to 
medications and falls (Frankenthal et al., 2014). Therefore, future studies should 
consider focussing on inappropriately prescribed drugs among older adults with history 
of falls and by reducing anticholinergic burden rather than focussing on FRID 
consisting of inevitable medications for disease management. 
While, this study comprised a pre-planned subgroup analysis of a larger 
randomized-controlled study rather than a study with the designated primary purposes 
of assessing the effects of medication review among older individuals with recurrent or 
injurious falls. Nevertheless, to our knowledge, this study represents the only Malaysian 
study thus far to evaluate medication management using actual falls recurrence as the 
primary outcome. The prospective design and randomly assigned intervention and non-
intervention groups are the strengths of the study. However, as it was a substudy of a 
multifactorial intervention RCT, our participants in the intervention arm would have 
also received individually tailored multifactorial interventions including physiotherapy, 
home safety assessment, visual interventions, cardiovascular assessments and falls 
education.  Moreover, the if the follow up were reduced to three months, we might have 
gotten a clearer picture of the effect of drug intervention on falls as compared to one 
year long follow ups where the patients might be put on some new drugs or some drugs 
might be omitted from their regimens by their physicians as the participants may get 
older, frailer and develop new pathologies. Moreover, another reason for nonsignificant 
effect of intervention may also be because the change in the number of FRID was 
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smaller and the defaulter rate was higher thus this study did not have the power to detect 
differences. 
The results of this subanalysis of a larger randomized controlled study therefore 
challenge the recommendations of existing guidelines on medication review 
(AGS/BGSguidelines, 2011). It further supports the results of two previous meta-
analyses suggesting the limited evidence on the benefits of cardiovascular medication 
review on falls outcomes (Cumming, 1998; Leipzig et al., 1999b). As few of our 
participants were on antipsychotic and other centrally acting drugs, this will explain the 
discrepancies between our findings and that of previously published studies advocating 
medication review among older fallers. The findings of our study will now inform the 
power calculations and study design of a larger, possibly multicentre, randomized 
controlled study evaluating the potential benefits of details medication review, using the 
tools evaluated earlier in this thesis, of medication management among older 
individuals with a history of falls. Outcome measures should include other disease 
outcomes aside from falls recurrence, and follow-up duration should extend beyond the 
one year commonly used in falls intervention studies.  
8.6. Conclusion 
We can conclude that although regular review of medications is advisable among 
older patients receiving multiple medications but the focus of the medication could not 
be FRID reduction or withdrawal as it may not be feasible while taking patient’s 
comorbidities and other health factors into account. Therefore, it is emphasized that 
withdrawal of medications must be individually tailored depending upon patients’ 
cumulative risk factors for the risk of falls, longer term effect of medication withdrawal 
on comorbidities and after weighing the benefit versus risk ratio.  
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Table 8.1: Baseline characteristics of the intervention and non-intervention group. 
 
Characteristics Intervention (n=66) Non-intervention 
(n=71) 
P value 
Age, mean(SD) 75.6(6.7) 77.0(6.8) 0.23 
Gender (Male) , n(%) 19(28.8) 28(39.4) 0.19 
Smoker, n(%) 1(1.5) 5(7) 0.11 
Alcohol, n(%) 2(3) 5(7) 0.28 
Body Mass Index, mean(SD) 24.1(3.7) 22.4(3.6) 0.06 
Medical History, n(%)    
No. of comorbidities 3(2) 3(2) 0.74 
Diabetes 25(37.9) 32(45.1) 0.39 
Hypertension 45(68.2) 56(78.9) 0.15 
Arthritis 19(28.8) 17(23.9) 0.52 
Neoplasm 1(1.5) 2(2.8) 0.60 
Thyroid diseases 4(6.1) 4(5.6) 0.93 
Circulatory diseases 12(18.2) 15(21.1) 0.63 
Cataract 30(45.5) 33(46.5) 0.90 
Blood Pressure    
Systolic blood pressure, mean(SD) 131.9(20.4) 125.1(28.1) 0.11 
Diastolic blood pressure, mean(SD) 64.2(13.6) 66.4(12.9) 0.35 
Orthostatic Hypotension, n(%) 18(25.4) 17(24.8) 0.99 
 
 
Table 8.2: FRID usage at baseline in the intervention and non-intervention group. 
FRID, n(%) Intervention 
(n=66) 
Non-intervention 
(n=71) 
P value 
Antihistamines 7(10.6) 4(5.6) 0.38 
Thyroid meds 5(7.6) 3(4.2) 0.40 
Alpha-blockers 12(18.2) 7(9.9) 0.15 
beta-blockers 20(30.3) 18(25.4) 0.51 
ACE_Inhibitors 11(16.7) 14(19.7) 0.64 
Angiotensin receptor antagonists 17(25.8) 23(32.4) 0.39 
Calcium Channel Blockers 25(37.9) 31(43.7) 0.49 
Nitrates 2(3) 3(4.2) 0.22 
Proton Pump Inhibitors 5(7.6) 8(11.3) 0.86 
NSAIDS 8(12.1) 3(4.2) 0.08 
Aspirin 18(27.3) 21(29.6) 0.76 
Biguanides 18(27.3) 21(29.6) 0.76 
Sulfonylureas 16(24.2) 12(16.9) 0.28 
DPP4I 4(6.1) 3(4.2) 0.39 
Insulin 4(6.1) 8(11.3) 0.28 
 
Table 8.3: Hazard Ratio for Falls using Cox Regression. 
 
 
 
HR= hazard ratio, CI= confidence Interval, Dependent variable= time until first fall, Independent 
variable= Intervention versus non-intervention group. 
Medical Review B Wald Test P-value HR(95%CI) 
Time to first fall 0.104 0.134 0.715 0.90(0.51-1.5) 
Time to second fall 0.146 0.137 0.711 0.86(0.40-1.8) 
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Figure 8.1: Flowchart for Medication Intervention in MyFAIT study. 
 
Figure 8.2: Survival Analysis; Comparison between two groups in the incidence of falls 
that occurred after 12 months of follow up 
Log Rank=1.94, p=0.16 
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Fig 8.3: survival analysis for time to second fall 
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CHAPTER 9: CONCLUSION 
9.1. Discussion 
This study sought to investigate the culprit medications and their mechanisms 
associated with falls and demonstrated that the use of single FRID is safer and fails to 
show any association with falls even among our high risk fallers sample. The presence 
of PIP, multiple FRID and ACB even with the lowest score; instead of polypharmacy is 
associated with falls among older adults. The prescription of antihypertensive is safer 
among older adults with history of serious and injurious falls contrary to previous 
preconceptions. However, lower SBP while standing is significantly associated with 
falls. The anticholinergic burden is seen to mediate through poor functional 
performance scores i.e. TUG and FR. An attempt to reduce FRID burden via careful 
medication review remains, however unsuccessful and it is not feasible to withdraw 
antihypertensives or antidiabetics etc. without potentially adversely affecting patient’s 
disease management. 
The most significant finding of this study is that the individual FRID especially 
antihypertensives are safer for use among older adults with a history of recurrent or 
injurious falls. Therefore the medication reviews for older fallers should specifically 
focus on the multiple FRID, anticholinergic activity of drugs as well as the 
inappropriateness of drugs instead of counting the total number for prescribed drugs or 
withdrawing the FRID necessary for optimal disease management. Our study is in line 
with the recent studies which have now beginning to highlight this issue that the type of 
medication is more important than the number (Bennett et al., 2014; Milos et al., 2014) . 
Our study was the first to state that the increased number of high risk medication may 
be the reason for previously established association between the total number of drugs 
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and falls. The presence of polypharmacy, therefore, should alarm the physician for the 
careful review of medication but should not be a criterion for medication withdrawal 
among older fallers. As, the association of postural blood pressure drop (widely 
considered as a side effect of antihypertensives), with falls and antihypertensives has 
never been evaluated in a single study, our study suggests that the presence of lower 
SBP while standing instead of OH must be evaluated in older fallers irrespective of the 
use of antihypertensives.  
The present study was also the first to suggest that in an older faller with a poor TUG 
and FR score, anticholinergic burden, even at low doses needs to be evaluated and 
withdrawal of these drugs should be considered. In addition, the association of PIP with 
falls using STOPP2 identifies the risk drugs in a systematic way which may therefore 
make it easier to swap them with safer alternatives without affecting the quality of 
disease management. The deprescribing of medication based on simple review of the 
FRID was unfeasible and unsuccessful in the reduction of falls like most studies 
involving non-psychotropics withdrawals (Casteel et al., 2011; Sjoberg et al., 2013; 
Weber et al., 2008) because of the obvious greater risk of exposing an older adult to end 
organ damage and mortality. 
While this was the first study to examine the association between medications 
and falls among older adults in the Malaysia, our study has limitations. First, 
generalization is an issue because we involved the community dwellers in the urban 
setting, the use of FRID, over the counter anticholinergics or PIP may be higher in rural 
areas. Our case control analysis has the limitation that falls were recorded 
retrospectively and therefore may be subject to recall bias. Moreover, causal 
relationships could not be established because of its cross sectional design. The 
prospective study is limited because the adults were followed up for falls only and not 
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for other comorbidities, compliance and quality of life or adverse drug events because 
of limited time and resources.  
9.2. Future Recommendations 
The current study highlights the new dimensions as well as highlights the 
problem areas in the previously established association between FRID and falls. While 
it is suggested by our study that the polypharmacy and FRID can no longer be 
considered as a single entity while assessing the risk of falls for an older adult, there are 
a few things that should have been done differently. The comprehensive association 
between postural blood pressure changes, antihypertensives and falls requires 
prospective intervention studies to determine the blood pressure treatment targets with 
the justifiable use of antihypertensives for a high risk group of older fallers without 
increasing the risk of future falls. Moreover, the prospective intervention studies on 
medication reviews to reduce inappropriate prescribing and anticholinergic load while 
simultaneously including the patient compliance and effect of those reviews not only on 
falls but also on pathologies for the longer term may provide useful answers as well as 
more applicability in terms of clinical outcomes among high risk fallers. The following 
flow chart (Fig. 9.1) shows a recommendation for future improvement according to the 
findings of this study. 
9.3. Conclusion 
The presence of multiple FRID, cumulative anticholinergic burden and PIP is 
more likely to be associated with falls than mere polypharmacy. While the medication 
reviews based on polypharmacy and FRID withdrawal have only been successful for 
psychotropics, the deprescribing of anticholinergics and other inappropriate drugs 
should be considered for falls prevention among older adults. The presence of low SBP 
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while standing instead of OH, needs to be evaluated among high risk fallers on 
antihypertensives. Prescriptions for older patients should be individualized and subject 
to frequent periodical reviews while consistently striving to minimize inappropriate 
prescribing. Large, adequately powered , randomized-controlled studies, evaluating the 
benefits of medicines management informed by anticholinergic burden scores and 
appropriate prescribing tools and based on recent published knowledge on medications 
and falls, are now urgently required. 
 
Figure 9.1: Flow chart for evaluation and review of medication among older fallers 
based on literature review (*, ≥2 falls or 1 fall with injury; ◊, ≥2 comorbidities). 
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APPENDIX A 
 
Appendix A: Number of participants on drugs with anticholinergic activity calculated using the 
anticholinergic cognitive burden (ACB) scale. 
Score 1 (n=112) Score 2 (n=2) Score 3 (n=17) 
Medications Number  Medications Number  Medications Number  
Atenolol   33 Carbamazepine  2 Amitriptyline  5 
Captopril  1   Chlorpheniramine  5 
Colchicine  8   Dimenhydrinate  2 
Dipyridamole   1   Orphenidrine  3 
Digoxin  2   Olanzapine  1 
Furosemide  10   Perphenazine 1 
Fluvoxamine  2     
Hydrocortisone  2     
Metoprolol  26     
Nifedipine  10     
Prednisolone  4     
Ranitidine  9     
Theophylline  4     
APPENDIX B 
 
APPENDIX B: Screening Tool of Older Persons’ Prescriptions (STOPP) version 2. 
List of inappropriate prescriptions according to STOPP Version 2 No. 
Section A: Indication of medication 
Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop 
diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a 
single drug class should be observed prior to considering a new agent). 
4 
Section B: Cardiovascular System  
Beta blocker with bradycardia (< 50/min), type II heart block or complete heart 
block (risk of complete heart block, asystole)  
1. 
Aldosterone antagonists (e.g. spironolactone) with concurrent potassium-
conserving drugs (e.g. ACEI’s, ARB’s) without monitoring of serum potassium 
(risk of dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be 
monitored regularly, i.e. at least every 6 months). 
2 
Section C: Antiplatelet/Anticoagulant Drugs 
Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin 
inhibitors or factor Xa inhibitors with concurrent significant  bleeding risk, i.e. 
uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
16 
Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, 
stronger evidence and fewer side-effects).  
11 
NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased 
risk of peptic ulcer disease)  
2 
Section D: Central Nervous System and Psychotropic Drugs  
Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of 
prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all 
10 
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benzodiazepines should be withdrawn gradually if taken for more than  4  weeks 
as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped 
abruptly). 
First-generation antihistamines (safer, less toxic antihistamines now widely 
available) 
8 
Section H: Musculoskeletal System  
NSAID with severe hypertension (risk of exacerbation of hypertension) or severe 
heart failure (risk of exacerbation of heart failure).  
4 
Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain 
where Paracetamol has not been tried (simple analgesics preferable and usually 
as effective for pain relief) 
6 
Corticosteroids (other than periodic intra-articular injections for mono-articular 
pain) for osteoarthritis (risk of systemic corticosteroid side-effects).  
2 
COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of 
myocardial infarction and stroke)  
5 
NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of 
peptic ulcer disease) 
2 
Section I: Urogenital System 
Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic 
hypotension (risk of precipitating recurrent syncope)  
10 
Section J. Endocrine System  
Sulphonylureas with a long duration of action (e.g. glibenclamide, glimepiride) 
with type 2 diabetes mellitus (risk of prolonged hypoglycaemia).  
57 
Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of 
suppressing hypoglycaemic symptoms).  
30 
Section K: Drugs that predictably increase the risk of falls in older people 
Benzodiazepines (sedative, may cause reduced sensorium, impair balance).  10 
Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism).  2 
Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-
acting nitrates, ACE inhibitors, angiotensin I receptor blockers) with persistent 
postural hypotension i.e. recurrent drop in systolic blood pressure ≥ 20mmHg 
(risk of syncope, falls). 
12 
 Hypnotic Z-drugs (zolpidem)(may cause protracted daytime sedation, ataxia).  1 
Section L: Analgesic Drugs 
Use of regular (as distinct from PRN) opioids without concomitant laxative (risk 
of severe constipation).  
6 
Section N: Antimuscarinic/Anticholinergic Drug Burden 
Concomitant use of two or more drugs with antimuscarinic/anticholinergic 
properties (e.g. bladder antispasmodics, intestinal antispasmodics, tricyclic 
antidepressants, first generation antihistamines) (risk of increased 
antimuscarinic/anticholinergic toxicity)  
23 
Total 223 
  
 
 
